<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Remote care through telehealth for people with inflammatory bowel disease - Gordon, M - 2023 | Cochrane Library</title> <meta content="Remote care through telehealth for people with inflammatory bowel disease - Gordon, M - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014821.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Remote care through telehealth for people with inflammatory bowel disease - Gordon, M - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014821.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014821.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Remote care through telehealth for people with inflammatory bowel disease" name="citation_title"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="morris@betterprescribing.com" name="citation_author_email"/> <meta content="Vassiliki Sinopoulou" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Svetlana Lakunina" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Teuta Gjuladin-Hellon" name="citation_author"/> <meta content="Kelly Bracewell" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD014821.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014821.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014821.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014821.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Chronic Disease; *Colitis, Ulcerative; *COVID-19; *Crohn Disease [therapy]; Neoplasm Recurrence, Local; Quality of Life; *Telemedicine" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014821.pub2&amp;doi=10.1002/14651858.CD014821.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014821\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014821\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","hr","id","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD014821.pub2",title:"Remote care through telehealth for people with inflammatory bowel disease",firstPublishedDate:"May 4, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014821.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014821.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014821.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014821.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014821.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014821.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014821.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014821.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014821.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014821.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3994 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014821.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0140"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/appendices#CD014821-sec-0145"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/supinfo/CD014821-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/supinfo/CD014821-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Remote care through telehealth for people with inflammatory bowel disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0005">Vassiliki Sinopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0006">Svetlana Lakunina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0007">Teuta Gjuladin-Hellon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0008">Kelly Bracewell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information#CD014821-cr-0009">Anthony K Akobeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information/en#CD014821-sec-0156">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014821.pub2">https://doi.org/10.1002/14651858.CD014821.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014821-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014821-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014821-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014821-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014821-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014821-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD014821-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014821-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014821-abs-0001" lang="en"> <section id="CD014821-sec-0001"> <h3 class="title" id="CD014821-sec-0001">Background</h3> <p>People with inflammatory bowel disease (IBD) require intensive follow‐up with frequent consultations after diagnosis. IBD telehealth management includes consulting by phone, instant messenger, video, text message, or web‐based services. Telehealth can be beneficial for people with IBD, but may have its own set of challenges. It is important to systematically review the evidence on the types of remote or telehealth approaches that can be deployed in IBD. This is particularly relevant following the coronavirus disease 2019 (COVID‐19) pandemic, which led to increased self‐ and remote‐management. </p> </section> <section id="CD014821-sec-0002"> <h3 class="title" id="CD014821-sec-0002">Objectives</h3> <p>To identify the communication technologies used to achieve remote healthcare for people with inflammatory bowel disease and to assess their effectiveness. </p> </section> <section id="CD014821-sec-0003"> <h3 class="title" id="CD014821-sec-0003">Search methods</h3> <p>On 13 January 2022, we searched CENTRAL, Embase, MEDLINE, three other databases, and three trials registries with no limitations on language, date, document type, or publication status. </p> </section> <section id="CD014821-sec-0004"> <h3 class="title" id="CD014821-sec-0004">Selection criteria</h3> <p>All published, unpublished, and ongoing randomised controlled trials (RCTs) that evaluated telehealth interventions targeted at people with IBD versus any other type of intervention or no intervention. </p> <p>We did not include studies based on digital patient information resources or education resources, unless they formed part of a wider package including an element of telehealth. We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring. </p> </section> <section id="CD014821-sec-0005"> <h3 class="title" id="CD014821-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data from the included studies and assessed their risk of bias. We analysed studies on adult and paediatric populations separately. We expressed the effects of dichotomous outcomes as risk ratios (RRs) and the effects of continuous outcomes as mean differences (MDs) or standardised mean differences (SMDs), each with their 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE methodology. </p> </section> <section id="CD014821-sec-0006"> <h3 class="title" id="CD014821-sec-0006">Main results</h3> <p>We included 19 RCTs with a total of 3489 randomised participants, aged eight to 95 years. Three studies examined only people with ulcerative colitis (UC), two studies examined only people with Crohn's disease (CD), and the remaining studies examined a mix of IBD patients. Studies considered a range of disease activity states. The length of the interventions ranged from six months to two years. The telehealth interventions were web‐based and telephone‐based. </p> <p><b>Web‐based monitoring versus usual care</b> </p> <p>Twelve studies compared web‐based disease monitoring to usual care.</p> <p>Three studies, all in adults, provided data on disease activity. Web‐based disease monitoring (n = 254) is probably equivalent to usual care (n = 174) in reducing disease activity in people with IBD (SMD 0.09, 95% CI −0.11 to 0.29). The certainty of the evidence is moderate. </p> <p>Five studies on adults provided dichotomous data that we could use for a meta‐analysis on flare‐ups. Web‐based disease monitoring (n = 207/496) is probably equivalent to usual care (n = 150/372) for the occurrence of flare‐ups or relapses in adults with IBD (RR 1.09, 95% CI 0.93 to 1.27). The certainty of the evidence is moderate. One study provided continuous data. Web‐based disease monitoring (n = 465) is probably equivalent to usual care (n = 444) for the occurrence of flare‐ups or relapses in adults with CD (MD 0.00 events, 95% CI −0.06 to 0.06). The certainty of the evidence is moderate. One study provided dichotomous data on flare‐ups in a paediatric population. Web‐based disease monitoring (n = 28/84) may be equivalent to usual care (n = 29/86) for the occurrence of flare‐ups or relapses in children with IBD (RR 0.99, 95% CI 0.65 to 1.51). The certainty of the evidence is low. </p> <p>Four studies, all in adults, provided data on quality of life. Web‐based disease monitoring (n = 594) is probably equivalent to usual care (n = 505) for quality of life in adults with IBD (SMD 0.08, 95% CI −0.04 to 0.20). The certainty of the evidence is moderate. </p> <p>Based on continuous data from one study in adults, we found that web‐based disease monitoring probably leads to slightly higher medication adherence compared to usual care (MD 0.24 points, 95% CI 0.01 to 0.47). The results are of moderate certainty. Based on continuous data from one paediatric study, we found no difference between web‐based disease monitoring and usual care in terms of their effect on medication adherence (MD 0.00, 95% CI −0.63 to 0.63), although the evidence is very uncertain. When we meta‐analysed dichotomous data from two studies on adults, we found no difference between web‐based disease monitoring and usual care in terms of their effect on medication adherence (RR 0.87, 95% CI 0.62 to 1.21), although the evidence is very uncertain. </p> <p>We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on healthcare access, participant engagement, attendance rate, interactions with healthcare professionals, and cost‐ or time‐effectiveness. The certainty of the evidence is very low. </p> </section> <section id="CD014821-sec-0007"> <h3 class="title" id="CD014821-sec-0007">Authors' conclusions</h3> <p>The evidence in this review suggests that web‐based disease monitoring is probably no different to standard care in adults when considering disease activity, occurrence of flare‐ups or relapse, and quality of life. There may be no difference in these outcomes in children, but the evidence is limited. Web‐based monitoring probably increases medication adherence slightly compared to usual care. </p> <p>We are uncertain about the effects of web‐based monitoring versus usual care on our other secondary outcomes, and about the effects of the other telehealth interventions included in our review, because the evidence is limited. </p> <p>Further studies comparing web‐based disease monitoring to standard care for the clinical outcomes reported in adults are unlikely to change our conclusions, unless they have longer follow‐up or investigate under‐reported outcomes or populations. Studies with a clearer definition of web‐based monitoring would enhance applicability, enable practical dissemination and replication, and enable alignment with areas identified as important by stakeholders and people affected by IBD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014821-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014821-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014821-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014821-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014821-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014821-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD014821-abs-0012">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014821-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014821-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD014821-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014821-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014821-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014821-abs-0002" lang="en"> <h3>The use of technology for remote care in inflammatory bowel disease</h3> <p><b>Key messages</b> </p> <p>• Remote care is probably the same as usual care (e.g. face‐to‐face care in clinics and hospitals) for improving inflammatory bowel disease symptoms in adults; there is limited evidence for children.<br/>• Remote care is probably the same as usual care for avoiding relapses and flare‐ups; the same may be true for children.<br/>• Remote care is probably the same as usual care for improving quality of life in adults; there is limited evidence for children. </p> <p><b>What is inflammatory bowel disease?</b> </p> <p>Inflammatory bowel disease refers to two main conditions that cause inflammation of the gut. These are ulcerative colitis and Crohn's disease. Ulcerative colitis only affects the large intestine. Crohn's disease can affect any part of the digestive tract, from mouth to bottom. </p> <p>Inflammatory bowel disease mainly causes stomach pain or discomfort, diarrhoea that can be bloody, weight loss, and tiredness. </p> <p><b>What did we want to find out?</b> </p> <p>Providing care from a distance, also called telehealth, is becoming more common, especially since the coronavirus 2019 (COVID‐19) pandemic. Using technology to provide remote care could benefit people with inflammatory bowel disease. Telehealth can take place via telephone, instant messaging, video, text message, web‐based services, or other means. </p> <p>We wanted to find which communication technologies are used for remote care in inflammatory bowel disease, how they are used, if they are accessible to everyone, and what are their benefits or drawbacks. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled trials (RCTs; studies where participants are randomly assigned to one of two or more treatment groups) comparing telehealth with any other treatment for people with inflammatory bowel disease. RCTs give us the highest standard of evidence. </p> <p>We applied no limitations for age or type of remote care in our search, but we excluded studies that did not focus on providing care, such as studies providing only patient information or education. We also excluded studies that provided remote blood or stool test monitoring with no other type of remote monitoring. </p> <p><b>What did we find?</b> </p> <p>We found 19 relevant RCTs, which enroled a combined total of 3489 people aged eight to 95 years. Remote care was delivered online (e.g. smartphone applications, websites) or by telephone. </p> <p>Twelve studies compared web‐based care to usual care, three compared telephone‐based care to usual care, three compared web‐based care to "sham" care, one compared web‐based care to self‐care, and one compared psychological and telephone support to usual care. </p> <p>Web‐based remote care is probably no different to usual care in adults for improving symptoms, avoiding relapses or flare‐ups, and enhancing quality of life. </p> <p>We also found that people who receive web‐based care are probably less likely to skip their medicines compared to those that receive usual care. We are moderately certain about these results based on the current evidence. </p> <p>The evidence on children is limited.</p> <p>With the currently available information, we cannot make any judgements on other parameters such as access to care, whether people with inflammatory bowel disease approve of these programmes and are encouraged to attend appointments, to what degree clinical professionals are involved in them, and costs or time. </p> <p>The evidence on other forms of remote care was also very limited.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>One limitation of the evidence was that the RCTs provided unclear descriptions of the remote care programmes, which means that any organisation wishing to copy and adopt these interventions would have difficulty doing so. The descriptions of usual care (the alternative treatment group in many studies) were also unclear. This means that standard care might be different from one study to another, which could make our findings less accurate. </p> <p>Few studies looked at forms of remote care other than web‐based care.</p> <p>Another limitation is that the different studies measured different results (outcomes) of treatment. </p> <p>Finally, some studies used poor quality research methods.</p> <p><b>What next?</b> </p> <p>No further studies comparing web‐based care to usual care in adults are necessary, unless they last for longer periods of time or give more details that would help clinicians adopt them anywhere in the world. This includes details on the type and number of staff needed, resources, equipment, costs, accessibility, and data security. More studies on children may be useful, as well as studies that examine differences based on sex and social or financial status. In any case, future studies should concentrate on measuring the results that matter most to people with inflammatory bowel disease and their care providers. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is up‐to‐date as of January 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014821-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014821-sec-0140"></div> <h3 class="title" id="CD014821-sec-0141">Implications for practice</h3> <section id="CD014821-sec-0141"> <p>The evidence in this review demonstrates that web‐based disease monitoring is probably no different to standard care when considering disease activity, occurrence of flare‐ups or relapse, and quality of life in adults with inflammatory bowel disease (IBD), and it probably improves medication adherence slightly. Evidence in children is limited. </p> <p>The effects of web‐based disease monitoring versus usual care on the remaining secondary outcomes are unclear, as are the effects of the other telehealth interventions included in our review, as there are insufficient high‐quality data. </p> </section> <h3 class="title" id="CD014821-sec-0142">Implications for research</h3> <section id="CD014821-sec-0142"> <p>For the comparison web‐based monitoring versus standard care, we consider that further studies are unlikely to change the findings of this review. Several outcomes demonstrate that the intervention is no more effective than standard care. </p> <p>Longer‐term studies with outcome measures after some years could provide more relevant findings for a chronic disease such as IBD. Additionally, future studies should provide more detailed reports of the interventions to allow practical dissemination and replication. This includes details on the type and number of staff needed, resources, equipment, costs, accessibility, and data security. Further studies on children could be useful, as well as studies that examine differences in efficacy between subgroups (e.g. sex or socio‐economic status). </p> <p>There is also a need to investigate the impact of other forms of remote telehealth, including those reported in this review in small numbers. Nine ongoing studies are currently examining other remote care strategies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014821-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014821-sec-0008"></div> <div class="table" id="CD014821-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Web‐based disease monitoring compared to usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease <br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring <br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 higher<br/>(0.11 lower to 0.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 participants<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equivalent to a mean 36‐point reduction on the CDAI and a mean 1.7‐point reduction on the SCCAI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 6–12 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.09</b><br/>(0.93 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>868 participants<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000<br/>(375 to 512) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse (continuous; adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of flare‐ups was 0.19 (SD 0.42)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 more flare‐ups (0.06 fewer to 0.06 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>909 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; children)</b> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b><br/>(0.65 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>337 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/>(219 to 509) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.08 higher<br/>(0.04 lower to 0.20 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1099 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equivalent to a mean 22‐point increase on the IBDQ scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>IBDQ</b> : Inflammatory Bowel Disease Questionnaire; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SCCAI:</b> Simple Clinical Colitis Activity Index; <b>SMD:</b> standardised mean difference; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for risk of bias related to blinding.<br/><sup>b</sup> Downgraded once for risk of bias related to blinding, selective reporting, and other sources.<br/><sup>c</sup> Downgraded once for risk of bias related to blinding and imbalance in the numbers of participants reaching end of study, and once for imprecision due to low participant numbers.<br/><sup>d</sup> Downgraded once for risk of bias related to blinding and attrition. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014821-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Web‐based disease monitoring compared to sham monitoring</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to sham monitoring</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring <br/><b>Comparison:</b> sham monitoring </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham monitoring</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 6 months–2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no changes in QoL. Another study reached no conclusion.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447 participants</p> <p>(2 studies)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for serious risk of bias concerns (all domains) and twice for very serious imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014821-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Web‐based disease monitoring compared to self‐screening</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to self‐screening</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring<br/><b>Comparison:</b> self‐screening </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with self‐screening</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no differences in disease activity.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no differences in relapses.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported greater improvement in QoL in the control group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to serious risk of bias concerns (randomisation, blinding, and selective reporting), and twice for very serious imprecision (very low participant and event numbers). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014821-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Telephone‐based disease monitoring compared to face‐to‐face monitoring</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Telephone‐based disease monitoring compared to face‐to‐face monitoring </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease <br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> telephone‐based disease monitoring <br/><b>Comparison:</b> face‐to‐face monitoring </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with face‐to‐face monitoring</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with telephone‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study, whilst reporting no data on this outcome, mentioned there was no significant change. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b><br/>(0.47 to 2.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/>(134 to 586) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; children)</b> </p> <p>Follow‐up: 6 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.24</b><br/>(0.03 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/>(3 to 195) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study, whilst reporting no data on QoL, mentioned there was no significant change. Another study reported median QoL scores, which were not very different between groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 participants</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (children)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean of 106 points (SD 15.5) on the IMPACT QoL (35 lowest to 175 highest)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7 points higher<br/>(0.29 lower to 14.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for serious risk of bias concerns related to blinding and selective reporting, and twice for very serious imprecision due to very low participant numbers and events.<br/><sup>b</sup> Downgraded one for serious risk of bias concerns related to blinding, and twice for very serious imprecision due to very low participant numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014821-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Cognitive behavioural therapy manual and telephone support compared to usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy manual and telephone support compared to usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> CBT manual and telephone support<br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT manual and telephone support</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014821-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014821-sec-0009"></div> <section id="CD014821-sec-0010"> <h3 class="title" id="CD014821-sec-0010">Description of the condition</h3> <p>Inflammatory bowel disease (IBD) is an umbrella term that encompasses three main disease subtypes that affect the gastrointestinal tract: ulcerative colitis (UC), Crohn's disease (CD), and IBD unclassified. IBS prevalence exceeds 0.3% in Europe, North America, and Oceania; and incidence is rapidly rising in newly industrialised countries (<a href="./references#CD014821-bbs2-0094" title="NgSC , ShiHY , HamidiN , UnderwoodFE , TangW , BenchimolEI , et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet2017;390(10114):2769-78.">Ng 2017</a>). It has no known cure but can be managed; therefore, it places a huge financial burden on healthcare systems (<a href="./references#CD014821-bbs2-0076" title="GhoshN , PremchandP . A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterology2015;6(3):169-74.">Ghosh 2015</a>). Approximately 25% of cases are diagnosed before 18 years of age, and the main treatment modalities are pharmacological therapy, dietary therapy, and surgery. Guided management and care can improve disease activity, symptoms, clinical outcomes (e.g. need for surgery), and quality of life (QoL; <a href="./references#CD014821-bbs2-0072" title="ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(59):B4478.">Elkjaer 2012</a>). After diagnosis, intensive follow‐up and frequent consultations are required to optimise IBD care, at least for some stages of the disease course (<a href="./references#CD014821-bbs2-0066" title="BernsteinKI , PromislowS , CarrR , RawsthorneP , WalkerJR , BernsteinCN . Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflammatory Bowel Diseases2011;17(2):590-8.">Bernstein 2011</a>). </p> </section> <section id="CD014821-sec-0011"> <h3 class="title" id="CD014821-sec-0011">Description of the intervention</h3> <p>IBD telehealth management refers to the remote delivery of healthcare management from the healthcare professional to the person with IBD (<a href="./references#CD014821-bbs2-0093" title="McLeanS , ProttiD , SheikhA . Telehealthcare for long-term conditions. BMJ2011;342:d120.">McLean 2011</a>). It includes consulting by phone, instant messenger, video, text message, or web‐based services. Communication can be live, such as by telephone, or delayed, such as by email (<a href="./references#CD014821-bbs2-0092" title="McLeanS , SheikhA . Does telehealthcare offer a patient-centred way forward for the community-based management of long-term respiratory disease?Primary Care Respiratory Journal2009;18(3):125-6.">McLean 2009</a>). During a telehealth session, the person with IBD provides information about their condition and health status. The information becomes electronically available to the clinician or other healthcare professional, who uses it to provide feedback based on their professional judgement (<a href="./references#CD014821-bbs2-0093" title="McLeanS , ProttiD , SheikhA . Telehealthcare for long-term conditions. BMJ2011;342:d120.">McLean 2011</a>; <a href="./references#CD014821-bbs2-0099" title="SoodS , MbarikaV , JugooS , DookhyR , DoarnCR , PrakashN , et al. What is telemedicine? A collection of 104 peer-reviewed perspectives and theoretical underpinnings. Telemedicine and e-Health2007;13(5):573-90.">Sood 2007</a>). Telehealth can be beneficial for certain subgroups of people with IBD who might face problems accessing traditional healthcare resources that require their physical presence, such as older people, people from socio‐economically disadvantaged backgrounds, and people with physical or learning disabilities. However, these subgroups may face a separate set of barriers to accessing telehealth resources (<a href="./references#CD014821-bbs2-0067" title="ChoiNG , MartiCN , BruceML , HegelMT , WilsonNL , KunikME . Six-month postintervention depression and disability outcomes of in-home telehealth problem-solving therapy for depressed, low-income homebound older adults. Depression and Anxiety2014;31(8):653-61.">Choi 2014</a>; <a href="./references#CD014821-bbs2-0075" title="ForduceyPG , GlueckaufRL , BergquistTF , MaheuMM , YutsisM . Telehealth for persons with severe functional disabilities and their caregivers: facilitating self-care management in the home setting. Psychological Services2012;9(2):144.">Forducey 2012</a>; <a href="./references#CD014821-bbs2-0098" title="RimmerJH , WangE , PellegriniCA , LulloC , GerberBS . Telehealth weight management intervention for adults with physical disabilities: a randomized controlled trial. American Journal of Physical Medicine &amp; Rehabilitation2013;92(12):1084-94.">Rimmer 2013</a>). Telehealth is not synonymous with telemedicine, which "refers to the use of live synchronised videoconferencing, allowing for interactive video communications between a provider and a patient" (<a href="./references#CD014821-bbs2-0082" title="GroomLL , McCarthyMM , StimpfelAW , BrodyAA . Telemedicine and telehealth in nursing homes: an integrative review. Journal of the American Medical Directors Association2021;22(9):1784-801.">Groom 2021</a>). </p> </section> <section id="CD014821-sec-0012"> <h3 class="title" id="CD014821-sec-0012">How the intervention might work</h3> <p>Telehealth consultations work similarly to face‐to‐face consultations; the only difference is that any procedure that requires the patient's physical presence cannot occur (e.g. blood tests or physical examination; <a href="./references#CD014821-bbs2-0084" title="HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41.">Heida 2018</a>). Therefore, while telehealth consultations might be a useful substitute when face‐to‐face consultations are not possible or recommended, it is unknown how effective they are compared to face‐to‐face consultations. The breadth of available telehealth options also means that each option has its own advantages and disadvantages. </p> <p>Telehealth consultations may reduce potential barriers to multidisciplinary team communication across team members and organisations and achieve successful communication in real time. This could facilitate more timely data monitoring and sharing of questions and concerns voiced by the person with IBD among the entire multidisciplinary team, including the primary care professionals (<a href="./references#CD014821-bbs2-0069" title="CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory Bowel Diseases2012;18(6):1018-25.">Cross 2012</a>). </p> </section> <section id="CD014821-sec-0013"> <h3 class="title" id="CD014821-sec-0013">Why it is important to do this review</h3> <p>It is important to systematically review the evidence on the effects of remote or telehealth approaches that can be deployed for IBD care. This has become particularly relevant since the coronavirus 19 (COVID‐19) pandemic and resulting need for increased self‐management and remote management, which these interventions can facilitate (<a href="./references#CD014821-bbs2-0065" title="Al-AniAH , PrenticeRE , RentschCA , JohnsonD , ArdalanZ , HeerasingN , et al. Prevention, diagnosis and management of COVID-19 in the IBD patient. Alimentary Pharmacology &amp; Therapeutics2020;52(1):54-72.">Al‐Ani 2020</a>). It is also key to ascertain the effective components of remote or telehealth packages so that they can be replicated and disseminated. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014821-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014821-sec-0014"></div> <p>To identify the communication technologies used to achieve remote healthcare for people with inflammatory bowel disease and to assess their effectiveness. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014821-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014821-sec-0015"></div> <section id="CD014821-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014821-sec-0017"> <h4 class="title">Types of studies</h4> <p>All published, unpublished, and ongoing randomised controlled trials (RCTs) that evaluated telecommunication technologies for the management of IBD versus face‐to‐face interventions or no intervention. Cross‐over studies and cluster‐RCTs were eligible for inclusion, but quasi‐randomised trials (using inappropriate randomisation) were ineligible. </p> <p>We did not include studies on digital patient information resources (e.g. information on IBD organisation websites, such as Crohn's and Colitis UK), or education resources alone, unless they formed part of a wider package that included an element of telehealth as defined in this review. A separate Cochrane Review is focussing on education resources for people with IBD (<a href="./references#CD014821-bbs2-0079" title="GordonM , SinopoulouV , AkobengAK , LakuninaS , Gjuladin-HellonT . Patient education interventions for the management of inflammatory bowel disease. Cochrane Database of Systematic Reviews2021, Issue January. Art. No: CD013854. [DOI: 10.1002/14651858.CD013854]">Gordon 2021a</a>). </p> <p>We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring. </p> </section> <section id="CD014821-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of all ages with a confirmed IBD diagnosis. Subsets such as CD, UC, or intermediate colitis were eligible. </p> </section> <section id="CD014821-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies on IBD management interventions that took place via phone, instant messaging, video, text message, or web‐based services, or any other means of remote communication, whether live (e.g. telephone conversations) or delayed (e.g. email). </p> <p>We considered any control intervention, such as face‐to‐face interventions, no intervention. Studies that compared different telehealth interventions to each other were also eligible. </p> <p>We aimed to perform separate analyses for trials that evaluated telehealth plus traditional consultations versus traditional consultations alone and trials that evaluated telehealth versus traditional consultations. </p> </section> <section id="CD014821-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Our review included dichotomous and continuous outcome measures. Study outcomes were irrelevant for determining study eligibility. </p> <section id="CD014821-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014821-list-0001"> <li> <p>Disease activity at study end, using a recognised disease activity scoring system, measured clinically, endoscopically, or histologically, and as defined by study authors (separate for adults and children, if sufficient data available). We planned to analyse clinical, endoscopic, and histological data separately. </p> </li> <li> <p>Flare‐ups or relapses at study end, measured clinically, endoscopically, or histologically, and as defined by study authors (separate for adults and children, if sufficient data available). We planned to analyse clinical, endoscopic, and histological data separately. </p> </li> <li> <p>QoL at study end, using validated scales or tools, and as defined by study authors (separate for adults and children, if sufficient data available) </p> </li> </ul> </p> </section> <section id="CD014821-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014821-list-0002"> <li> <p>Number of episodes of accessing healthcare (outpatient, remote, or inpatient) at study end, as defined by study authors </p> </li> <li> <p>Medication adherence at study end, as defined and measured by study authors</p> </li> <li> <p>Participant engagement (adherence/compliance) with the intervention at study end, as defined by study authors </p> </li> <li> <p>Rate of attendance or engagement with any or all elements of the intervention (number of planned appointments attended, number of planned interactions attended) at study end, as defined by study authors </p> </li> <li> <p>Rate of attendance of interactions with healthcare professionals during the intervention (as part of the intervention or otherwise), as defined by study authors </p> </li> <li> <p>Costs or cost/time‐effectiveness during study, as defined by study authors</p> </li> </ul> </p> </section> <section id="CD014821-sec-0023"> <h5 class="title">Qualitative outcomes</h5> <p> <ul id="CD014821-list-0003"> <li> <p>Programme attributes (technology type, design, cost, user guidance, live contact, management of delayed contact, contact with other members of the multidisciplinary team, time to response, data security) during study </p> </li> <li> <p>Programme requirements (cost, software, infrastructure, training needs, access requirements (for the person with IBD and the healthcare provider)) during study </p> </li> </ul> </p> </section> </section> </section> <section id="CD014821-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014821-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception, applying no restrictions on the language of publication. </p> <p> <ul id="CD014821-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 1) via Ovid Evidence‐Based Medicine Reviews Database (EBMR; searched 13 January 2022; <a href="./appendices#CD014821-sec-0146">Appendix 1</a>) </p> </li> <li> <p>MEDLINE and MEDLINE ALL via Ovid (1946 to 13 January 2022; <a href="./appendices#CD014821-sec-0147">Appendix 2</a>) </p> </li> <li> <p>Embase via Ovid (1974 to 13 January 2022; <a href="./appendices#CD014821-sec-0148">Appendix 3</a>) </p> </li> <li> <p>PsycINFO via Ovid (1806 to 13 January 2022; <a href="./appendices#CD014821-sec-0149">Appendix 4</a>) </p> </li> <li> <p>CINAHL via EBSCO (1937 to 13 January 2022; <a href="./appendices#CD014821-sec-0150">Appendix 5</a>) </p> </li> <li> <p>AMED (Allied and Complementary Medicine database) via Ovid (1985 to 13 January 2022; <a href="./appendices#CD014821-sec-0151">Appendix 6</a>) </p> </li> </ul> </p> <p>We searched the following trial registries by combining terms related to IBD and telehealth.</p> <p> <ul id="CD014821-list-0005"> <li> <p>Cochrane Gut Group Specialised Register</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="./appendices#CD014821-sec-0152">Appendix 7</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP;<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; <a href="./appendices#CD014821-sec-0153">Appendix 8</a>) </p> </li> </ul> </p> </section> <section id="CD014821-sec-0026"> <h4 class="title">Searching other resources</h4> <p>As complementary search methods, we carefully checked the references of included studies and relevant systematic reviews for other potentially eligible studies. We sought unpublished trials by contacting experts in the field, and we scanned relevant conference abstracts that were identified in the search (Embase and CENTRAL) to capture any studies presented but not yet published in full. </p> <p>We attempted to obtain translations of papers when necessary.</p> </section> </section> <section id="CD014821-sec-0027"> <h3 class="title" id="CD014821-sec-0027">Data collection and analysis</h3> <p>We carried out data collection and analysis according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014821-bbs2-0086" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.1/.">Higgins 2020</a>). </p> <section id="CD014821-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts identified from the literature search, discarding studies that were clearly irrelevant. We obtained the full reports of all potentially eligible studies, and two review authors independently assessed them against our inclusion criteria. We resolved disagreements by discussion, or by consulting a third review author where necessary. We presented studies excluded at this or subsequent stages in the <a href="./references#CD014821-sec-0163" title="">Characteristics of excluded studies</a> table and recorded the main reason for exclusion. We outlined the selection process in a PRISMA flowchart (<a href="./references#CD014821-bbs2-0096" title="PageMJ , MoherD , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ2021;372(160):no pagination.">Page 2021</a>). </p> </section> <section id="CD014821-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from the included studies using piloted data extraction forms. We collected the following variables, where available. </p> <p> <ul id="CD014821-list-0006"> <li> <p>Trial setting: country and number of trial centres</p> </li> <li> <p>Trial registration details: registration number, date of registration, registered outcomes </p> </li> <li> <p>Methods: study design, total study duration, dates</p> </li> <li> <p>Participant characteristics: age, socio‐demographics, ethnicity, disease status, disease type, diagnostic criteria, total number </p> </li> <li> <p>Eligibility criteria: inclusion and exclusion criteria</p> </li> <li> <p>Intervention and comparator: type of telehealth and control intervention, people delivering the intervention, resources required to deliver the intervention, time to response, people with access to the intervention, data security </p> </li> <li> <p>Outcomes: outcome definition, unit of measurement, time of collection</p> </li> <li> <p>Results: number of participants allocated to each group, missing participants, sample size </p> </li> <li> <p>Funding source and conflicts of interest</p> </li> </ul> </p> <p>For studies requiring translation, we used online translation software or, if necessary, we sought translations by speakers of the relevant languages. </p> </section> <section id="CD014821-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>During data extraction, two review authors independently assessed all included studies for risk of bias, using the Cochrane risk of bias tool (RoB 1), as outlined in the C<i>ochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014821-bbs2-0085" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). RoB 1 includes the following risk of bias domains. </p> <p> <ul id="CD014821-list-0007"> <li> <p>Sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>We judged the studies to be at low, high, or unclear risk of bias for each domain assessed. </p> <p>After data extraction, two review authors compared the extracted data to discuss and resolve discrepancies before transferring the data to the <a href="./references#CD014821-sec-0162" title="">Characteristics of included studies</a> table in Review Manager Web (<a href="./references#CD014821-bbs2-0097" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> <p>We judged risk of bias for cluster‐RCTs as prescribed in Section 16.3.2 of the C<i>ochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014821-bbs2-0085" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD014821-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we expressed the treatment effect as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). For continuous outcomes, we expressed the treatment effect as mean differences (MDs) with 95% CIs. However, if studies assessed the same continuous outcome on a different scale, we estimated the treatment effect using the standardised mean difference (SMD). We presented SMDs as standard deviation (SD) units and interpreted them as follows: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </section> <section id="CD014821-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. For studies comparing more than two intervention groups, we made multiple pair‐wise comparisons between all possible pairs of intervention groups. To avoid double counting, we divided shared intervention groups evenly among the comparisons. For dichotomous outcomes, we divided both the number of events and the total number of participants. For continuous outcomes, we only divided the total number of participants, and left the means and SDs unchanged. </p> <p>We pooled data from cross‐over studies if they were reported separately before and after cross‐over (we only used data from before cross‐over). For cluster‐RCTs, we only used study data if the study authors had used appropriate statistical methods for taking the clustering effect into account. </p> <p>If studies reported dichotomous event data per episode instead of per participant, we contacted the study authors for further data to avoid unit of analysis issues. If studies reported outcomes at several time points, we used the longest follow‐up. </p> </section> <section id="CD014821-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to request missing data where necessary.</p> <p>For analyses of dichotomous outcomes, we used the numbers randomised as denominators and numbers of events as numerators. For analyses of continuous outcomes, we used the sample numbers as reported by the study authors for each particular continuous outcome. If the sample numbers were not reported, we estimated them based on reported attrition percentages. We attempted to estimate missing SDs using relevant statistical tools and calculators if studies reported other variance measures. </p> <p>Studies that did not report measures of variance were judged at high risk of selective reporting. </p> <p>We used the same methods in our sensitivity analyses.</p> </section> <section id="CD014821-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We scrutinised studies to ensure they were clinically homogenous in terms of participants, interventions, comparators, and outcomes. To test for statistical heterogeneity, we used a Chi² test, considering a P value below 0.1 indicative of heterogeneity. To quantify statistical heterogeneity, we used the I² statistic, interpreting the values according to the following thresholds (<a href="./references#CD014821-bbs2-0086" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.1/.">Higgins 2020</a>). </p> <p> <ul id="CD014821-list-0008"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>We examined possible explanations for heterogeneity when sufficient data were available, including factors such as participant characteristics (e.g. age, sex), condition severity, healthcare system, and country. </p> <p>Where we detected a considerable degree of statistical heterogeneity (I² value above 75%), we did not pool the data in a meta‐analysis. We also investigated possible sources of considerable statistical heterogeneity (e.g. clinical differences, risk of bias) and conducted sensitivity analyses where relevant. If we were unable to explain considerable statistical heterogeneity, we presented the results narratively. </p> </section> <section id="CD014821-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We used an inclusive search strategy in an attempt to minimise reporting biases. Had we included 10 or more studies in a meta‐analysis, we would have investigated publication bias by creating a funnel plot and visually inspecting funnel plot asymmetry, or by following other methods described in the <i>Cochrane Handbook of Systematic Reviews</i> (<a href="./references#CD014821-bbs2-0086" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.1/.">Higgins 2020</a>). We would also have tested funnel plot asymmetry by performing a linear regression of the intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate (<a href="./references#CD014821-bbs2-0071" title="EggerM , SmithGD , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>). </p> </section> <section id="CD014821-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We summarised the study characteristics narratively, then performed meta‐analyses where two or more studies assessed similar populations, interventions, and outcomes. We planned to perform separate analyses of studies on paediatric populations, adult populations, and different sub‐intervention types, using Review Manager Web (<a href="./references#CD014821-bbs2-0097" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We synthesised data using the random‐effects model. We pooled RRs for dichotomous outcomes and MDs or SMDs for continuous outcomes, alongside 95% CIs. When we were unable to carry out a meta‐analysis (e.g. due to lack of uniformity in data reporting), we presented a narrative summary of the included studies. </p> <p>We grouped qualitative outcomes by the key attributes defined in <a href="#CD014821-sec-0022">Secondary outcomes</a>, and presented them in additional tables. We also presented summary descriptive statistics (number of specific remote telehealth solutions used, mean costs, resources, etc.) to help readers ascertain the core attributes across studies. We presented these data narratively and in additional tables. </p> </section> <section id="CD014821-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where we detected heterogeneity, we investigated possible causes and addressed them using methods described in <a href="./references#CD014821-bbs2-0086" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.1/.">Higgins 2020</a>. </p> <p>For our primary outcomes, we presented our analyses separately based on age (adult/paediatric), and we undertook subgroup analyses based on disease type, which we considered the variable most likely to impact outcomes differently. </p> <p>The statistical methods described in <a href="#CD014821-sec-0036">Data synthesis</a> applied to the subgroup analyses. </p> </section> <section id="CD014821-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we planned to undertake sensitivity analyses on the primary outcomes to assess whether the findings of the review were robust to the decisions made during the review process. In particular, we intended to exclude studies at high or unclear risk of selection and performance bias. Where analyses included studies with reported and estimated SDs, we planned to exclude those with estimated SDs, to assess whether this exclusion would affect the findings of the review. We investigated whether the choice of model (fixed‐effect versus random‐effects) impacted the results, and we explored heterogeneity in case of major inconsistencies between the results of the two models. </p> </section> <section id="CD014821-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results for all comparisons in summary of findings tables. We exported data for each comparison and primary outcome to GRADEpro software to assess the certainty of the evidence (<a href="./references#CD014821-bbs2-0081" title="GRADEpro Guideline Development Tool [Software]. Version Accessed March 2021. McMaster University (developed by Evidence Prime, Inc), 2020. Available from www.gradepro.org.">GRADEpro GDT</a>). We included all three primary outcomes in the summary of findings tables. We considered that the most important outcomes for decision‐makers were those from the comparison 'web‐based disease monitoring versus usual care'. </p> <p>Based on risk of bias, inconsistency, imprecision, indirectness, and publication bias, we rated the certainty of the evidence for each outcome as high, moderate, low, or very low. The GRADE Working Group has defined these ratings as follows. </p> <p> <ul id="CD014821-list-0009"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We justified all decisions to downgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014821-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014821-sec-0040"></div> <section id="CD014821-sec-0041"> <h3 class="title">Description of studies</h3> <p>The <a href="./references#CD014821-sec-0162" title="">Characteristics of included studies</a> table, <a href="./references#CD014821-sec-0163" title="">Characteristics of excluded studies</a> table, <a href="./references#CD014821-sec-0164" title="">Characteristics of studies awaiting classification</a> table, and <a href="./references#CD014821-sec-0165" title="">Characteristics of ongoing studies</a> table provide detailed information. </p> <section id="CD014821-sec-0042"> <h4 class="title">Results of the search</h4> <p>We completed our literature search on 13 January 2022, identifying 3946 records through database searching and three additional records from alternative sources. After removal of duplicates, 2622 unique records remained. After title and abstract screening, we retrieved 132 full‐text articles; of these, 70 reports of 19 RCTs met our eligibility criteria. <a href="#CD014821-fig-0001">Figure 1</a> presents the study selection process in a PRISMA flow diagram. </p> <div class="figure" id="CD014821-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart of study retrieval and selection." data-id="CD014821-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart of study retrieval and selection.</p> </div> </div> </div> </section> <section id="CD014821-sec-0043"> <h4 class="title">Included studies</h4> <p>For details of study and participant characteristics, see <a href="#CD014821-tbl-0006">Table 1</a>. </p> <div class="table" id="CD014821-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial registration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease type<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease state (relapse/remission)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Numbers randomised </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concurrent therapies<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ethnicity<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Socio‐economic status<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Conflicts of interest</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Funding</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02319798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 36; CG: 35 </p> <p>UC/IC:<br/>IG: 8; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 44<br/>CG: 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The authors report grants from Research for Patient Benefit Programme, UK National Institute for Health Research, during the conduct of the study" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The project was funded by Research for Patient Benefit Programme, UK National Institute for Health Research (grant number PB‐PG‐0408‐16218)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02492555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 13 (26%); CG: 10 (19.2%) </p> <p>UC:<br/>IG: 35 (70%); CG: 39 (75%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission or mild‐moderate disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 50<br/>CG: 52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None:<br/>IG: 9 (18.0%); CG: 10 (19.2%) </p> <p>5‐ASA:<br/>IG: 27 (54.0%); CG: 24 (46.2%) </p> <p>Corticosteroids:<br/>IG: 4 (8.0%); CG: 4 (7.7%) </p> <p>Immunomodulators:<br/>IG: 3 (6.0%); CG: 9 (17.3%) </p> <p>Biological therapy:<br/>IG: 7 (14.0%); CG: 5 (9.6%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of education after high school:</p> <p>Short:<br/>IG: 2; CG: 4<br/>Medium:<br/>IG: 40; CG: 31<br/>Higher/academic:<br/>IG: 6; CG: 13 </p> <p>Occupation:<br/>Yes:<br/>IG: 38; CG: 42<br/>No:<br/>IG: 12; CG: 10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ankersen DV has received grants from Ferring Pharmaceuticals, Crohn Colitis patient society Denmark, North Zealand University Hospital and nonfinancial support from Calpro AS; Weimers P has received grants from Ferring lægemidler and Tillotts Pharma AG as well as nonfinancial support from Janssen‐ Cilag A/S, Calpro AS, and Vifor Pharma Nordiska AB; Marker D has received non‐financial support from Calpro AS and Pharmacosmos; Bennedsen M has received other financial support from AbbVie, Tillotts, Takeda, MSD and Pfizer; Saboori S has received non‐financial support from Janssen‐Cilag and Salofalk; Paridaens K is an employee of Ferring Pharmaceuticals; Burisch J has received grants from AbbVie, Takeda, Tillotts Pharma and personal fees from AbbVie, Janssen‐Cilag, Celgene, Samsung Bioepis, MSD, Pfizer and Takeda; Munkholm P has none to declare." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Calpro AS; CrohnColitis patient society Denmark; and North Zealand UniversityHospital and FerringPharmaceuticals." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02322307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 162<br/>CG: 158 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>82.2%<br/>Black: 5.3%<br/>Hispanic: 9.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>College education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The study is supported by the Crohn's &amp; Colitis Foundation of America (grant #253624) and the National Institutes of Health (5K23 DK97451‐02)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01860651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 8; CG 13 </p> <p>UC:<br/>IG: 19; CG: 13<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD (remission):<br/>IG: 2; CG: 5 </p> <p>CD (mild):<br/>IG: 5; CG: 6 </p> <p>CD (moderate):<br/>IG: 0; CG: 2 </p> <p>CD (severe):<br/>IG: 1; CG: 0 </p> <p>UC (remission):</p> <p>IG: 14; CG: 9</p> <p>UC (mild):<br/>IG: 5; CG: 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 27<br/>CG: 26 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethnicity is reported in the trial registration, but not in the paper.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"European Crohn’s and Colitis Organization, Queen Louise’s Hospital Foundation, TrygFoundation, CALPRO A/S, Tillotts Pharma, Capital Region Denmark, Alice and Frimodts Foundation, Ulcerative colitis and Crohn’s Danish Patient Society, and Merck Sharp and Dome." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG+CG: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00620126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed: remission and active disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 25<br/>CG: 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids:<br/>Total: 5; IG: 3; CG: 2 </p> <p>Immune suppressants:<br/>Total: 20; IG: 14; CG: 6 </p> <p>Infliximab:<br/>Total: 14; IG: 7; CG: 7<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>Total: 31; IG: 16; CG: 15 </p> <p>Other:<br/>Total: 16; IG: 9; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease knowledge:<br/>Limited:<br/>Total: 7; IG: 4; CG: 3<br/>Good:<br/>Total: 30; IG: 15; CG: 15<br/>Excellent:<br/>Total: 10; IG: 4; CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Broad Medical Research Program (BRMP‐0190), University of Maryland General Clinical Research Center Grant (M01 RR 16500), General Clinical Research Centers Program, National Center for Research Resources (NCRR), NIH, and the Baltimore Education and Research Foundation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01692743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>IG1: 79; IG2: 78; CG: 79 </p> <p>UC/IC:<br/>IG1: 36; IG2: 38; CG: 38 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed, remission (148) and active disease (200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: 115<br/>IG2: 116<br/>CG: 117 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminosalicylates:<br/>Total: 108; IG1: 29; IG2: 39; CG: 40 </p> <p>Corticosteroids:<br/>Total: 64; IG1: 17; IG2: 27; CG: 20 </p> <p>Mercaptopurine/azathioprine:<br/>Total: 111; IG1: 33; IG2: 42; CG: 36 </p> <p>Anti‐TNF:<br/>Total: 206; IG1: 66; IG2: 68; CG: 72<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>Total: 319; IG1: 108; IG2: 111; CG: 100 </p> <p>African American:<br/>Total: 24; IG1: 5; IG2: 5; CG: 14 </p> <p>Asian: <br/>Total: 1; IG1: 1; IG2: 0; CG: 0 </p> <p>Other:<br/>Total: 3; IG1: 1; IG2: 0; CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insurance status:<br/>None:<br/>Total: 14; IG1: 0; IG2: 1; CG: 13<br/>Medical assistance:<br/>Total: 6; IG1: 1; IG2: 2; CG: 3<br/>Medicare:<br/>Total: 15; IG1: 6; IG2: 1; CG: 8<br/>Commercial:<br/>Total: 198; IG1: 67; IG2: 70; CG: 61<br/>Other:<br/>Total: 64; IG1: 24; IG2: 27; CG: 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Agency for Healthcare Research and Quality (1R01HS018975‐01A1) and the University of Maryland general clinical research centers program." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02173002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> <p>Remission:<br/>IG: 394; CG: 380 </p> <p>Active:<br/>IG: 71; CG: 64 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 465<br/>CG: 444 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No medication/mesalazine:<br/>IG: 147; CG: 173 </p> <p>Immunosuppresants:<br/>IG: 131; CG: 122 </p> <p>Biologics:<br/>IG: 166; CG: 170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education:<br/>University:<br/>IG: 54; CG: 49<br/>Higher vocational education:<br/>IG: 103; CG: 98<br/>Intermediate vocational education:<br/>IG: 160; CG: 157<br/>Secondary edication:<br/>IG: 56; CG: 55<br/>Primary education:<br/>IG: 6; CG: 8<br/>Missing data:<br/>IG: 86; CG: 77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"MJdJ reports non‐financial support from Merck Sharpe &amp; Dohme, outside the submitted work. AEvdM‐dJ reports grants and non‐financial<br/>support from Takeda, personal fees from AbbVie, and non‐financial support from Tramedico, all outside the submitted work. AAvB reports<br/>personal fees from AbbVie, MSD, Ferring, Tramedico, Takeda, Pfizer, and Janssen, all outside the submitted work. GD reports speaker’s fees from Shire, AbbVie, and Takeda, and a grant for investigator‐initiated<br/>research from Takeda, all outside the submitted work. AAM reports grants from Grünenthal, Zon MW GGG (government), Will Pharma, BioActor, Pentax Europe, Falk Pharma, and Almiral Pharma, all outside the submitted work. AB received research grants to her department from<br/>AbbVie, Amgen, and Merck, and advisory board honoraria from Janssen and Sandoz, all unrelated to the current work. MJP reports personal fees from AbbVie, Ferring, Janssen, and Takeda, and grants from Falk, all outside the submitted work. All other authors declare no competing<br/>interests." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Academic incentive fund of the Maastricht University Medical Centre (31962340B)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02943538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD: IG1: 13/21; IG2: 13/21; CG: 14/21</p> <p>UC:<br/>IG1: 8/21; IG2: 8/21; CG: 7/21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission and active</p> <p>Remission:<br/>CD:<br/>IG1: 6; IG2: 9; CG: 10<br/>UC: IG1: 2; IG2: 1; CG: 2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: 21<br/>IG2: 21<br/>CG: 21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunomodulators:<br/>IG1: 10; IG2: 9; CG: 10 </p> <p>Biologics:<br/>IG1: 4; IG2: 4; CG: 4 </p> <p>Combination therapy:<br/>IG1: 5; IG2: 6; CG: 6 </p> <p>Corticosteroids:<br/>IG1: 2; IG2: 2; CG: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education:<br/>Primary education: 9/30; secondary education: 21/30; university: 29/30 </p> <p>Work Productivity and Activity Impairment:<br/>Not working:<br/>IG1: 7/21; IG2: 5/21; CG: 8/21 </p> <p>Percentage of work hours missed:<br/>IG1: median 40% (IQR 15%–62.5%); IG2: median 32.5% (IQR 7.5%–57.5%); CG: median 27.5% (IQR 0%–52%) </p> <p>Work impairment score: IG1: median 7 (IQR 3–10); IG2: median 10 (IQR: 2.25–10); CG: median 7 (IQR 2.75–10) </p> <p>Social impairment score: IG1: median 3.5 (IQR 2–7); IG2: median 6 (IQR 2.75–8); CG: median 3.5 (IQR 1–5.75) </p> <p>Satisfaction score: CG: median 49.5 (IQR 42.5–53.75); IG1: median 53 (IQR 50–59); IG2: median 52 (IQR 47.5–55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"DD is the general manager of Connected Health Services."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Grants from the Instituto de Salud Carlos III‐Fondo de Investigaciones Sanitarias (FIS PI12/00277) and cofunded by FEDER (Fondo Europeo de Desarrollo Regional)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild/moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 117<br/>CG: 116 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA systemic:<br/>Asacol: <br/>IG: 78; CG: 68<br/>Pentasa:<br/>IG: 8; CG: 7<br/>Dipentum:<br/>IG: 2; CG: 4<br/>Premid:<br/>IG: 2; CG: 2<br/>Salazopyrin:<br/>IG: 3; CG: 6<br/>Mezavant:<br/>IG: 0; CG: 0<br/>None:<br/>IG: 12; CG: 19 </p> <p>Suppositories:<br/>Asacol:<br/>IG: 3; CG: 2<br/>Pentasa:<br/>IG: 12; CG: 9<br/>Mesasal:<br/>IG: 3; CG: 1<br/>Prednisolon:<br/>IG: 1; CG: 0<br/>None:<br/>IG: 88; CG: 94 </p> <p>Enema /Foam:<br/>Asacol:<br/>IG: 4; CG: 4<br/>Pentasa:<br/>IG: 7; CG: 6<br/>Colifoam:<br/>IG: 4; CG: 4<br/>Pred‐clysma:<br/>IG: 0; CG: 0<br/>None:<br/>IG: 90; CG: 92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marital status:<br/>Married:<br/>IG: 69/105: CG: 82/106<br/>Single:<br/>IG: 36/105; CG: 24/106 </p> <p>Education:<br/>Academic:<br/>IG: 33/105; CG: 29/106 in CG<br/>Other education:<br/>IG: 55/105; CG: 64/106<br/>During education:<br/>IG: 16/105; CG: 5/106<br/>No education:<br/>IG: 1/105; CG: 8/106 </p> <p>Occupation:<br/>Paid:<br/>IG: 82/105; CG: 86/106<br/>Unpaid:<br/>IG: 1/105; CG: 4/106<br/>Support:<br/>IG: 15/105; CG: 6/106<br/>Pensioner:<br/>IG: 7/105; CG: 10/106 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PM is member of the advisory boards in Ferring, Tillots, MSD and Swedish Orphan. ME is member of the advisory board in Swedish Orphan. HS is member of the advisory board in Swedish Orphan. CO’M is on the International Advisory Board of Abbott, MSD, and Shire Pharmaceutical Company. He has unrestricted educational grants from Abbott and MSD" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Colitis Crohn Patient Organisation, Moran’s Foundation, Vibeke Binder &amp; Povl Riis’ Foundation, Bayer Health Care Funding, Augustinus Foundation, Munkholms Foundation, Tillotts Funding, Scientific Council at Herlev Hospital, Prof. Fagerhol Research Foundation, Aase &amp; Einar Danielsen Foundation, Ole Trock‐Jansen &amp; Hustrus Foundation, and European Crohn Colitis Organisation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NTR3759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 39; CG: 42<br/>UC:<br/>IG: 45; CG: 44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 84<br/>CG: 86 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunomodulators:<br/>IG: 69; CG: 65 </p> <p>Aminosalicylates:<br/>IG: 57; CG: 52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emotional quotient:<br/>Low (≤ 89):<br/>IG: 5; CG: 5<br/>Average (90–109):<br/>IG: 37; CG: 30<br/>High (≥ 110):<br/>IG: 46; CG: 51<br/>Missing:<br/>IG: 21; CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PFvR, AH and AMK received funding for joint research projects from BÜHLMANN Laboratories and CisBio Bioassays. All other authors had no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 2 years, and no other relationships or activities that could appear to have influenced the submitted work." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This work was supported by ZonMw Health Care Efficiency Research [grant number 837001001], Innovation Fund Dutch Insurance Companies [grant number B12‐204–2509], and NutsOhra Fund [grant number 1301‐002]. RKW is supported by the Netherlands Organization for Scientific Research [NWO] [grant number 016.136.308]. Reagents for the Quantum Blue® calprotectin point‐of‐care tests were an unrestricted donation by Bühlmann Laboratories AG. An unrestricted start‐up grant for the development of the web‐based programme IBD‐live was awarded by Ferring Pharmaceuticals BV." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02707068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 32<br/>CG: 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 21<br/>CG: 18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lialda:<br/>IG: 7; CG: 11 </p> <p>Apriso:<br/>IG: 1; CG: 0 </p> <p>Balsalazide:<br/>IG: 5; CG: 4 </p> <p>Sulfasalazine:<br/>IG: 1; CG: 0 </p> <p>Asacol/delzicol:<br/>IG: 0; CG: 2 </p> <p>Asacol HD:<br/>IG: 7; CG: 1 </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Employment:<br/>Student:<br/>IG: 3; CG: 5<br/>Part‐time:<br/>IG: 1; CG: 1;<br/>Full‐time:<br/>IG: 16; CG: 11<br/>Unemployed:<br/>IG: 1; CG: 1 </p> <p>Education:<br/>High school:<br/>IG: 4; CG: 0<br/>College:<br/>IG: 3; CG: 5<br/>Bachelors and above:<br/>IG: 14; CG: 13 </p> <p>Marital status:<br/>Single:<br/>IG: 9; CG: 7<br/>Significant other/married:<br/>IG: 10; CG: 11<br/>Divorced/widowed:<br/>IG: 2; CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Freddy Caldera has received research support from Takeda Pharmaceuticals and Sanofi. He has been a consultant for Takeda and Celgene. All remaining authors report no proprietary interest in the products named in this article." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This study was supported by research support from Takeda Pharmaceuticals."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>IG: 44/94; CG: 19/37 </p> <p>UC: <br/>IG: 46/94; CG: 18/37 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 94<br/>CG: 37 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids:<br/>IG: 6; CG: 3 </p> <p>Azathioprine/6 ‐ mercaptopurine:<br/>IG: 30; CG: 17 </p> <p>Methotrexate:<br/>IG: 0; CG: 1 </p> <p>Mesalazine:<br/>IG: 49; CG: 20 </p> <p>Antibiotics:<br/>IG: 0; CG: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marital status:<br/>Single:<br/>IG: 29; CG: 14<br/>Married/partner:<br/>IG: 55; CG: 20<br/>Divorced/separated: IG: 6; CG: 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACTRN12615000342516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 37; CG: 36 </p> <p>UC:<br/>IG: 13; CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 53<br/>CG: 54 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA:<br/>IG: 20; CG: 20 </p> <p>Biologics:<br/>IG: 15; CG: 18 </p> <p>Thiopurine/methotrexate:<br/>IG: 37; CG: 27 </p> <p>None:<br/>IG: 2; CG: 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This work was supported by the Healthcare Otago Charitable Trust (no grant number) and The New Zealand Society of Gastroenterology Janssen Research Fellowship (no grant number) in 2015 and the gut health network, a research theme located at the Department of Medicine, University of Otago." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT03241992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 36; CG: 36 </p> <p>UC:<br/>IG: 28; CG: 27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 64<br/>CG: 63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mesalamine:<br/>IG:19; CG: 18 </p> <p>Immunomodulators:<br/>IG: 17; CG: 25 </p> <p>Biologics:<br/>IG 39; CG 40 </p> <p>Steroids:<br/>IG: 6; CG: 9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>IG: 48; CG: 49 </p> <p>Black:<br/>IG: 8; CG: 7 </p> <p>Other:<br/>IG: 6; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This project was funded by a generous gift from Aimee &amp; Kleanthis Dendrinos and Robin &amp; Andrew Davis." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 133<br/>CG: 69 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐operative CD</p> <p>Relapse:<br/>IG: 33; CG: 39 </p> <p>Remission:<br/>IG: 87; CG: 80 </p> <p>CG: Relapse 39, Remission 80.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 120<br/>CG: 119 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The project was funded by Nursing Project of Military Medical Science and Technology Youth Cultivation Plan, No. 19QNP077." </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Numbers refer to number of participants unless otherwise specified. </p> <p>5‐ASA: 5‐aminosalicylic acid; CD: Crohn's disease; CG: control group; IBD: inflammatory bowel disease; IC: indeterminate colitis IG: intervention group; IQR: interquartile range; n: number of participants; NR: not reported; UC: ulcerative colitis. </p> </div> </div> <section id="CD014821-sec-0044"> <h5 class="title">Setting</h5> <p>Six studies were conducted in the USA (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>), one in Canada (<a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>), two in the UK (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>), three in Denmark (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>), one in China (<a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), one in Spain (<a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>), two in the Netherlands (<a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>), one in New Zealand (<a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>), and one in Czechia (<a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>). One study did not report the location (<a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>). </p> <p>All studies were conducted in hospitals and tertiary centres. Nine studies were single‐centre RCTs (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), and nine were multicentre RCTs (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). One study provided no information in this regard (<a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>). </p> <p>One study was a cluster‐RCT (<a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>). </p> </section> <section id="CD014821-sec-0045"> <h5 class="title">Participants</h5> <p>Participant age ranged from eight years (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>) to 95 years (<a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>). Three studies examined paediatric populations (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>). All other studies were in adults (aged 16 years and older). </p> <p>Three studies examined exclusively UC populations (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>), two studies examined exclusively CD populations (<a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), and the remaining studies examined a mix of IBD types. </p> <p>Six studies included people with both active and inactive states of the disease (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), six studies included people with an inactive state of the disease (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>), two studies included people with mild to moderate disease (<a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>), one study included people in remission or with low disease activity (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>), and four studies did not report on the activity of the disease (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>). </p> <p>Twelve studies reported trial registrations (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). </p> </section> <section id="CD014821-sec-0046"> <h5 class="title">Interventions</h5> <p>The studies evaluated the following interventions.</p> <p> <ul id="CD014821-list-0010"> <li> <p>Telephone consultations versus face‐to‐face consultations (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>) </p> </li> <li> <p>Mobile phone application disease monitoring versus self‐screening (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>) </p> </li> <li> <p>Mobile phone application disease monitoring versus sham education application (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>, abstract only) </p> </li> <li> <p>Web‐based disease monitoring versus usual care (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>) </p> </li> <li> <p>Telephone follow‐up visits versus clinic follow‐up visits (<a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>, abstract only) </p> </li> <li> <p>Web‐based care management portal versus usual care (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>) </p> </li> <li> <p>Web‐based care management portal weekly versus every other week versus usual care (<a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>) </p> </li> <li> <p>Web‐based care management portal versus usual care (<a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>) </p> </li> <li> <p>Remote web‐based monitoring versus telephone‐based monitoring versus usual care (<a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>) </p> </li> <li> <p>Web‐based education and self‐treatment versus usual care (<a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>) </p> </li> <li> <p>Automated email alerts and web‐based telemonitoring versus usual care (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>) </p> </li> <li> <p>Cognitive behavioural therapy (CBT) self‐complete manual and telephone support versus usual care in waitlist (<a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>, abstract only) </p> </li> <li> <p>Web‐based phone application for medication adherence versus sham application (<a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>) </p> </li> <li> <p>Web‐based application telemonitoring versus usual care (<a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>) </p> </li> <li> <p>Web‐based IBD‐specific information and electronic reminders for medication adherence versus sham web‐based information unrelated to IBD (<a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>) </p> </li> <li> <p>Decision‐aid online programme for choice of combination therapy versus usual care (<a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>, abstract only) </p> </li> <li> <p>Web‐based application disease monitoring versus usual care (<a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>, abstract only) </p> </li> <li> <p>Web‐based disease monitoring and medication adherence versus usual care (<a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>) </p> </li> </ul> </p> <p><a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> were three‐arm studies. All other studies had two arms. </p> </section> <section id="CD014821-sec-0047"> <h5 class="title">Outcomes</h5> <p>The length of the interventions ranged from eight weeks (<a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>) to three years (<a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>). </p> <section id="CD014821-sec-0048"> <h6 class="title">Primary outcomes</h6> <section id="CD014821-sec-0049"> <p><b>Disease activity</b></p> <p>Eight studies reported disease activity as an outcome. <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> measured IBD activity using a colour‐coded system based on the Harvey Bradshaw Index (HBI) for CD participants, the Simple Clinical Colitis Activity Index (SCCAI) for participants with UC/indeterminate colitis, and Total Inflammatory Burden Score (TIBS) for both populations. <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a> used the Seo Index to measure disease activity. <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> and <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> used the HBI for CD participants and the SCCAI for UC participants. <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> used the HBI for CD participants and the partial Mayo score for UC participants. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> measured disease activity using faecal calprotectin (FC) levels, but provided no details in the report. <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a> and <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> stated that disease activity was an outcome but provided no data. </p> </section> <section id="CD014821-sec-0050"> <p><b>Flare‐ups or relapse</b></p> <p>Ten studies measured flare‐ups or relapses. Seven studies reported the number of relapses in each intervention group over the study period (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> and <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> reported mean number of flare‐ups during the study as continuous data. <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> reported relapses that needed hospitalisation. </p> </section> <section id="CD014821-sec-0051"> <p><b>Quality of life</b></p> <p>Thirteen studies reported QoL (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). Four studies used the Inflammatory Bowel Disease Questionnaire (IBDQ; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). Five studies used the Short Inflammatory Bowel Disease Questionnaire (SIBDQ; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> and <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> used the IMPACT questionnaire. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> used the IBDQ‐9, the EuroQol five‐dimension questionnaire (EQ‐5D), and Visual Analogue Scales (VAS). <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> and <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>) did not report the method used to measure QoL. </p> </section> </section> <section id="CD014821-sec-0052"> <h6 class="title">Secondary outcomes</h6> <section id="CD014821-sec-0053"> <p><b>Number of episodes of accessing healthcare</b></p> <p>Nine studies reported the number of episodes of accessing healthcare (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported the number of participants in each group that had one or more hospital admissions. <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> reported total numbers of outpatient visits, on‐demand outpatient visits, acute hospitalisations, planned outpatient visits, and contacts in total. <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> reported total encounters, IBD‐related hospitalisations, non‐IBD‐related hospitalisations, non‐invasive diagnostic tests, electronic encounters, and telephone encounters (per 100 participants per year). <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> reported the mean number of hospital admissions and outpatient visits. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported the number of outpatient visits. <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> reported the number of acute and routine hospital visits per group. <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> reported face‐to‐face encounters with healthcare providers. <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> reported the mean number of visits to doctors and IBD nurses and the mean number of hospitalisations per participant. <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> reported the mean number of gastroenterologist appointments, surgical appointments, IBD hospitalisations, and nights in hospital. </p> </section> <section id="CD014821-sec-0054"> <p><b>Medication adherence</b></p> <p>Seven studies measured medication adherence (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> and <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> used self‐assessment questionnaires with the Medication Adherence Report Scale (MARS). <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>, <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>, and <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a> used the Morisky Medication Adherence Scale (MMAS). <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> used the Morisky‐Green Index. <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a> used the Medication Possession Ratio (MPR). </p> </section> <section id="CD014821-sec-0055"> <p><b>Participant engagement</b></p> <p>Eleven studies studied participant engagement (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> reported participant satisfaction. <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> reported adherence as the number of entries in their web programme by participants. <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> defined adherence as 80% or more completion of self‐assessments. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> measured adherence as compliance with more than 80% of checkups. <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> assessed compliance via a compliance questionnaire. <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> reported compliance as more than 80% response to alerts. <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> reported the percentage of participants completing at least one telephone session. <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> reported the results of two system usability scales (SUS). <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> reported non‐compliance numbers without any further details. <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a> reported the percentage of participants logging into their web application. <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a> reported feedback from participants without providing further details. </p> </section> <section id="CD014821-sec-0056"> <p><b>Rate of attendance or engagement with any or all elements of the intervention</b></p> <p>Only three studies reported attendance/engagement as number of planned appointments/interactions attended (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported the median number of consultations scheduled by the hospital and the median number of consultations attended per person. <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> reported the number of planned outpatient visits. <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> reported the number of people completing FC readings. </p> </section> <section id="CD014821-sec-0057"> <p><b>Rate of attendance of interactions with healthcare professionals</b></p> <p>Only <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>) reported rate of interactions attended. <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported the percentage of participants who had at least one consultation allocated. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported percentage of outpatient visits. </p> </section> <section id="CD014821-sec-0058"> <p><b>Costs or cost/time‐effectiveness</b></p> <p>Eight studies reported costs or cost/time‐effectiveness (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>). <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> estimated costs to the UK National Health Service (NHS). <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> estimated economic gains. <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a> reported the average parking and travel costs with an average loss of income. <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> stated mean annual direct costs and mean annual savings. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> used cost and effect data to obtain cost‐effectiveness and cost‐utility, but provided no specific details. <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> converted the number of medications plus professional visits into financial savings for the department. <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> reported mean annual cost‐saving. <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> estimated the reduction on average annual costs between the groups. </p> </section> </section> <section id="CD014821-sec-0059"> <h6 class="title">Qualitative synthesis</h6> <section id="CD014821-sec-0060"> <p><b>Type of Telehealth</b></p> <p><a href="#CD014821-tbl-0007">Table 2</a> and <a href="#CD014821-tbl-0008">Table 3</a> provide details of the contents of each intervention. </p> <div class="table" id="CD014821-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intervention details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of telehealth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of control intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention length</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Is the education part of a package of measures (e.g. diagnostic tools, etc.)?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measurement points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up measurement points</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"A call from the gastroenterology doctor at the time of their appointment. The consulting doctor contacted the patient and parents via a telephone number (home or mobile) that the parents and patient had previously supplied as the number they would like to be contacted on." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone consultations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Routine appointments in hospital as usual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 12, 18, 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"If patients experienced a recurrence of disease visualized on constant care web application (web‐app), they were instructed to contact the electronic care (eCare) personnel by phone or via the patient's personal web‐wall, for an early consultation to assess the need of individualized treatment adjustment or diagnostic investigation. Daily web ward rounds were performed by the eCare nurses in close collaboration with a medical doctor." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phone application disease monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients allocated to the CG were instructed in how to screen themselves every 3 months.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐screening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"HealthPROMISE app: Patients track their Quality Of Life and symptoms every 2 weeks, providers can use the visual data to provide better care." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phone application disease monitoring<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient education application, no further details provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient education application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 495, day 575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Electronic traffic light system, which guides the scheduling of infliximab treatment at intervals of 4 to 12 weeks. The traffic light system is based on patient‐registered symptom scores and measures of fecal calprotectin (FC), combined into a total inflammation burden score (TIBS). The repeatedly measured TIBS form a curve on a traffic light graph system consisting of the colors green, yellow, and red. Depending on the color, patients are advised regarding the timing of their next IFX treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based disease monitoring<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital's IBD care guidelines (national pediatric IBD standard<br/>care in Denmark), with outpatient visits every 3rd month, including <br/>blood samples and FC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone follow‐up visits by an IBD nurse practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone follow‐ups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic follow‐up visit by an IBD nurse practitioner</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mobile phone for participants and a decision support server and website for staff and providers. The web system send texts to participants grading their IBD symptoms and collected data from each testing session. Educational tips were also sent via text. The provider could individualise alerts and action plans for each participant. If pre‐determined criteria were met the nurse reviewed and if necessary management changes were made. Medication changes were also updated and communicated to the patient." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Comprehensive assessment, a guideline‐concordant therapy plan, scheduled and as‐needed clinic visits, scheduled and as‐needed telephone calls, administration of educational fact sheets about disease‐specific topics. Administration of educational materials was not standardised and was at the discretion of the provider."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific education provided by C&amp;C Foundation of America<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months, 12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mobile phone for participants and website for providers. The web system sends texts to participants to grade their IBD symptoms. The website provides an interface for staff and providers for participants profiles and collected data from each testing session. The provider can individualize alerts and action plans for each participant. If pre‐determined criteria were met after testing, simultaneous action plans and email alerts were sent to the participant and nurse respectively. The nurse reviewed the information and if necessary consulted the provider for management changes. Medication changes were updated in the participant profile and communicated to the participant." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The standard of care for participants in this study is modeled after the standard of care at all three study sites. Comprehensive assessment, a guideline concordant therapy plan scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease‐specific topics when appropriate."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Educational curriculum: education tips either twice weekly (IG1) or every week (IG2). Educational materials for CG administration was not standardized and was at the discretion of the treating provider."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"MyIBDcoach is a secured webpage with an HTML application for tablet or smartphone. The system includes monthly monitoring modules, as well as intensified monitoring modules, outpatient visit modules, e‐learning modules, a personal care plan, and an administrator page used by the health‐care provider. When parameters recorded by the monitoring modules exceeded predefined thresholds, the safety and continuity of care were ensured by the creation of alerts (red flags) on the administrator page of each local hospital. If an alert was received, a health‐care provider on the local team contacted the patient for further assessment within two working days. Visits to the outpatient clinic were based on the nature and severity of the clinical complaints. At any time, patients were able to communicate easily with their health‐care provider by sending a message to the health‐care providers’ administration office." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in the standard care group continued their routine follow‐up visits following the local protocol, with an opportunity to schedule an extra visit if symptoms relapsed."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: "Follow‐up and monitoring were performed telematically using the integrated platform for management of chronically ill patients (NOMHADCHRONIC app). Patients connected to the platform via the Internet using a computer or an app on a mobile phone or tablet had to self‐complete questionnaires. In addition, they received advice, reminders, educational material about their disease, and information on prevention. This information was received by the case managers and filtered using an intelligent prioritization system with generation of alerts and push notifications according to an integrated intervention protocol" </p> <p>IG2: "The G_NT patients were asked about their health through telephone calls by the nursing staff in the IBD Unit. Authors performed telephone assessment periodically by using structured interviews to evaluate health status, and clinical activity was self‐recorded at home. The interventions depended on the results of the interview and changes in the medication or follow‐up schedule established by nurses with the support of medical staff, according to the alerts and action plans designed in the intervention protocol. Furthermore, they provided these patients with all educational elements made available to the other 2 groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: remote web‐based monitoring</p> <p>IG2: nurse‐assisted telephone care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The CG patients received the normal care provided in the IBD Unit (Outpatient Clinic) for patients with moderately to highly complex IBD, based on national and European clinical guidelines. Treatment was adjusted according to the evolution of disease activity and medication adherence, which was measured using specific indexes and biological markers used to report the study outcomes during office visits or telephone calls. </p> <p>This care was complemented by ad hoc hospital care in case of flareups or if the patient’s health deteriorated for any reason. Ad hoc intensive care was maintained until the patient’s condition stabilized, at which point he or she returned to follow‐up based on standard care in the Unit." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 and 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients received a remote education session on IBD and training on the web‐based programme on how to recognise relapses and start treatment guided by the programme. </p> <p>In case of relapse, patients were requested to log on daily and complete the disease activity score (SCCAI) until they entered the green zone. Patients should then log on once a week for a total of 4 weeks after the initiation of relapse. Once remission was achieved patients had to use the program once a month until the next relapse occurred." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education and self‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in the control group continued the conventional treatment and follow‐up in the IBD out‐patient clinic." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web platform, education from staff members</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Participants received automated email alerts to fill in a symptom score and to send in a stool sample. The results of both the symptom score and the calprotectin stool test were uploaded on the IBD‐live website and cumulated in a colour‐coded disease flare risk stratification that was visible to the individual participant and the local IBD team. This resulted in an individual prediction for flare with associated treatment advice and test interval." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Automated email alerts, and web‐based telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular checks in the consultation room as before the trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Quality Of LIfe Tool for IBD (QOLITI). The cognitive‐behavioural therapy (CBT)‐inspired manual contains several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which is completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. 3 x 30 minutes of telephone support by a trained healthcare professional along with the manual were included. Telephone calls occurred at two, four and six weeks post‐randomisation." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT self‐complete manual and telephone consultations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (waitlist)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, educational manual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence iPhone application that included medication reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based phone application for medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham application installed that included educational materials and the capability of recording medication intake, without medication reminders </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients were telemonitored and connected with their doctors and IBD nurses through an IBD Assistant application. They received email reminders at regular intervals to fill in standard electronic assessments. In case of deterioration, they had an emergency questionnaire that advised on contacting a doctor. All communication with the doctor was made primarily through the IBD Assistant web application, personal visits were carried out only after a previous recommendation via the IBD Assistant application. FC was measured at least 4 times/12months with at home CalpoSmart system." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based application telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were usual check‐ups every 3 months in outpatient clinics with their gastroenterologists, during which the patients were examined clinically and laboratory. In case of any difficulties, patients had an unscheduled acute consultation, or were visited by a doctor on the basis of unfavorable examination results." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"IBDsmart is an app that allows inflammatory bowel disease (IBD) patients to regularly fill in symptom scores and get them sent to their doctor. It is used by the patients by logging in and filling out a questionnaire. When they fill out the questionnaire, a score is produced which indicates the severity of the disease. This way long term trends of symptom scores are kept on the smartphone and the healthcare team can be contacted immediately via the app in cases where disease severity is high. IBDoc is an app that allows IBD patients to measure their faecal calprotectin levels and get their results sent to their doctor. The way the app works is the participant provides a stool sample which is analysed using a medical device which produces an output that can be read via the camera by an app. The calprotectin app communicates with the IBD app which produces a faecal calprotectin score which is high, medium, or low; the level indicates how much physical disease activity is occurring in the patient. These results can also be sent to the healthcare professional team." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Usual outpatient treatment. The usual treatment group will not have access to the smartphone apps. Usual outpatient treatment, for the purposes of this study, entails the patient seeing their treating gastroenterologist as they usually would." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, 9, 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients received information via an application about IBD every 2 weeks along with reminders to take their medications. They also received a reminder about getting vaccinated for influenza and pneumococcal pneumonia at 2 weeks, and 3 months after enrollment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based IBD‐specific information and electronic reminders for medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were sent generic messages unrelated to IBD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham web‐based information unrelated to IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, educational information about IBD sent via messages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"A decision aid including an online program reviewing benefits and risks of treatment options combined with a personalised risk prediction tool for Crohn’s disease." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decision‐aid online programme for choice of combination therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard of care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, benefits and risks of treatment review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Subjects downloaded and used an application daily to record symptoms, track pain, stress levels, frequency and quality of bowel movements." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based application disease monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The control group was educated about websites providing information on IBD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of intervention (varied 8–38 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 104 days<br/>CG: 87 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Nurse‐led web‐based follow‐up program for disease monitoring, patient medication reminders, medication education and nurse‐caregiver‐patient communication" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based disease monitoring and medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The patients in the control group received regular health education and guidance on drugs by designated nurses during their in‐patient stay. They were handed a brochure with drug guidance upon discharge. The content of the brochure included basic knowledge of drugs, drug usage and effects, how to deal with common problems, and how to attend follow‐ups in outpatient clinic. Every two months, doctors followed‐up guidance by telephone." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Disease monitoring, patient reminders, patient education, nursing‐patient group chat for questions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of months 1, 2, 4, 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CG: control group; FC: faecal calprotectin; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported. </p> </div> </div> <div class="table" id="CD014821-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Telehealth details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Staff and programmes delivering the intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Resources required for the intervention and who provided them</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access issues as reported in studies (e.g. disabilities, financial issues)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Data security</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: gastroenterologist</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenterologist provided by the hospital; telephone access</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None apart from lack of access to a telephone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: eCare Nurse</p> <p>CG: eCare Nurse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone (participants' own); eCare nurses + doctors for the web rounds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone, access to the Internet (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: programme</p> <p>CG: hospital staff <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone, access to internet (participants' own). Training by principal investigator<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD nurse practitioner<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Home telemanagement/ standard care staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] for participants without an active telephone line, a cell phone is provided to transmit self‐testing results over a secure wireless network." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data transmitted from the participant's home were deidentified and encrypted.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: "Results are available immediately after self‐test completion. Clinical care issues that require immediate attention are directed to the provider's office or on call service at each site. Providers are available to study nurse coordinators daily to provide guidance for management changes. </p> <p>CG: face‐to‐face appointments"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web portal, nursing staff, doctors</p> <p>CG: doctors, nursing staff<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: mobile phone (participants' own), electronic weight scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: "If an alert was received, a health‐care provider on the local team contacted the patient for further assessment within two working days." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: website</p> <p>CG: standard hospital care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: computer/tablet/smartphone and internet access (participants' own), administration office<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: the platform, specialised medical staff and nurses</p> <p>Telephone IG: nursing staff</p> <p>CG: hospital staff<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone, mobile phone, internet access (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"TECCU Web platform protects the confidentiality of health data. The access to patient station and to work station requires a personal password only known by the patient and healthcare providers, respectively. Moreover, healthcare providers register patients in the platform with a generic name and a code only identifiable by investigators. Finally, to avoid data correlation by a nonauthorized person, data included in the Web platform are not connected to other hospital information systems. Thus, only case managers and health professionals can see all the clinical history separately."<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web platform, education from staff members</p> <p>CG: staff members (regular care)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: programme</p> <p>CG: specialists not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to telephone, internet, and email (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants required to have access to telephone, internet, and email, and good knowledge of Dutch </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: telephone calls + self‐management</p> <p>CG: self‐management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Manuals, task books, telephones and personnel, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Suicidal patients will be directly referred to liaison psychiatry or their GP and will not be able to access the study as the intensity of the manual intervention is within the low‐moderate range." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG/CG: iPhone app</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPhone, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: Web IBD Assistant App</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PC, tablet, or smartphone, and working email address (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: no smartphone/PC, language barrier, no email, no wifi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone app + gastroenterologist</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone (can be borrowed). 17/50 participants used a borrowed smartphone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: people unable to provide written consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG/CG: Electronic Health Record (EHR) patient portal (EPIC's Mychart)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer with internet (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: non‐English speaking, cognitive impairment that would impair participation, no computer with internet. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: online programme</p> <p>CG: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone app</p> <p>CG: self‐education using websites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphones (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients with Blackberry® smart phones were excluded as the app was not fully optimized for this device." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: mobile app</p> <p>CG: nurses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phones, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People "not able to use the app" were excluded from the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CG: control group; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported. </p> </div> </div> <p>Three studies compared telephone consultations to usual care (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>). Two studies compared web‐based disease monitoring programmes to usual care (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). Four studies evaluated web‐based care management programmes versus usual care (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>). Two studies evaluated web‐based monitoring together with automated email alerts versus usual care (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>). <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> investigated a mobile phone application for disease monitoring versus self‐screening. <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a> compared a mobile phone application for disease monitoring to a patient education application. <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> compared web‐based online education and self‐treatment to usual care. <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a> compared a web‐based phone application for medication adherence to a sham application (containing educational materials and capability to record medication intake). <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a> evaluated a web‐based application with IBD‐specific information and reminders for medication adherence versus a sham application. <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a> evaluated a web‐based application for disease monitoring versus websites with information regarding IBD. <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a> evaluated nurse‐led web‐based disease monitoring and medication adherence application versus usual care. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> evaluated remote web‐based monitoring versus nurse‐assisted telephone care versus usual care. </p> </section> <section id="CD014821-sec-0061"> <p><b>Other components of the intervention</b></p> <p>Seven studies reported educational components as part of the telehealth intervention (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). <a href="#CD014821-tbl-0007">Table 2</a> provides further details. Three studies measured FC as part of the diagnostic assessment (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). </p> </section> <section id="CD014821-sec-0062"> <p><b>Length of intervention, resources, access issues, data security</b></p> <p>Length of the intervention varied between eight weeks (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>) and three years (<a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>). For details, see <a href="#CD014821-tbl-0007">Table 2</a>. </p> <p>Necessary resources were a mobile phone in 16 studies (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), a computer in four studies (<a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>), and internet connection in seven studies (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> and <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> stated that they provided devices to their participants. <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a> required participants to have an electronic weight scale. <a href="#CD014821-tbl-0008">Table 3</a> provides further details. </p> <p>Not having access to a smartphone, computer, or internet was explicitly reported as an access issue in four studies (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). Three studies reported language barrier as an access issue (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a> excluded people who were unable to use the web application. <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a> excluded people with Blackberry phones. <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a> excluded those with a degree of cognitive impairment that would impair participation. <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a> excluded people who were unable to provide written consent. <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> excluded people with suicidal ideations. <a href="#CD014821-tbl-0008">Table 3</a> provides further details. </p> <p>Two studies commented on data security: <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a> mentioned that the data transmitted from participants' homes was de‐identified and encrypted, and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> mentioned confidentiality measures to secure the data provided. <a href="#CD014821-tbl-0008">Table 3</a> provides further details. </p> </section> </section> </section> <section id="CD014821-sec-0063"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>Fourteen studies reported their sources of funding (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Four studies were funded via government grants (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>), nine studies by private sources (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), and one study by a charity and non‐profit research association (<a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). </p> <p>Five studies provided no information regarding their source of funding (<a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). </p> <p>Twelve studies made conflicts of interest declarations (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). Five studies declared no conflicts of interest (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>), four studies declared that several authors received grants or non‐financial support from private providers (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>), one study reported receiving research grants during the conduct of the study (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>), and two studies declared that several authors had connections to healthcare companies unrelated to the study (<a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>) </p> <p>Seven studies provided no conflicts of interest declarations (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). </p> </section> </section> <section id="CD014821-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies (42 records; see <a href="./references#CD014821-sec-0163" title="">Characteristics of excluded studies</a>). The main reason for exclusion was wrong intervention in 14 studies (<a href="./references#CD014821-bbs2-0020" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . Home monitoring of disease activity and fecal calprotectin in adult patients with inflammatory bowel disease-interim analysis of 68 patients. United European Gastroenterology Journal2017;5(5):A287. ">Ankersen 2017</a>; <a href="./references#CD014821-bbs2-0022" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed eHealth in children and adolescents with inflammatory bowel disease. Inflammatory Bowel Diseases2017;23(9):1473-82. CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed eHealth in children and adolescents with inflammatory bowel disease. Inflammatory Bowel Diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's and Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , WewerV . Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 23 May 2013). ">Carlsen 2017b</a>; <a href="./references#CD014821-bbs2-0025" title="ElkjaerM , BurischJ , AvnstromS , LyngeE , MunkholmP . Development of a web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. European Journal of Gastroenterology &amp; Hepatology2010;22(6):695-704. ">Elkjaer 2010b</a>; <a href="./references#CD014821-bbs2-0028" title="JambaulikarGD , LeeJ , AholoukpeM , RegueiroM , SchwartzDA , GhaziLJ , et al. Internal locus of control and increased self-efficacy are associated with higher quality of life in patients with inflammatory bowel disease. Gastroenterology2015;148(4):S841. ">Jambaulikar 2015</a>; <a href="./references#CD014821-bbs2-0034" title="NCT01852097. An online intervention to address barriers to IBD medication adherence [A pilot randomised controlled trial to determine the feasibility, acceptability and effectiveness of a CBT based online intervention to address practical and perceptual barriers to medication adherence in inflammatory bowel disease]. clinicaltrials.gov/ct2/show/NCT01852097 (first received 13 May 2013). ">NCT01852097</a>; <a href="./references#CD014821-bbs2-0035" title="NCT02265588. Healthy approach to physical and psychological problems in youngsters with IBD (HAPPY-IBD). clinicaltrials.gov/ct2/show/NCT02265588 (first received 16 October 2014). ">NCT02265588</a>; <a href="./references#CD014821-bbs2-0036" title="NCT02707068. Quality Of LIfe Tool for IBD [Quality Of LIfe Tool for IBD (QOLITI): pilot testing of a self-administered intervention to target psychological distress in inflammatory bowel disease]. clinicaltrials.gov/ct2/show/NCT02707068 (first received 14 March 2016). ">NCT02707068</a>; <a href="./references#CD014821-bbs2-0037" title="NCT03486158. The CalproSmartNOR Study – a new clinical tool for monitoring patients with inflammatory bowel disease. clinicaltrials.gov/ct2/show/study/NCT03486158 (first received 3 April 2018). ">NCT03486158</a>; <a href="./references#CD014821-bbs2-0038" title="NCT03695783. The IBD&amp;me randomized controlled trial [Impact of a web-based decision aid on shared decision-making in patients with inflammatory bowel disease: the ibd&amp;me randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03695783 (first received 3 April 2018). ">NCT03695783</a>; <a href="./references#CD014821-bbs2-0041" title="OserM , SzigethyE , WallaceML , WeaverEK , CulpA , KoganJ , RegueiroMD . Randomized adaptive trial of digital behavioral program for anxiety and depression in ibd patient centered medical home. Gastroenterology2018;154(6):S-153. ">Oser 2018</a>; <a href="./references#CD014821-bbs2-0042" title="RBR-79dn4k. Effect of a program on drug use in patients with Ulcerative Colitis [Impact of an intervention program on nonadherence to drugs in ulcerative colitis patients: randomized clinical trial]. ensaiosclinicos.gov.br/rg/RBR-79dn4k (first received 1 February 2020). ">RBR‐79dn4k</a>; <a href="./references#CD014821-bbs2-0044" title="SuttonRT , WierstraK , HuangVW . Knowledge translation dataset: an e-health intervention for pregnancy in inflammatory bowel disease. Data in Brief2019;23(101654995):103647. ">Sutton 2019</a>; <a href="./references#CD014821-bbs2-0045" title="TrippDA , VerreaultP , GatesJ , RopeleskiM , BeyakM . Development and piloting of a cognitive-behavioral selfmanagement program for patients with inflammatory bowel disease: an early stage update. Gastroenterology2017;152(5):S799. ">Tripp 2017</a>; <a href="./references#CD014821-bbs2-0046" title="ZhangY , PiB , XuX , LiY , ChenX , YangN . Influence of narrative medicine-based health education combined with an online patient mutual assistance group on the health of patients with inflammatory bowel disease and arthritis. Psychology Research and Behavior Management2020;13(101514563):1-10. ">Zhang 2020</a>), wrong population in one study (<a href="./references#CD014821-bbs2-0033" title="NCT00310362. Use of telehealth in-home messaging to improve GI (gastrointestinal) endoscopy completion rates. clinicaltrials.gov/ct2/show/NCT00310362 (first received 3 April 2006). ">NCT00310362</a>), and wrong study design in 12 studies (<a href="./references#CD014821-bbs2-0021" title="CambaAH , CarrilloM , RamosL , AlonsoI , Alvarez-BuyllaNH , FernandezOA , et al. E-mail reminders and adherence rates to medical treatment in patients with inflammatory bowel disease. Journal of Crohn's and Colitis2013;7:S112. CambaAH , Carrillo-PalauM , RamosL , Alonso-AbreuI , HernandezN , AlarconO , et al. E-mail reminders and adherence rates to medical treatment in patients with inflammatory bowel disease. Gastroenterology2013;5(144):S779. ">Camba 2013</a>; <a href="./references#CD014821-bbs2-0023" title="CreedE , ClarkK . Virtual biologics clinic for IBD patients improving patient and service experience. BMJ2019;68:A234. ">Creed 2019</a>; <a href="./references#CD014821-bbs2-0024" title="Del HoyoJ , AguasM . Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2021;19(1):206-7. ">Del Hoyo 2021</a>; <a href="./references#CD014821-bbs2-0026" title="GrayWN , WagonerST , SchaeferMR , ReedB , MorganP , HolbrookE , et al. Transition to adult IBD care: a pilot multi-site, telehealth hybrid intervention. Journal of Pediatric Psychology2020;jl8:7801773. ">Gray 2020</a>; <a href="./references#CD014821-bbs2-0027" title="GreenleyR , KunzJ , GumidyalaA , NguyenE , PoulopoulosN , ThomasonM , et al. P-173 Improving oral medication adherence in adolescents with IBD: year 3 results of the PHONE trial. Inflammatory Bowel Diseases2013;19 Suppl 1:S95. GreenleyR , NguyenE , KunzJ , GumidyalaA , ThomasonM , WalterJ , et al. O-10 Improving oral medication adherence in pediatric IBD by teaching problem solving skills: year 2 results of the PHONE trial. Inflammatory Bowel Diseases2012;Suppl 1:S6. GreenleyR , NguyenE , KunzJ , GumidyalaA , ThomasonM , WalterJ , et al. P-160 Improving oral medication adherence in pediatric IBD by teaching problem solving skills: year 2 results of the PHONE trial. Inflammatory Bowel Diseases2012;18 Suppl 1:S79-80. GreenleyR , NguyenE , KunzJH , BiankV , Blank, E, MirandaA , et al. Phone intervention to improve pediatric oral medication adherence: preliminary acceptability and feasibility: P-148. Inflammatory Bowel Diseases2011;17 Suppl 2:S57. GreenleyRN , GumidyalaAP , NguyenE , PlevinskyJM , PoulopoulosN , ThomasonMM , et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflammatory Bowel Diseases2015;21(11):2649-57. NCT01237847. A brief intervention to improve adherence in teens with inflammatory bowel disease (PHONE). clinicaltrials.gov/ct2/show/NCT01237847 (first received 10 November 2010). ">Greenley 2015</a>; <a href="./references#CD014821-bbs2-0029" title="KrierM , KaltenbachT , McQuaidK , SoetiknoR . Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Official Journal of the American College of Gastroenterology2011;106(12):2063-7. KrierMJ , KaltenbachTR , McQuaidKR , SoetiknoRM . Broadening the access to specialized IBD care using a consumer grade affordable telemedicine system. Gastroenterology2010;138 Suppl 1:S473. NCT01296841. Telemedicine to provide inflammatory bowel disease outpatient care. clinicaltrials.gov/ct2/show/study/NCT01296841 (first received 16 February 2011). ">Krier 2011</a>; <a href="./references#CD014821-bbs2-0030" title="MastronardiM , CurloM , PolignanoM , VenaN , RossiD , GiannelliG . Remote monitoring empowerment of patients with IBDs during the SARS-CoV-2 pandemic. Healthcare2020;8(4):337. ">Mastronardi 2020</a>; <a href="./references#CD014821-bbs2-0031" title="MilohT , ShubM , MontesR , IngeboK , SilberG , PasternakB . Text messaging effect on adherence in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;64(6):939-42. ">Miloh 2017</a>; <a href="./references#CD014821-bbs2-0032" title="ChaudharyN , JuniorJ , TukeyM , FalchukKR , CheifetzA , MossAC . S1053 Impact of a patient support program on mesalamine adherence in patients with ulcerative colitis. Gastroenterology2009;136(5):A178. MossAC , ChaudharyN , TukeyM , JuniorJ , CuryD , FalchukKR , et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis—a prospective study. Journal of Crohn's and Colitis2010;4(2):171-5. ">Moss 2010</a>; <a href="./references#CD014821-bbs2-0039" title="NCT04151420. Real life remote monitoring of mild, moderate and severe infectious complications in ibd by patient reported assessment. clinicaltrials.gov/ct2/show/NCT04151420 (first received 5 November 2019). ">NCT04151420</a>; <a href="./references#CD014821-bbs2-0040" title="NCT04165265. The use of web-app constant-care in patients with acute severe ulcerative colitis treated with rescue therapy. clinicaltrials.gov/ct2/show/NCT04165265 (first received 15 November 2019). ">NCT04165265</a>; <a href="./references#CD014821-bbs2-0043" title="SnoeiL , vanBodegravenA , OldenburgB , StijnenT , KapteinAA . Prototype evaluation of a self-management Internet diary for patients with ulcerative colitis. Patient Preference and Adherence2009;3(101475748):179-87. ">Snoei 2009</a>). </p> </section> <section id="CD014821-sec-0065"> <h4 class="title">Studies awaiting classification</h4> <p>There are nine studies (10 records) awaiting classification (<a href="./references#CD014821-bbs2-0047" title="BonnaudG , HaennigA , AltweggR , CaronB , BoivineauL , ZallotC , et al. Real-life pilot study on the impact of the telemedicine platform EasyMICI–MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology2021;56(5):530-6. ">Bonnaud 2021</a>; <a href="./references#CD014821-bbs2-0048" title="HommelKA , GrayWN , HenteE , LoreauxK , IttenbachRF , MadduxM , et al. The Telehealth Enhancement of Adherence to Medication (TEAM) in pediatric IBD trial: design and methodology. Contemporary Clinical Trials2015;43:105-13. NCT01536509. Improving medication adherence in pediatric inflammatory bowel disease (TEAM). clinicaltrials.gov/ct2/show/NCT01536509 (first received 22 February 2012). ">Hommel 2015</a>; <a href="./references#CD014821-bbs2-0049" title="NCT02085083. Improving outcomes in the pediatric to adult care transition in inflammatory bowel disease (IMPACT-IBD). clinicaltrials.gov/ct2/show/NCT02085083 (first received 12 March 2014). ">NCT02085083</a>; <a href="./references#CD014821-bbs2-0050" title="NCT02694042. Mission is remission®: how can a disease self-management website change care?clinicaltrials.gov/ct2/show/NCT02694042 (first received 29 February 2016). ">NCT02694042</a>; <a href="./references#CD014821-bbs2-0051" title="NCT03059186. A gratitude intervention in improving well-being and coping in people living with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT03059186 (first received 23 February 2017). ">NCT03059186</a>; <a href="./references#CD014821-bbs2-0052" title="NCT03186872. Improving quality of care with a digital behavioral program in ibd patient centered medical home. clinicaltrials.gov/ct2/show/NCT03186872 (first received 14 June 2017). ">NCT03186872</a>; <a href="./references#CD014821-bbs2-0053" title="NCT04754620. Distant management of Crohn's disease by smartphones is feasible and effective additionally it reduces the costs. clinicaltrials.gov/ct2/show/NCT04754620 (first received 15 February 2021). ">NCT04754620</a>; <a href="./references#CD014821-bbs2-0054" title="NTR2892. Adherence as a lifetime effort [Promoting recall of information and treatment adherence]. www.trialregister.nl/trial/2753 (first received 11 May 2011). ">NTR2892</a>; <a href="./references#CD014821-bbs2-0055" title="NTR4648. Improving adherence in ulcerative colitis patients on 5-ASA. https://www.trialregister.nl/trial/4406 (first received 17 June 2014). ">NTR4648</a>). </p> </section> <section id="CD014821-sec-0066"> <h4 class="title">Ongoing studies</h4> <p>We identified nine ongoing studies (10 records; <a href="./references#CD014821-bbs2-0056" title="ACTRN12617000389303. Teleconsulting versus normal consulting in the care of inflammatory bowel disease in rural Southern District Health Board patients. [Establishing the role of Teleconsulting in the care of chronic conditions in rural areas of the Southern District Health Board (SDHB): A randomised controlled trial (RCT) in patients with inflammatory bowel disease]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372543&amp;isReview=true (first received 16 March 2017). ">ACTRN12617000389303</a>; <a href="./references#CD014821-bbs2-0057" title="IRCT20200613047757N1. Designing a mobile-based inflammatory bowel disease management system by using gamification techniques and determining its effectiveness on disease activity index, mental health and quality of life [Evaluation of the effectiveness of mobile-based inflammatory bowel disease management system by using gamification techniques on disease activity index, mental health and quality of life]. www.irct.ir/trial/59842 (first received 16 November 2021). ">IRCT2020061304775</a>; <a href="./references#CD014821-bbs2-0058" title="NCT03985800. Specialty medical homes to improve outcomes for patients with IBD and behavioral health conditions. clinicaltrials.gov/ct2/show/NCT03985800 (first received 14 June 2019). ">NCT03985800</a>; <a href="./references#CD014821-bbs2-0059" title="NCT04207008. Trial of a decision support intervention for adolescents and young adults with ulcerative colitis (iBDecide). clinicaltrials.gov/ct2/show/NCT04207008 (first received 20 December 2019). ">NCT04207008</a>; <a href="./references#CD014821-bbs2-0060" title="NCT04388865. Patient Automated Text Hovering for IBD (PATH-IBD). clinicaltrials.gov/ct2/show/NCT04388865 (first received 14 May 2020). ">NCT04388865</a>; <a href="./references#CD014821-bbs2-0061" title="NCT04653259. Digital nutrition therapy for patients with IBD (LYFEMD). clinicaltrials.gov/ct2/show/NCT04653259 (first received 4 December 2020). ">NCT04653259</a>; <a href="./references#CD014821-bbs2-0062" title="NCT04861597. Digital behavioral interventions in inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT04861597 (first received 27 April 2021). ">NCT04861597</a>; <a href="./references#CD014821-bbs2-0063" title="ISRCTN71618461. A supported online self-management for symptoms of fatigue, pain and urgency/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial [A randomised controlled trial of supported online self-management for symptoms of fatigue, pain and urgency/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial]. www.isrctn.com/ISRCTN71618461 (first received 2 September 2019). NortonC , SyredJ , KerryS , ArtomM , SweeneyL , HartA , et al. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. Trials2021;22(1):1-18. ">Norton 2021</a>; <a href="./references#CD014821-bbs2-0064" title="RBR-7t8fv7. Clinical trial of the effectiveness of telephone nursing care to individuals with inflammatory bowel disease. ensaiosclinicos.gov.br/rg/RBR-7t8fv7 (first received 25 July 2016). ">RBR‐7t8fv7</a>). </p> </section> </section> <section id="CD014821-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>For a graphical presentation of the results of our risk of bias assessment, see <a href="#CD014821-fig-0002">Figure 2</a> and <a href="#CD014821-fig-0003">Figure 3</a>. Further details can be found in the risk of bias tables (in the <a href="./references#CD014821-sec-0162" title="">Characteristics of included studies</a> table). </p> <div class="figure" id="CD014821-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014821-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014821-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014821-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014821-sec-0068"> <h4 class="title">Allocation</h4> <p>Ten studies clearly described random sequence generation and allocation concealment, so we judged them at low risk of selection bias in both domains (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a><a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Seven studies provided insufficient information on random sequence generation and allocation concealment, so we judged them at unclear risk of selection bias (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). We considered <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> at unclear risk in relation to random sequence generation and low risk for allocation concealment (overall unclear risk of selection bias), and we judged <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> at low risk regarding random sequence generation and unclear risk for allocation concealment (overall low risk of selection bias). </p> </section> <section id="CD014821-sec-0069"> <h4 class="title">Blinding</h4> <p>Due to the nature of the interventions, 15 studies could not blind participants and personnel and so were at high risk of performance bias (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Only <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a> was at low risk of performance bias, and we judged three studies at unclear risk (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). </p> <p>We considered three studies at low risk of detection bias as they mentioned or confirmed blinding of outcomes assessors (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>). Seven studies provided insufficient information for judgement (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>), and nine studies were at high risk because they confirmed or stated that assessors were unblinded (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). </p> </section> <section id="CD014821-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We considered eleven studies at low risk of attrition bias because they provided sufficient information to make a judgement (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). The remaining seven studies were at unclear risk as they provided insufficient information to make a clear judgement (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). We rated one study at high risk of attrition bias (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>). </p> </section> <section id="CD014821-sec-0071"> <h4 class="title">Selective reporting</h4> <p>We judged eight studies at low risk of reporting bias, as they reported all outcomes set out in their trial registrations (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). We considered one study at high risk, as the prioritisation of outcomes differed between the protocol and the published manuscript (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>). The remaining studies provided insufficient information for judgement (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). </p> </section> <section id="CD014821-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>We rated fifteen studies at low risk of other potential sources of bias (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Four studies provided insufficient information for judgement (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). </p> </section> </section> <section id="CD014821-sec-0073"> <h3 class="title" id="CD014821-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD014821-tbl-0001"><b>Summary of findings 1</b> Web‐based disease monitoring compared to usual care</a>; <a href="./full#CD014821-tbl-0002"><b>Summary of findings 2</b> Web‐based disease monitoring compared to sham monitoring</a>; <a href="./full#CD014821-tbl-0003"><b>Summary of findings 3</b> Web‐based disease monitoring compared to self‐screening</a>; <a href="./full#CD014821-tbl-0004"><b>Summary of findings 4</b> Telephone‐based disease monitoring compared to face‐to‐face monitoring</a>; <a href="./full#CD014821-tbl-0005"><b>Summary of findings 5</b> Cognitive behavioural therapy manual and telephone support compared to usual care</a> </p> <section id="CD014821-sec-0074"> <h4 class="title">1. Web‐based disease monitoring versus usual care</h4> <p>Twelve studies evaluated web‐based disease monitoring versus usual care (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0017" title="SiegelCA , ThompsonKD , SiegelLS , MacKenzieT , DubinskyM . Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S076-7. ">Siegel 2018</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Two of these studies were in paediatric populations (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>). </p> <section id="CD014821-sec-0075"> <h5 class="title">Primary outcomes</h5> <p><a href="./full#CD014821-tbl-0001">summary of findings Table 1</a> presents the effect measures (where calculated) and GRADE judgements for the primary outcomes. </p> <section id="CD014821-sec-0076"> <h6 class="title">Disease activity</h6> <p>Five studies reported disease activity (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>).  </p> <p>Three studies provided data that we could use for meta‐analysis (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). All three studies enrolled only adults. Web‐based disease monitoring (n = 254) is probably equivalent to usual care (n = 174) in reducing disease activity in adults with IBD (SMD 0.09, 95% CI −0.11 to 0.29; <a href="./references#CD014821-fig-0004" title="">Analysis 1.1</a>). The certainty of the evidence is moderate, downgraded for risk of bias mainly due to lack of blinding. Subgroup comparison showed similar disease activity in the UC and CD groups. A fixed‐effect sensitivity analysis showed no difference in the results (<a href="./references#CD014821-fig-0005" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> and <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> did not provide suitable data for meta‐analysis. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> measured disease activity only by proxy (FC levels) and reported no variance measure. At 24 weeks, the median FC level for clinical activity was 137 μg/g in the web‐based group and 230 μg/g in the control. <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a> reported HBI mean scores of 3.48 in the web‐based group and 2.71 in the control, and Partial Mayo mean scores of 2.71 in the web‐based group and 2.57 in the control. We were unable to draw any conclusions from these results. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and for risk of bias concerns (lack of blinding, selective reporting, and other bias). </p> </section> <section id="CD014821-sec-0077"> <h6 class="title">Flare‐ups or relapse</h6> <p>Seven studies reported flare‐ups or relapse with suitable data for meta‐analysis (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). Six studies enrolled adults (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>), and one study enrolled children (<a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>). </p> <p>Web‐based disease monitoring (n = 207/496) is probably equivalent to usual care (n = 150/372) for the occurrence of flare‐ups or relapses in adults with IBD (RR 1.09, 95% CI 0.93 to 1.27; 5 studies; <a href="./references#CD014821-fig-0006" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence to moderate for risk of bias (lack of blinding, reporting bias, and other bias). Subgroup comparison showed no major differences between the mixed IBD, UC, and CD groups. A fixed‐effect sensitivity analysis showed no difference in the results (<a href="./references#CD014821-fig-0007" title="">Analysis 1.4</a>). </p> <p><a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> provided continuous data for flare‐ups or relapses. Web‐based disease monitoring (n = 465) is probably equivalent to usual care (n = 444) for the occurrence of flare‐ups or relapses in adults with CD (MD 0.00 events, 95% CI −0.06 to 0.06; <a href="./references#CD014821-fig-0008" title="">Analysis 1.5</a>). We downgraded the certainty of the evidence to moderate for lack of blinding.  </p> <p><a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> evaluated a paediatric population of mixed CD and UC patients. Web‐based disease monitoring (n = 28/84) may be equivalent to usual care (n = 29/86) for the occurrence of flare‐ups or relapses in children with IBD (RR 0.99, 95% CI 0.65 to 1.51; <a href="./references#CD014821-fig-0009" title="">Analysis 1.6</a>). We downgraded the certainty of the evidence to low for imprecision (low participant numbers) and risk of bias concerns (lack of blinding and imbalance in number of participants reaching end of study between the two groups).  </p> <p><a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> <div class="table" id="CD014821-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Primary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1a. Disease activity at study end</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1b. Flare‐ups/relapses measured clinically/endoscopically/histologically (n, unless otherwise specified)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1c. Quality of life</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease relapses over 24 months<br/>IG: 1/44<br/>CG: 4/42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median IMPACT QoL at 12 months:<br/>IG (n = 36): median 113 points (IQR 105–125); calculated SD 14.8<br/>CG (n = 31): median 106 points (IQR 95–116); calculated SD 15.5 </p> <p>Mean IMPACT QoL:<br/>IG: mean 108.2 points (95% CI 101.6–114.7)<br/>CG: mean 102.5 points (95% CI 96.5–108.4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Two assessors classified disease activity as (1) Chronic continuous course, red throughout 1 year; (2) Chronic continuous course, yellow throughout 1 year; (3) Chronic continuous course, red and yellow throughout1 year; (4) Continuous remission course, green throughout 1 year; (5) Intermittent course; green, yellow and red throughout 1 year; and (6) Intermittent course; green with a single relapse (yellow or red) throughout 1 year." </p> <p>Mean % over 1 year:</p> <p>SCCAI scores:<br/>IG (n = 37) green/yellow/red: 82%/15%/3%<br/>CG (n = 35) green/yellow/red: 87%/10%/3% </p> <p>HBI scores:<br/>IG (n = 6) green/yellow/red: 72%/28%/0%<br/>CG (n = 9) green/yellow/red: 66%/34%/0% </p> <p>TIBS scores:<br/>IG (n = 43) green/yellow/red: 60%/26%/14%<br/>CG (n = 39)<br/>green/yellow/red: 61%/22%/16% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors stated they "analysed the number of relapses (FC and SCCAI) in each intervention group based on 83 (99%) and 70 (97%) patients respectively"; however, the numbers randomised were 50 and 52. </p> <p>"Moderate" and "Severe" relapses combined:<br/>IG (FC): 22<br/>CG (FC): 17<br/>IG (SCCAI): 14<br/>CG (SCCAI): 9 </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short IBDQ change in QoL:<br/>IG: mean 0.56 points (SD 6.78)<br/>CG: mean 4.04 points (SD 9.24) </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: SIBDQ QoL at 575 days mean 25.2 points (SD 11.3)<br/>CG: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated as an outcome but no data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated as an outcome but no data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not provide data, but commented there was no significant change.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not provide data, but commented there was no significant change.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seo index scores:<br/>IG: mean 122 points (SD 39.3)<br/>CG: mean 113.6 points (SD 28) </p> <p>Remission rates at 12 months: <br/>IG: n = 19/25 (77%)<br/>CG: n = 16/22 (76%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapses at 12 months:<br/>IG: 6 <br/>CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ:<br/>IG: mean 178.1 points (unspecified variance measure 32.1)<br/>CG: mean 187.3 points (unspecified variance measure 32.2) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI:<br/>CG: mean 3.7 points (SD 3.6)<br/>IG1: mean 4.2 points (SD 3.9)<br/>IG2: mean 3.2 points (SD 3.4) </p> <p>SCCAI:<br/>CG: mean 1.4 points (SD 1.4)<br/>IG1: mean 1.7 points (SD 1.9)<br/>IG2: mean 2.0 points (SD 1.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>CG: 29/79 (36.5%) <br/>IG1: 31/79 (39.1%) <br/>IG2: 23/78 (29.6%) </p> <p>UC/IC:<br/>CG: 7/36 (18.5%) <br/>IG1: 8/36 (21.7%) <br/>IG2: 13/38 (33.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ at study end:<br/>CG: mean 179.3 points (unspecified variance measure 28.2)<br/>IG1: mean 181.5 points (unspecified variance measure 28.2)<br/>IG2: mean 179.2 points (unspecified variance measure 32.8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of flares during the 12 months of follow‐up:<br/>"Flares were defined as clinical symptoms indicative of disease activity with, as a rule, concomitant calprotectin of more than 250 μg/g in the stool or active disease determined by endoscopy, MRI, or CT. In daily practice, in case of clinically severe symptoms suggestive for disease activity, the treating physician occasionally judged these symptoms to be evident enough to adjust therapy. Therefore, to capture all clinical flares, clinical episodes were defined as flares if symptoms suggestive of disease activity resulted in a dose escalation or initiation of a new drug to induce remission." </p> <p>IG: mean 0.19 events (unspecified variance measure 0.42)<br/>CG: mean 0.19 events (unspecified variance measure 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIBDQ at study end:<br/>IG mean 54.44 points (unspecified variance measure 9.05)<br/>CG: mean 53.71 points (unspecified variance measure 9.87) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured only by proxy (FC levels) and no variance given:</p> <p>"At 24 weeks, the median FC level for clinical activity improved progressively from a baseline value of 490 μg/g to 137 μg/g in IG2(teccu) and from 526 μg/g to 115.5 μg/g in IG1(tele); however, this reduction was smaller in CG, from 330 μg/g to 230 μg/g." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive disease after 24 weeks<br/>IG1: 14/21 (66.7%) → 7 relapses<br/>IG2: 17/21 (81%) → 4 relapses<br/>CG: 15/21 (71.4%) → 6 relapses </p> <p>"Remission was evaluated using the modified HBI for patients with CD. For patients with UC, we used the SCCAI (also known as the Walmsley index) for remote checkups together with the partial Mayo score for face‐to‐face visits. For remote checkups in patients with UC, clinical remission was defined as a Walmsley score ≤ 2,whereas mild‐to‐moderate and severe activities were defined as scores of 3‐5 and &gt;5, respectively. Patients with CD and an HBI &lt; 5 were considered to be in clinical remission, whereas patients with scores of 5‐7, 8‐16, or &gt;16 were considered to have mild, moderate, or severe activity, respectively. In the face‐to‐face visits, clinical remission was defined as a partial Mayo score ≤2 and no individual Mayo sub‐score &gt; 1; scores of 2‐5, 6‐8, and were defined as mild, moderate, and severe disease activity, respectively" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured with the IBDQ‐9 and the EQ‐5D. VAS were also used.</p> <p>Median IBDQ‐9 at end:<br/>IG1: 53 points <br/>IG2: 52.5 points <br/>CG: 53 points  </p> <p>Median EQ‐5D at end:<br/>IG1: 1 point<br/>IG2: 1 point<br/>CG: 1 point </p> <p>Median VAS values at study end:<br/>NR </p> <p>Figure 6 possibly presents variance but unclear if SDs or something else.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI score &gt; 5 used to define a relapse.</p> <p>Total relapses:<br/>IG: 93/169<br/>CG: 87/164 </p> <p>Denmark:<br/>IG: 60/105 (51%) + 12 (randomised but did not participate) = 72/117<br/>CG: 60/106 (52%) + 10 (randomised but did not participate) = 70/116<br/>Mean relapses:<br/>IG: mean 1.1 events (range 0–6)<br/>CG: mean 0.8 events (range 0–4) </p> <p>Ireland:<br/>IG: 20/51 (39%) + 1 (randomised but did not participate) = 21/52<br/>CG: 10/41 (24%) + 7 (randomised but did not participate) = 17/48<br/>Mean relapses:<br/>IG: mean 0.6 events (range 0–4)<br/>CG: 0.2 events (range 0–1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Disease specific QoL was improved in the web‐group, as well as general health, vitality, role emotional, and social functioning, compared to control group"<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Disease flares – disease activity requiring therapy intensification (steroid therapy, exclusive enteral nutrition, aminosalicylate dose escalation, or introduction of anti‐TNF antibodies)" </p> <p>Flare‐ups during 52 weeks:<br/>IG: 28/84<br/>CG: 29/86 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐specific IMPACT‐III scores</p> <p>Mean change in QoL:<br/>IG: 1.32 points<br/>CG: −0.32 points<br/>No variance provided. </p> <p>IG: 54% reported a positive change.</p> <p>CG: 44% reported a positive change.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI mean score at end of study (no variance provided):<br/>IG: 3.48 points<br/>CG: 2.71 points </p> <p>Partial Mayo mean scores at end of study (no variance provided):<br/>IG: 2.71 points<br/>CG: 2.57 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR, study only reported the relapses that required hospitalisation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI:<br/>3 months<br/>IG: mean 1.6 points (SD 1.7)<br/>CG: mean 0.5 points (SD 0.7)<br/>6 months<br/>IG: mean 2.5 points (SD 2.2)<br/>CG: mean 1.9 points (SD 2.0)<br/>9 months<br/>IG: mean 3.4 points (SD 2.7)<br/>CG: mean 2.6 points (SD 4.8) <br/>12 months<br/>IG: mean 1.5 points (SD 1.1)<br/>CG: mean 1.7 points (SD 1.9) </p> <p>HBI:<br/>3 months<br/>IG: mean 4.3 points (SD 3.5)<br/>CG: mean 3.6 points (SD 2.3)<br/>6 months: <br/>IG: mean 4.2 points (SD 3.8)<br/>CG: mean 2.5 points (SD 3.1)<br/>9 months: <br/>IG: mean 3.9 points (SD 4.0)<br/>CG: mean 1.8 points (SD 1.9)<br/>12 months: <br/>IG: mean 2.4 points (SD 3.4)<br/>CG: mean 2.0 points (SD 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC flare‐ups (months 3–12)<br/>IG: 9/13 (70%)<br/>CG: 6.14 (42.7%) </p> <p>CD flare‐ups (months 3–12)<br/>IG: 17/37 (47.2%)<br/>CG: 9/36 (25.7%) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ (CD)<br/>3 months<br/>IG: mean 173.9 points (SD 30.0)<br/>CG: mean 160.1 points (SD 35.1)<br/>6 months<br/>IG: mean 177.5 points (SD 27.9)<br/>CG: mean 163.1 points (SD 36.7)<br/>9 months<br/>IG: mean 178.9 points (SD 27.8)<br/>CG: mean 159.0 points (SD 31.4)<br/>12 months<br/>IG: mean 178.0 points (SD 20.6)<br/>CG: mean 167.3 points (SD 32.6) </p> <p>IBDQ (UC)<br/>3 months<br/>IG: mean 184.6 points (SD 21.7)<br/>CG: mean 186.6 points (SD 21.0)<br/>6 months<br/>IG: mean 188.0 points (SD 28.6)<br/>CG: mean 175.5 points (SD 31.8)<br/>9 months<br/>IG: mean 181.6 points (SD 30.4)<br/>CG: mean 181.9 points (SD 27.7)<br/>12 months<br/>IG: mean 189.5 points (SD 24.5)<br/>CG: mean 179.6 points (SD 24.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median SIBDQ at 6 months (no variance provided):<br/>IG: 58 points<br/>CG: 57.5 points </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ at study end:<br/>IG: mean 172.9 points (unspecified variance measure 26.8)<br/>CG: mean 169.3 points (unspecified variance measure 29.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CD: Crohn's disease; CG: control group; CT: computerised tomography; EQ‐5D: EuroQol five‐dimension questionnaire; FC: faecal calprotectin; HBI: Harvey‐Bradshaw Index; IBD: inflammatory bowel disease; IBDQ: Inflammatory Bowel Disease Questionnaire; IG: intervention group; IQR: interquartile range; MRI: magnetic resonance imaging; n: number of participants; NR: not reported; QoL: quality of life; SCCAI: Simple Colitis Clinical Activity Index; SD: standard deviation; SIBDQ: Short Inflammatory Bowel Disease Questionnaire TIBS: total inflammation burden scoring; TNF: tumour necrosis factor; UC: ulcerative colitis; VAS: visual analogue scale. </p> </div> </div> </section> <section id="CD014821-sec-0078"> <h6 class="title">Quality of life</h6> <p>Eight studies measured QoL (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>). </p> <p>Four studies on adults provided data that we could use for a meta‐analysis (<a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>). Web‐based disease monitoring (n = 594) is probably equivalent to usual care (n = 505) for QoL in adults with IBD (SMD 0.08, 95% CI −0.04 to 0.20; <a href="./references#CD014821-fig-0010" title="">Analysis 1.7</a>). We downgraded the certainty of the evidence by one level to moderate for risk of bias concerns (lack of blinding and attrition). Subgroup comparison showed no major differences between mixed IBD, UC, and CD. </p> <p>A fixed‐effect sensitivity analysis showed no difference in the results (<a href="./references#CD014821-fig-0011" title="">Analysis 1.8</a>). </p> <p><a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a> reported an IBDQ mean of 172.9 (undefined measure of variance 26.8) for the web‐based group and 165.9 (undefined measure of variance 24.7) for the control group. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported an IBDQ‐9 mean of 53 and EQ‐5D mean of 1 for the web‐based group, and an IBDQ‐9 mean of 53 and EQ‐5D mean of 1 for the control group, without measures of variance. <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a> provided only commentary on the results of the outcome ("Disease specific QoL was improved in the web‐group, as well as general health, vitality, role emotional, and social functioning, compared to control group"). <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a> provided mean IMPACT changes of 1.32 for the web‐based group and −0.32 for the control group, without a measure of variance. The study authors also commented that 54% of participants in the web‐based group and 44% in the control group reported positive changes. We were unable to reach any conclusions based on these data. We downgraded the certainty of the evidence for all of the above findings to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). </p> <p><a href="#CD014821-tbl-0009">Table 4</a> provides more details. </p> </section> </section> <section id="CD014821-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD014821-sec-0080"> <h6 class="title">Number of episodes of accessing healthcare</h6> <p>Eight studies reported number of episodes of accessing healthcare (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>); however, no meta‐analysis was possible owing to substantial differences between studies in the types of healthcare access reported, methodology, and reporting of the data. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on healthcare access. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> <div class="table" id="CD014821-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Secondary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2a. Number of episodes of accessing healthcare (outpatient/remote/inpatient)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2b. Medication adherence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2c. Participant engagement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2d. Rate of attendance/engagement (number of planned appointments/interactions attended)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2e. Rate of attendance of interactions with professionals</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2f. Costs or cost/time‐effectiveness (as judged by study authors)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with ≥ 1 hospital admissions due to IBD:<br/>IG: 1/44<br/>CG: 1/42 </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of consultations scheduled by the hospital for each participant that were not then cancelled by the hospital:<br/>IG: median 4.5 (IQR 3–5.3); imputed SD 1.7<br/>CG: median 5 (IQR 3–6); imputed SD 2.2 </p> <p>Number of consultations attended per participant:<br/>IG: median 4 (IQR 3–4); imputed SD 0.74<br/>CG: median 3 (IQR 2–4); imputed SD 1.48 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with ≥ 1 consultation, as allocated before the 12‐ month follow‐up:<br/>IG: 36 (82%)<br/>CG: 40 (95%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs to the NHS:</p> <p>"Estimates of NHS costs for the intervention (including staff costs and telephone costs) showed that telephone consultation had a mean cost of UK £35.41 per patient consultation compared with £51.12 for face–face consultation, difference £15.71" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication was measured by a self‐assessment questionnaire (MARS)</p> <p>MARS score:<br/>IG: median 23.57 points (IQR 21.50–24.25); calculated SD 2.03<br/>CG: median 24.17 points (IQR 23.50–24.80); calculated SD 0.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The 88 patients that completed the study were asked seven questions at follow‐up. There was no statistical difference between the two intervention groups on any of the seven yes/no questions assessing patient satisfaction." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits:<br/>IG: total 85; median 2 (IQR 2–3) </p> <p>CG: total 185; median 8 (IQR 4‐9)</p> <p>On‐demand outpatient visits:<br/>IG: total 47; median (IQR 0–3); </p> <p>CG: total 39; median 1 (IQR 0–2)</p> <p>Acute/hospitalisations:<br/>IG: total 3; median 0 (IQR 0–0); </p> <p>CG: total 10; median 0 (IQR 0–1)</p> <p>Planned outpatient visits:<br/>IG: total 38; median 2 (IQR 1–2); </p> <p>CG: total 146; median 7 (IQR 3–7)</p> <p>Contacts in total:<br/>IG: total 88; median 2 (IQR 2–4); </p> <p>CG: total 195; median 8.5 (IQR 4–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean MARS scores (from trial registration):<br/>IG: mean 23.3 points (95% CI 22.9–23.6); calculated SD 0.88<br/>CG: mean 23.3 points (95% CI 22.9–23.7); calculated SD 0.97<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The adherence to the web program was 81% (384/475 expected entries)."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Planned outpatient visits:<br/>IG: total 38; median 2 (IQR 1–2) <br/>CG: total 146; median 7 (IQR 3–7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"From a socioeconomic perspective, the reduced school absence and fewer outpatient visits in the web group represent an economic gain, as parents do not require leave from work, and it saves the time and expense of travel to/from our hospital." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The average parking and travel costs for patients randomised to intervention were CAN $25.83, and their average loss of income was CAN $17.00. The median duration of healthcare contact was longer in the intervention group (52 minutes [IQR 38–81] vs 17 minutes [IQR 15.0–21.2]), with wait time was longer in intervention (median 31.6 minutes [IQR 8–56] vs 0 minutes" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on the MMAS.</p> <p>For the purpose of evaluating percent of participants adherent to therapy, the variable was dichotomised to "adherent" or "non‐adherent." Any response of yes to one of the 4 items was scored as "non‐adherent." </p> <p>IG: 14/25 (57%)<br/>CG: 14/22 (67%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extracted from the electronic medical records during 1 year before and after randomization. Post‐randomisation numbers reported as rates adjusted for 100 participants per year (hospitalisations, surgery, emergency department and office visits, procedures, intravenous therapeutics, and telephone and electronic encounters). Unclear if these are only for the randomised participants. </p> <p>CG: 2099<br/>IG1: 2235<br/>IG2: 1935 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Adherence was defined as the completion of 80% (278/348) or more of the weekly or every other week self‐assessments." </p> <p>No data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of hospital admissions, unique participants:<br/>IG: 16<br/>CG: 29  </p> <p>Mean outpatient visits:<br/>IG: gastroenterologist: mean 1.26 (SD 1.18); nurse: mean 0.29 (0.68); total: mean 1.55 (SD 1.50)<br/>CG: gastroenterologist: mean 1.98 (SD 1.19); nurse: mean 0.36 (0.84); total: mean 2.34 (SD 1.64) </p> <p>Mean telephone consultations:<br/>IG: gastroenterologist: mean 0.58 (SD 0.98); nurse: mean 0.7 (SD 1.59); total: mean 1.28 (SD 2.06)<br/>CG: gastroenterologist: mean 0.84 (SD 1.11): nurse: mean 0.74 (SD 1.9); total: mean 1.57 (SD 2.44) </p> <p>The number of outpatient visits and telephone consultations with gastroenterologists and nurses during the 12‐month period were retrieved from participants’ electronic medical records. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean MMAS score: <br/>IG: mean 7.01 points (SD 1.40)<br/>CG: mean 6.77 points (SD 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calculated mean annual direct costs, per participant:<br/>IG: EUR 7048<br/>CG EUR 7423 </p> <p>Calculated mean indirect costs, per participant:<br/>IG: EUR 1886<br/>CG: EUR 2058 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits:<br/>IG1 85 (29.5%)<br/>IG2 72 (25%)<br/>CG 131 (45.5%) </p> <p>Telephone calls:<br/>IG1 118 (66.7%)<br/>IG2 12 (6.8%)<br/>CG 47 (26.5%) </p> <p>Study authors recorded the number of outpatient visits and telephone consultations for all 3 groups during the study. As these numbers were per participant, we could not use them for meta‐analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medication adherence according to Morisky‐Green index:<br/>IG1 33.3% (7/21)<br/>IG2 57.1% (12/21) <br/>CG 66.7% (14/21) CG </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants who adhered to &gt; 80% of checkups (considered compliant):<br/>IG1 20 (95.2%)<br/>IG2 18 (85.7%)<br/>CG 19 (90.5%)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There is a high probability that the use of the TECCU Web‐platform produces a greater improvement in disease activity at a lower societal cost." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute visits:<br/>IG: 21<br/>CG: 107 </p> <p>Routine visits:<br/>IG: 35<br/>CG: 92 </p> <p>Emails/phone calls:<br/>IG: 86/21<br/>CG 7/17  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance:<br/>IG: 73%<br/>CG: 42%<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study authors converted the numbers of medications and professional visits into financial savings for department and found it cost‐effective.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean face‐to‐face encounters with health providers:<br/>IG: 3.6<br/>CG: 4.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance with study protocol (&gt; 80% response to alerts):<br/>IG: 48<br/>CG: 72 </p> <p>Did not respond to any emails:<br/>IG: 10<br/>CG: NR </p> <p>Insufficient compliance (&lt; 80% response to alerts):<br/>IG: 26<br/>CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Home tele‐monitoring led to a mean annual cost‐saving of €89 per participant in the intention‐to‐treat analysis. The intervention was most cost‐saving in participants who were compliant (mean annual saving 360 euros)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed at least 1 telephone session:<br/>IG: 80%<br/>CG: NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean adherence at study end (measured by MPR):<br/>IG: 0.539<br/>CG: 0.462 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median number of visits to doctor per participant<br/>IG: 0<br/>CG: 4 </p> <p>Median number of visits to IBD nurse per participant<br/>IG: 0.3<br/>CG: 0.9 </p> <p>Median number of hospitalisations<br/>IG: 1<br/>CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 4 non‐compliant<br/>CG: NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Annual average costs remotely / tele‐medically monitored patient (CZK 2,060 / patient / year) were 25% lower than the cost of the same standardly outpatient patient (CZK 2,580 / patient / year)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenterologist appointments:<br/>IG: mean 0.6 (SD 0.9)<br/>CG: mean 1.7 (SD 0.8) </p> <p>Surgical appointments:<br/>IG: mean 0.1: (SD 0.4)<br/>CG: mean 0.1: (SD 0.4) </p> <p>IBD hospitalisations:<br/>IG: mean 0.1 (SD 0.3)<br/>CG: mean 0.1 (SD 0.4) </p> <p>Nights in hospital:<br/>IG: mean 0.1 (SD 0.4)<br/>CG: mean 0.8 (SD 3.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"At the end of 12 months, patients in the smartphone app group completed 2 system usability scales. The questionnaires asked about the instructions provided for the apps, what issues with the apps they experienced during the study, and whether they would keep using the apps in the future and recommend them to other people with IBD." </p> <p>No data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For IBDoc,<br/>15 (30%) completed all readings.<br/>14 (28%) completed 4.<br/>6 (12%) completed 3.<br/>2 (4%) completed 2.<br/>6 (12%) completed 1.<br/>7 (14%) completed 0. </p> <p>For IBDsmart,<br/>25 (50%) completed all readings.<br/>9 (18%) completed 4.<br/>7 (14%) completed 3.<br/>1 (2%) completed 2.<br/>7 (14%) completed 1.<br/>1 (2%) completed 0. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33% reported logging onto MyChart monthly, whereas 32% logged on weekly, and 13% logged on every other week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The experimental group did feel that the mobile app was easy to use and subjectively improved their ability to track and correlate symptoms" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Month 1<br/>MMAS &lt; 6:<br/>IG: 27<br/>CG: 34<br/>MMAS ≥ 6:<br/>IG: 93<br/>CG: 85 </p> <p>Month 2<br/>MMAS &lt; 6:<br/>IG: 30<br/>CG: 35<br/>MMAS ≥ 6:<br/>IG: 90<br/>CG: 84 </p> <p>Month 4<br/>MMAS &lt; 6:<br/>IG: 23<br/>CG: 37<br/>MMAS ≥ 6:<br/>IG: 97<br/>CG: 82 </p> <p>Month 6<br/>MMAS &lt; 6:<br/>IG: 22<br/>CG: 42<br/>MMAS ≥ 6:<br/>IG: 98<br/>CG: 77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IBD: inflammatory bowel disease; IQR: interquartile range; MARS: Medication Adherence Rating Scale; MMAS: Morisky Medication Adherence Scale; MPR: Medication Possession Ratio; NHS: UK National Health Service; SD: standard deviation. </p> </div> </div> </section> <section id="CD014821-sec-0081"> <h6 class="title">Medication adherence</h6> <p>Five studies reported medication adherence (<a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a>). Four studies provided data suitable for meta‐analysis: continuous data in <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> and <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>, and dichotomous data in <a href="./references#CD014821-bbs2-0006" title="CrossR , CheeversN , RustgiA , HanahanA , SteeleAG , LydeckerA , et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. Gastroenterology2010;5(138):S-519. CrossRK , CheeversN , RustgiA , LangenbergP , FinkelsteinJ . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflammatory bowel diseases2012;18(6):1018-25. CrossRK , FinkelsteinJ . Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clinical Trials2009;6(6):649-57. NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00620126 (first received 21 February 2008). ">Cross 2012</a> and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>. </p> <p>The analysis of continuous data from <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a> showed that web‐based disease monitoring (n = 340) compared to usual care (n = 331) probably leads to slightly higher medication adherence in adults (MD 0.24 points, 95% CI 0.01 to 0.47; <a href="./references#CD014821-fig-0012" title="">Analysis 1.9</a>). We downgraded the certainty of the evidence by one level to moderate for risk of bias due to lack of blinding. </p> <p>The analysis of continuous data from <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a> showed no difference between web‐based disease monitoring (n = 15) and usual care (n = 18) in terms of their effect on medication adherence in children, although the results are very uncertain (MD 0.00, 95% CI −0.63 to 0.63; <a href="./references#CD014821-fig-0013" title="">Analysis 1.10</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias (lack of blinding). </p> <p>Meta‐analysis of the dichotomous data showed no difference between web‐based disease monitoring (n = 26/46) and usual care (n = 28/43) in terms of their effect on medication adherence in adults, although the results are very uncertain (RR 0.87, 95% CI 0.62 to 1.21; 2 studies; <a href="./references#CD014821-fig-0014" title="">Analysis 1.11</a>). We downgraded the certainty of the evidence to very low for imprecision (very low numbers of events) and risk of bias concerns (lack of blinding and attrition). Subgroup comparison showed no major differences between mixed IBD and UC. </p> <p><a href="./references#CD014821-bbs2-0019" title="WangK , PengN , QiJ , SunL , GongJ , ZhuW . Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病病人硫唑嘌呤服药依从性的研究]. Chinese Nursing Research2020;34(5):828-34. ">Wang 2020</a> reported MMAS scores of less than six points for 22 participants in the web‐based group and 42 in the control group, and scores of more than or equal to six points for 98 participants in the web‐based group and 77 in the control group at six months. We were unable to draw any conclusions from these data. We downgraded the certainty of the evidence to very low for imprecision (low event numbers) and risk of bias concerns (blinding and selective reporting). </p> <p><a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0082"> <h6 class="title">Participant engagement</h6> <p>Eleven studies reported or commented on participant engagement (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0007" title="AbutalebA , BuchwaldA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflammatory Bowel Diseases2018;24(20):2191-7. BilgramiZ , AbutalebA , Chudy-OnwugajeK , CrossR . TU1747–Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. Gastroenterology2019;156(6):S-1109. BilgramiZ , AbutalebA , Chudy-OnwugajeK , LangenbergP , RegueiroM , SchwartzDA , et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. Digestive diseases and sciences2020;65(1):96-103. CrossRK , JambaulikarG , LangenbergP , TracyJK , CollinsJF , KatzJ , et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. Contemporary Clinical Trials2015;42:132-44. CrossRK , LangenbergP , RegueiroM , SchwartzDA , TracyJK , CollinsJF , et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Official Journal of the American College of Gastroenterology2019;114(3):472-82. JambaulikarG , LangenbergP , KatzJ , QuinnC , FlasarM , RegueiroM , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). American Journal of Gastroenterology2014;109 Suppl 2:S521. NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). clinicaltrials.gov/ct2/show/NCT01692743 (first received 25 September 2012). QuinnCC , ChardS , RothEG , EckertJK , RussmanKM , CrossRK . The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. Journal of Medical Internet Research2019;21(6):e14165. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. Gastroenterology2019;156(3):S28-9. SchliepM , Chudy-OnwugajeK , AbutalebA , LangenbergP , RegueiroM , SchwartzDA , et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. Crohn's &amp; Colitis 3602020;2(1):otaa002. SivasailamB , CrossRK , GhaziL , PatilSA , QuezadaSM , RussmanK , et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. Inflammatory Bowel Diseases2018;24 Suppl 1:S60-1. ">Cross 2019</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>; <a href="./references#CD014821-bbs2-0018" title="StunkelL , KariaK , OkojiO , WarrenR , JeanT , JacobV , et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. Official Journal of the American College of Gastroenterology2012;107:S635-6. ">Stunkel 2012</a>); however, no meta‐analysis was possible owing to substantial differences between studies in the types of participant engagement reported, methodology, and reporting of the data. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0083"> <h6 class="title">Rate of attendance or engagement with any or all elements of the intervention</h6> <p>Three studies reported attendance or engagement with the intervention (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0015" title="McCombieA , WalmsleyR , BarclayM , HoC , LanglotzT , RegenbrechtH , GrayA , et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory bowel diseases2020;26(7):1098-109. WalmsleyRS , McCombieA , BarclayM , HoC , VisesioN , BrownS , SchulzM . Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. Congress of the ECCO2019;no volume:no pagination. ">McCombie 2020</a>); however, meta‐analysis was not possible owing to differences in how studies reported this outcome. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on attendance or engagement rate. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0084"> <h6 class="title">Rate of attendance of interactions with healthcare professionals</h6> <p><a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported attendance of interactions with healthcare professionals; however, meta‐analysis was not possible owing to differences in how the two studies reported this outcome. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on rate of attendance of interactions with healthcare professionals. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0085"> <h6 class="title">Costs or cost/time‐effectiveness</h6> <p>Eight studies provided estimations of costs or cost/time‐effectiveness (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0004" title="CarlsenK , HouenG , JakobsenC , KallemoseT , PaerregaardA , RiisLB , et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. Inflammatory bowel diseases2017;23(9):1473-82. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's &amp; Colitis2016;10:S53-4. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , HouenG , et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. Journal of Pediatric gastroenterology and Nutrition2016;62 Suppl 1:131. CarlsenK , JakobsenC , HansenLF , PaerregaardA , KallemoseT , RiisLB , et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. Journal of Crohn's &amp; Colitis2016;10:S421-2. CarlsenK , JakobsenC , HansenLF , PaerregaardA , RiisLB , MunkholmPS , et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. Journal of Crohn's and Colitis2016;10:S53. CarlsenK , JakobsenC , HouenG , KallemoseT , PaerregaardA , RiisLB , et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflammatory Bowel Diseases2017;23(3):357-65. NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT01860651 (first received 15 February 2019). ">Carlsen 2017a</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0008" title="NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02173002 (first received 24 June 2014). deJongM , Van Der MeulenA , Romberg-CampsM , BecxM , CilissenM , MaljaarsJ , et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. Gastroenterology 152;5:S186. deJongM , vanDer Meulen-De JongA , Romberg-CampsM , BecxM , MaljaarsJPW , CilissenM , et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. United European Gastroenterology Journal2018;6(8):A649. deJongM , van derMeulen-de JongA , Romberg-CampsM , BecxM , MarkusT , MaljaarsJ , MahmmodN , et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. Journal of Crohn's &amp; Colitis2016;10:S198. deJongM , van derMeulen-de JongA , Romberg-CampsM , DegensJ , BecxM , MarkusT , et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflammatory Bowel Diseases2017;23(4):485-93. deJongMJ , BoonenA , van derMeulen-deAE , Romberg-CampsMJ , vanBodegravenAA , MahmmodN , et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. Clinical Gastroenterology and Hepatology2020;18(8):1744-52. deJongMJ , van derMeulen-deAE , Romberg-CampsMJ , BecxMC , MaljaarsJP , CilissenM , et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet2017;390(10098):959-68. ">de Jong 2017</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="./references#CD014821-bbs2-0010" title="ElkjaerM , ShuhaibarM , BurischJ , BaileyY , ScherfigH , LaugesenB , et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut2010;59(12):1652-61. ElkjaerM . E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Danish Medical Journal2012;59(7):B4478. ">Elkjaer 2010a</a>; <a href="./references#CD014821-bbs2-0011" title="HeidaA , DijkstraA , GroenH , KoboldAM , VerkadeH , vanRheenenP . Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials2015;16(1):1. HeidaA , DijkstraA , KoboldA , KindermannA , KokkeF , deMeijT , et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition2017;65 Suppl 1:S3. HeidaA , DijkstraA , Muller KoboldA , RossenJW , KindermannA , KokkeF , et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(4):432-41. ">Heida 2018</a>; <a href="./references#CD014821-bbs2-0014" title="MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn's and Colitis2020;14 Suppl 1:S352-3. MalickovaK , PesinovaV , BortlikM , DuricovaD , MachkovaN , HrubaV , et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicína a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. Gastroenterology &amp; Hepatology2020;74(1):18-27. ">Malickova 2020</a>); however, meta‐analysis was not possible owing to differences in how studies reported this outcome. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to usual care on costs or cost/time‐effectiveness. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> <p>Owing to lack of data, we were unable to perform subgroup and sensitivity analyses prespecified in our protocol. </p> </section> </section> </section> <section id="CD014821-sec-0086"> <h4 class="title">2. Web‐based disease monitoring versus sham monitoring</h4> <p>Three studies evaluated web‐based disease monitoring versus sham monitoring (<a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a>; <a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a>; <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a>). We were unable to perform meta‐analyses for any primary or secondary outcomes (<a href="./full#CD014821-tbl-0002">summary of findings Table 2</a>).  </p> <section id="CD014821-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD014821-sec-0088"> <h6 class="title">Disease activity</h6> <p>No studies reported disease activity.</p> </section> <section id="CD014821-sec-0089"> <h6 class="title">Flare‐ups or relapse</h6> <p>No studies reported flare‐ups or relapse.</p> </section> <section id="CD014821-sec-0090"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD014821-bbs2-0003" title="AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. Gastroenterology2017;152(5):S600-1. AtrejaA , KhanS , OtoboE , RogersJ , UllmanT , GrinspanA , et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. Journal of Crohn's and Colitis2017;11 Suppl 1:S362-3. AtrejaA , KhanS , RogersJD , OtoboE , PatelNP , UllmanT , et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR research protocols2015;4(1):e23. AtrejaA , KhanS , SzigethyE , OtoboE , ShroffH , ChangH , et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. Official Journal of the American College of Gastroenterology2018;113:S1. AtrejaA , OtoboE , SzigethyE , KohliA , ShroffH , ChangH , et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. Inflammatory Bowel Diseases2018;24 Suppl 1:S21-2. AtrejaA , OtoboE , SzigethyE , ShroffH , ChangH , KeeferL , et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S077-8. AtrejaA , SzigethyE , OtoboE , ChangHL , KeeferL , RogersJ , et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. Gastroenterology2018;154(6):S-6. NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. clinicaltrials.gov/ct2/show/NCT02322307 (first received 23 December 2014). ">Atreja 2018</a> provided QoL results only for the web‐based group and not the sham group, while <a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a> provided QoL means at six months but without variance measures. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to sham monitoring on QoL. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). <a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> </section> <section id="CD014821-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD014821-sec-0092"> <h6 class="title">Number of episodes of accessing healthcare</h6> <p>No studies reported healthcare access.</p> </section> <section id="CD014821-sec-0093"> <h6 class="title">Medication adherence</h6> <p><a href="./references#CD014821-bbs2-0013" title="LeyD , MartinB , CalderaF . Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. Inflammatory Bowel Diseases2020;26(5):e33-4. ">Ley 2020</a> provided medication adherence means at study end but without any variance measures. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to sham monitoring on medication adherence. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, attrition bias, and reporting bias). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0094"> <h6 class="title">Participant engagement</h6> <p><a href="./references#CD014821-bbs2-0016" title="ReichJ , CanakisA , ShankarD , HarringtonJ , ApteM , WeinbergJ , et al. The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn's &amp; Colitis 3602019;1(3):otz039. ReichJ , HarringtonJE , ShankarD , JonesE , WeinbergJ , NorohnaA , et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. Official Journal of the American College of Gastroenterology2018;113:S349. ">Reich 2019</a> reported rates of participants logging onto their web application (monthly, weekly, and every other week). We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to sham monitoring on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and attrition bias). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0095"> <h6 class="title">Rate of attendance or engagement with any or all elements of the intervention</h6> <p>No studies reported attendance or engagement rate.</p> </section> <section id="CD014821-sec-0096"> <h6 class="title">Rate of attendance of interactions with healthcare professionals</h6> <p>No studies reported interactions with professionals.</p> </section> <section id="CD014821-sec-0097"> <h6 class="title">Costs or cost/time‐effectiveness</h6> <p>No studies reported costs or cost/time‐effectiveness.</p> </section> </section> </section> <section id="CD014821-sec-0098"> <h4 class="title">3. Web‐based disease monitoring versus self‐screening</h4> <p>One study evaluated web‐based disease monitoring versus self‐screening (<a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a>). We were unable to perform meta‐analyses for any primary or secondary outcomes (<a href="./full#CD014821-tbl-0003">summary of findings Table 3</a>).  </p> <section id="CD014821-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD014821-sec-0100"> <h6 class="title">Disease activity</h6> <p>The authors of <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> devised their own classification system for disease activity, presenting SCCAI, HBI, and TIBS mean scores without variance on their "traffic light" classification over one year. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to self‐screening on disease activity. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). <a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> <section id="CD014821-sec-0101"> <h6 class="title">Flare‐ups or relapse</h6> <p><a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> reported combined moderate and severe relapse numbers based on SCCAI and FC levels; however, the denominator in this calculation (total number of patients) far exceeded the number of people randomised, so it was unclear if these relapses were based on randomised data. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to self‐screening on relapses or flare‐ups. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). <a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> <section id="CD014821-sec-0102"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> reported mean changes in QoL in the two groups, but it was unclear if these groups comprised the randomised participants. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to self‐screening on QoL. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). <a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> </section> <section id="CD014821-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD014821-sec-0104"> <h6 class="title">Number of episodes of accessing healthcare</h6> <p> <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> did not report healthcare access. </p> </section> <section id="CD014821-sec-0105"> <h6 class="title">Medication adherence</h6> <p><a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> reported median (interquartile range (IQR)) adherence values for the two groups, but it was unclear if these groups comprised the randomised participants. We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to self‐screening on medication adherence. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0106"> <h6 class="title">Participant engagement</h6> <p><a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> reported no "statistical difference between the two intervention groups on any of the seven yes/no questions assessing patient satisfaction". We were unable to draw any conclusions on the effects of web‐based disease monitoring compared to self‐screening on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0107"> <h6 class="title">Rate of attendance or engagement with any or all elements of the intervention</h6> <p> <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> did not report attendance or engagement rate. </p> </section> <section id="CD014821-sec-0108"> <h6 class="title">Rate of attendance of interactions with healthcare professionals</h6> <p> <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> did not report interactions with professionals. </p> </section> <section id="CD014821-sec-0109"> <h6 class="title">Costs or cost/time‐effectiveness</h6> <p> <a href="./references#CD014821-bbs2-0002" title="AnkersenDV , MarkerD , WeimersP , BurischJ , MunkholmP . DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. Journal of Crohn's and Colitis2018;12 Suppl 1:S052–3. AnkersenDV , WeimersP , MarkerD , BennedsenM , SabooriS , ParidaensK , et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. World Journal of Gastroenterology2019;25(40):6158-71. NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity?clinicaltrials.gov/ct2/show/NCT02492555 (first received 8 July 2015). ">Ankersen 2019</a> did not report costs or cost/time‐effectiveness. </p> </section> </section> </section> <section id="CD014821-sec-0110"> <h4 class="title">4. Telephone‐based disease monitoring versus face‐to‐face monitoring</h4> <p>Three studies evaluated telephone‐based disease monitoring versus face‐to‐face monitoring: two enrolled adults (<a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>), and one enrolled children (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>). </p> <section id="CD014821-sec-0111"> <h5 class="title">Primary outcomes</h5> <p><a href="./full#CD014821-tbl-0004">summary of findings Table 4</a> presents the effect measures (where calculated) and GRADE judgements for the primary outcomes. </p> <section id="CD014821-sec-0112"> <h6 class="title">Disease activity</h6> <p>Two studies reported disease activity, but neither provided data suitable for meta‐analysis (<a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>; <a href="#CD014821-tbl-0009">Table 4</a>).  </p> <p><a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a> reported no significant change. <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> measured disease activity only by proxy (FC levels) and provided no variance measure. We were unable to draw any conclusions on the effects of telephone‐based disease monitoring compared to face‐to‐face monitoring on disease activity. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selective reporting). <a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> <section id="CD014821-sec-0113"> <h6 class="title">Flare‐ups or relapse</h6> <p>All three studies reported flare‐ups or relapse (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>). </p> <p><a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> provided data suitable for meta‐analysis from an adult population. We found no difference between telephone‐based disease monitoring (n = 7/21) and face‐to‐face monitoring (n = 6/21) in terms of their effect on the occurrence of flare‐ups or relapses in adults with IBD, but the results are very uncertain (RR 1.17, 95% CI 0.47 to 2.89; <a href="./references#CD014821-fig-0015" title="">Analysis 2.1</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding).  </p> <p><a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> provided data suitable for meta‐analysis from a paediatric population. We found no difference between telephone‐based disease monitoring (n = 1/44) and face‐to‐face monitoring (n = 4/42) in terms of their effect on the occurrence of flare‐ups or relapses in children with IBD, but the results are very uncertain (RR 0.24, 95% CI 0.03 to 2.05; <a href="./references#CD014821-fig-0016" title="">Analysis 2.2</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). </p> <p><a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a> reported "no significant change" but provided no data. We were unable to draw any conclusions from this information. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting). </p> <p><a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> <section id="CD014821-sec-0114"> <h6 class="title">Quality of life</h6> <p>All three studies reported QoL (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>). </p> <p><a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> provided data suitable for meta‐analysis from a paediatric population. It is unclear whether telephone‐based disease monitoring (n = 44) compared to face‐to‐face monitoring (n = 42) affects QoL in children with IBD (MD 7.00 points, 95% CI −0.29 to 14.29; <a href="./references#CD014821-fig-0017" title="">Analysis 2.3</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). </p> <p><a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported QoL means without measures of variance. We were unable to draw any conclusions based on these data. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting). </p> <p><a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a> reported "no significant change" but provided no data. We were unable to draw any conclusions from this information. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting). </p> <p><a href="#CD014821-tbl-0009">Table 4</a> provides further details. </p> </section> </section> <section id="CD014821-sec-0115"> <h5 class="title">Secondary outcomes </h5> <section id="CD014821-sec-0116"> <h6 class="title">Number of episodes of accessing healthcare</h6> <p><a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> and <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported number of episodes of accessing healthcare. </p> <p><a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported numbers of participants in each consultation group that had one or more hospital admissions due to IBD. It is unclear whether telephone‐based disease monitoring (n = 1/44) compared to face‐to‐face monitoring (n = 1/42) affects the number of episodes of accessing healthcare in children with IBD (RR 0.95, 95% CI 0.06 to 14.77; <a href="./references#CD014821-fig-0018" title="">Analysis 2.4</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). </p> <p><a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported the number of outpatient visits and telephone consultations. We were unable to draw any conclusions from these data. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0117"> <h6 class="title">Medication adherence</h6> <p>Only <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported numbers of participants adhering to their medication. It is unclear whether telephone‐based disease monitoring (n = 7/21) compared to face‐to‐face monitoring (n = 14/21) affects medication adherence in adults with IBD (RR 0.50, 95% CI 0.25 to 0.98; <a href="./references#CD014821-fig-0019" title="">Analysis 2.5</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0118"> <h6 class="title">Participant engagement</h6> <p>Only <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a> reported participant engagement, specifically the number of participants who adhered to more than 80% of checkups planned in the study protocol. It is unclear whether telephone‐based disease monitoring (n = 20/21) compared to face‐to‐face monitoring (n = 19/21) affects participant engagement in adults with IBD (RR 1.05, 95% CI 0.89 to 1.25; <a href="./references#CD014821-fig-0020" title="">Analysis 2.6</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0119"> <h6 class="title">Rate of attendance or engagement with any or all elements of the intervention</h6> <p>Only <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported attendance or engagement rate, specifically the number of scheduled consultations that each participant missed. It is unclear whether telephone‐based disease monitoring (n = 36) compared to face‐to‐face monitoring (n = 40) affects attendance or engagement rate in children with IBD (MD 1.00, 95% CI 0.48 to 1.52; <a href="./references#CD014821-fig-0022" title="">Analysis 2.8</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0120"> <h6 class="title">Rate of attendance of interactions with healthcare professionals</h6> <p>Only <a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a> reported attendance of interactions with healthcare professions, specifically the number of participants who attended at least one scheduled consultation before the 12‐month follow‐up. It is unclear whether telephone‐based disease monitoring (n = 36/44) compared to face‐to‐face monitoring (n = 40/42) affects the rate of attendance of interactions with healthcare professionals in children with IBD (RR 0.86, 95% CI 0.74 to 1.00; <a href="./references#CD014821-fig-0023" title="">Analysis 2.9</a>). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> <section id="CD014821-sec-0121"> <h6 class="title">Costs or cost/time‐effectiveness</h6> <p>All three studies provided narrative estimates on costs or time‐effectiveness (<a href="./references#CD014821-bbs2-0001" title="AkobengAK , O'LearyN , VailA , BrownN , WidiatmokoD , FagbemiA , et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine2015;2(9):1251-6. NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. clinicaltrials.gov/ct2/show/NCT02319798 (first received18 December 2014). ">Akobeng 2015</a>; <a href="./references#CD014821-bbs2-0005" title="ChauhanU , ArmstrongD , FarbodY , HalderSL , KaasalainenS , MarshallJK , et al. Telephone vs. clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner led study. Gastroenterology2016;1:S235. ChauhanU , ArmstrongD , HalderS , MarshallJ , TseF , Pinto SanchezM , et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology2016;2016:A257. ChauhanU , ArmstrongD , HalderSL , MarshallJK , TseF , SanchezMP , et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis2016;493:S505. ">Chauhan 2016</a>; <a href="./references#CD014821-bbs2-0009" title="AguasM , Del HoyoJ , FaubelR , MunozD , DominguezD , BastidaG , et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. Journal of Medical Internet Search2018;12:S214. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. JMIR Research Protocols2018;7(12):e9639. AguasM , Del HoyoJ , FaubelR , MuñozD , DomínguezD , BastidaG , et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. Journal of Crohn's and Colitis2018;12 Suppl 1:S252-3. AguasM , Del HoyoJ , MuñozD , FaubelR , BarriosA , NavarroB , et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. Journal of Crohn's and Colitis2017;11 Suppl 1:no pagination. Del HoyoJ , NosP , BastidaG , FaubelR , MuñozD , Garrido-MarínA , et al. Telemonitoring of Crohn’s disease and ulcerative colitis (TECCU): cost-effectiveness analysis. Journal of Medical Internet Research2019;21(9):e15505. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. Journal of Medical Internet Research2018;20(11):e11602. Del HoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. Gastroenterology2018;154(6):S797. NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016). delHoyoJ , NosP , FaubelR , MuñozD , DomínguezD , BastidaG , et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. Gastroenterology2018;154(6):S-800. ">Del Hoyo 2018</a>). We were unable to draw any conclusions on the effects of telephone‐based disease monitoring compared to face‐to‐face monitoring on cost or cost/time‐effectiveness. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). <a href="#CD014821-tbl-0010">Table 5</a> provides further details. </p> </section> </section> </section> <section id="CD014821-sec-0122"> <h4 class="title">5. Cognitive behavioural therapy manual and telephone support versus usual care</h4> <p>One study evaluated CBT manual and telephone support versus usual care (<a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a>). </p> <p>We were unable to perform meta‐analyses for any primary or secondary outcomes (<a href="./full#CD014821-tbl-0005">summary of findings Table 5</a>).  </p> <section id="CD014821-sec-0123"> <h5 class="title">Primary outcomes</h5> <section id="CD014821-sec-0124"> <h6 class="title">Disease activity</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report disease activity. </p> </section> <section id="CD014821-sec-0125"> <h6 class="title">Flare‐ups of relapse</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report flare‐ups or relapse. </p> </section> <section id="CD014821-sec-0126"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report QoL. </p> </section> </section> <section id="CD014821-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD014821-sec-0128"> <h6 class="title">Number of episodes of accessing healthcare</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report healthcare access. </p> </section> <section id="CD014821-sec-0129"> <h6 class="title">Medication adherence</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report medication adherence. </p> </section> <section id="CD014821-sec-0130"> <h6 class="title">Participant engagement</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> reported rates of participants completing at least one telephone session only for the intervention group. We were unable to draw any conclusions on the effects of CBT manuals and telephone support compared to usual care on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (randomisation, blinding, attrition, and selective reporting). </p> </section> <section id="CD014821-sec-0131"> <h6 class="title">Rate of attendance or engagement with any or all elements of the intervention</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report attendance or engagement rate. </p> </section> <section id="CD014821-sec-0132"> <h6 class="title">Rate of attendance of interactions with healthcare professionals</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report interactions with professionals. </p> </section> <section id="CD014821-sec-0133"> <h6 class="title">Costs or cost/time‐effectiveness</h6> <p><a href="./references#CD014821-bbs2-0012" title="HughesLD , FischerA , GoodliffeS , IrvingPM , Moss-MorrisR . PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. Gut2017;66 Suppl 2:A256-7. ">Hughes 2017</a> did not report costs or cost/time‐effectiveness. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014821-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014821-sec-0134"></div> <section id="CD014821-sec-0135"> <h3 class="title" id="CD014821-sec-0135">Summary of main results</h3> <p>This review included a wide range of interventions in a very contemporaneous area of interest. Since 2020, almost all people with IBD have had some elements of their care delivered by telehealth, but this approach had already formed a part of IBD healthcare provision for some time. </p> <p>The studies included in this review demonstrate the different means employed to deliver remote healthcare to people with IBD. Web‐based disease monitoring was the most commonly studied intervention and was compared to standard or usual care in 12 studies, with just three adding a sham or control web application to the control group. A single study compared web‐based disease monitoring with self‐screening, three studies compared telephone‐based disease monitoring with face‐to‐face monitoring, and one study evaluated a CBT manual combined with telephone support versus usual care. </p> <p>Most studies compared a form of remote telehealth to normal or usual care, but descriptions of normal care were limited, and no studies specified whether standard care groups were offered remote care, formally or informally. </p> <p>The analysis for the most common comparison (web‐based monitoring versus usual care) produced the following results. </p> <p> <ul id="CD014821-list-0011"> <li> <p>There is probably no difference between the interventions in IBD disease activity in adults. </p> </li> <li> <p>There is probably no difference between the interventions in IBD flare‐ups or relapse in adults. </p> </li> <li> <p>There may be no difference between the interventions in IBD flare‐ups or relapse in children. </p> </li> <li> <p>There is probably no difference between the interventions in QoL in adults.</p> </li> <li> <p>Web‐based monitoring compared to usual care probably improves medication adherence slightly in adults. </p> </li> </ul> </p> <p>The poor reporting of other outcomes measures severely limited the scope for meta‐analysis, and the certainty of evidence was very low. </p> </section> <section id="CD014821-sec-0136"> <h3 class="title" id="CD014821-sec-0136">Overall completeness and applicability of evidence</h3> <p>Further clarification on the specifics of the web‐based monitoring would support better replication and dissemination (<a href="#CD014821-tbl-0007">Table 2</a>; <a href="#CD014821-tbl-0008">Table 3</a>). Unlike pharmacological intervention reviews, reviews of this type should establish not only whether an intervention is effective or safe, but also what specific components of the intervention are effective. Most studies included in this review do not provide this information. Lack of detail is a recognised problem in non‐pharmacological trial reporting. An analysis of non‐pharmacological intervention trials found that 61% of reports did not provide details of the primary intervention, although trial authors forwarded this information on request in 72% of cases (<a href="./references#CD014821-bbs2-0087" title="Hoffmann TC , EruetiC , Glasziou PP . Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ2013;347:f3755.">Hoffman 2013</a>). In this review, we received only minimal information from study authors when we contacted them. It is important that future studies rectify this gap in the evidence base. </p> <p>The choice of outcomes in the included studies was another concern. The primary outcomes appeared somewhat arbitrary and involved many clinical measures. For pharmacological studies, national governing bodies often mandate the primary outcomes, but as this is not the case for studies of non‐pharmacological interventions, the analysis in this review is limited. In addition, follow‐up duration was generally short. </p> <p>Most studies used web‐based disease monitoring as the focus for remote care. Few studies evaluated other remote approaches. It appears that many ongoing studies are focusing on other forms of remote care (possibly as a result of the COVID‐19 pandemic), and future updates of this review will likely include these interventions. </p> <p>We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring, as this was a proxy for direct patient outcomes. This could be considered an incomplete aspect of our review and a potential focus of a new review. </p> <p>Finally, standard care was a frequent comparator in the included studies, but no studies provided clear descriptions of standard care in terms of the content, form, frequency, and professionals involved. Without this information, it is unclear to what extent each intervention differed from its respective control. As a result, the completeness and utility of the evidence is limited. </p> </section> <section id="CD014821-sec-0137"> <h3 class="title" id="CD014821-sec-0137">Quality of the evidence</h3> <p>There were significant issues related to risk of bias in the studies included in this review. Despite our requests to authors of included studies, we received few data to change our judgements in these key areas. </p> <p>Most studies did not blind participants, personnel, or outcome assessors, but this can be considered acceptable given the context of the review. As we explained in a previous review (<a href="./references#CD014821-bbs2-0080" title="GordonM , SinopoulouV , TabbersM , RexwinkelR , deBruijnC , DoveyT , et al. Psychosocial interventions for the treatment of functional abdominal pain disorders in children: a systematic review and meta-analysis. JAMA Pediatrics2022;176(4):no pagination.">Gordon 2022</a>), research has demonstrated that even in double‐blind trials, participant expectancies can limit the validity of the design; assessing participants' beliefs about their treatment could help to overcome this issue (<a href="./references#CD014821-bbs2-0068" title="ColagiuriB . Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clinical Trials2010;7(3):246-55.">Colagiuri 2010</a>). Nevertheless, blinding remains a concern and a potential limitation of the included studies in this review, and we have downgraded the certainty of the evidence for all our outcomes accordingly. </p> <p>Reporting of the interventions themselves is another source of potential bias, as it is difficult to determine what specific interventions each study delivered. As discussed in <a href="#CD014821-sec-0136">Overall completeness and applicability of evidence</a>, unclear reporting is a recognised problem within non‐pharmacological intervention studies (<a href="./references#CD014821-bbs2-0087" title="Hoffmann TC , EruetiC , Glasziou PP . Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ2013;347:f3755.">Hoffman 2013</a>), and within health education systematic reviews (<a href="./references#CD014821-bbs2-0077" title="GordonM . Are we talking the same paradigm? Considering methodological choices in health education systematic review. Medical Teacher2016;38:746-50.">Gordon 2016</a>), although the GRADE approach does not explicitly identify this issue (<a href="./references#CD014821-bbs2-0078" title="GordonM , GuyattG . Assessment of evidence quality in inflammatory bowel disease guidance: the use and misuse of GRADE. Gastroenterology2020;159:1209-15.">Gordon 2020</a>). Lack of detail in the reporting of interventions constitutes the most serious problem with the evidence base, limiting the utility of our outcomes, because these interventions cannot be replicated or disseminated. </p> <p>The outcome of paediatric flare‐ups or relapses for web‐based disease monitoring compared to usual care was downgraded twice for imprecision (low participant numbers) and risk of bias concerns (blinding and attrition). </p> <p>All reported primary outcomes for telephone‐based disease monitoring compared to face‐to‐face monitoring were downgraded three times for serous imprecision (very low participant numbers) and risk of bias concerns. </p> <p>The only secondary outcome we were able to meta‐analyse was medication adherence for web‐based disease monitoring compared to usual care. We considered the evidence for this outcome based on continuous data in adults to be of moderate certainty, downgrading once for risk of bias; and we considered the evidence based on continuous data in children and the evidence based on dichotomous data in adults to be of very low certainty, downgrading for very serious imprecision and risk of bias concerns. </p> </section> <section id="CD014821-sec-0138"> <h3 class="title" id="CD014821-sec-0138">Potential biases in the review process</h3> <p>Clinical heterogeneity is a major concern in this review. Most studies included people with both CD and UC at different disease states. Had we excluded studies that did not differentiate between CD and UC (most studies), we would have lost a key source of evidence in this area. Nevertheless, this clearly introduces a source of bias. </p> <p>Although some studies analysed IBD populations as one cohort while others analysed UC and CD populations separately, and despite the mix of disease states in the included studies, we do not consider indirectness to be an issue. The constituents of the interventions were homogenous in their scope for web‐based monitoring, and varied only in the type of telehealth method adopted. There is no clinical evidence to suggest indirectness between subgroups of IBD and disease state. However, we recognise the variation in the methods used by the included studies may be a limitation of this review. Our outcomes are direct measures for efficacy and safety in IBD treatment. </p> <p>We decided to only include studies where the remote component was the primary focus and not part of a larger package, and we may have missed studies with relevant evidence as a result. </p> </section> <section id="CD014821-sec-0139"> <h3 class="title" id="CD014821-sec-0139">Agreements and disagreements with other studies or reviews</h3> <p>This is the first Cochrane Review on remote care for people with IBS.</p> <p>One systematic review from 2014 concluded that distance management of IBD significantly decreased clinic visit utilisation but did not significantly affect relapse rates or hospital admission rates (<a href="./references#CD014821-bbs2-0088" title="HuangVW , ReichKM , FedorakRN . Distance management of inflammatory bowel disease: systematic review and meta-analysis. World Journal of Gastroenterology2014;20(3):829.">Huang 2014</a>). Another systematic review, published in 2022, concluded that digital health technologies may be effective in decreasing healthcare utilisation and costs, though may not improve risk of relapse, QoL, or treatment adherence in people with IBD (<a href="./references#CD014821-bbs2-0095" title="NguyenNH , MartinezI , AtrejaA , SitapatiAM , SandbornWJ , Ohno-MachadoL , et al. Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review. The American Journal of Gastroenterology 117;1:78-97.">Nguyen 2022</a>). Similarly, we found no effect on relapse rates and QoL in comparison to usual care, but we had insufficient evidence to judge clinic visits, hospital admissions, and costs. The evidence we found on medication adherence was heterogeneous, with one meta‐analysis suggesting telehealth may be non‐inferior to usual care (though the evidence is very uncertain), and another suggesting telehealth is probably slightly better than usual care. </p> <p>The international guidelines for IBD provide no evidence base to support the use of remote telehealth as a standalone or replacement intervention, only as an addendum to normal care (<a href="./references#CD014821-bbs2-0073" title="FeuersteinJD , IsaacsKL , SchneiderY , SiddiqueSM , Falck-YtterY , SinghS , et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology2020;158(5):1450-61.">Feuerstein 2020</a>; <a href="./references#CD014821-bbs2-0074" title="FeuersteinJD , HoEY , ShmidtE , SinghH , Falck-YtterY , SultanS , et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology2021;160(7):2496-508.">Feuerstein 2021</a>; <a href="./references#CD014821-bbs2-0075" title="ForduceyPG , GlueckaufRL , BergquistTF , MaheuMM , YutsisM . Telehealth for persons with severe functional disabilities and their caregivers: facilitating self-care management in the home setting. Psychological Services2012;9(2):144.">Forducey 2012</a>; <a href="./references#CD014821-bbs2-0089" title="KoCW , SinghS , FeuersteinJD , Falck-YtterC , Falck-YtterY , CrossRK , et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology2019;156(3):748-64.">Ko 2019</a>; <a href="./references#CD014821-bbs2-0090" title="LambCA , KennedyNA , RaineT , HendyPA , SmithPJ , LimdiJK , et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut2019;68 Suppl 3:s1-s106.">Lamb 2019</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014821-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow chart of study retrieval and selection." data-id="CD014821-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart of study retrieval and selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014821-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014821-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 1: Disease activity (adults)" data-id="CD014821-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 1: Disease activity (adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 2: Disease activity (adults; fixed‐effect sensitivity analysis)" data-id="CD014821-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 2: Disease activity (adults; fixed‐effect sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 3: Flare‐ups/relapse (dichotomous; adults)" data-id="CD014821-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 3: Flare‐ups/relapse (dichotomous; adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 4: Flare‐ups/relapse (dichotomous; adults;  fixed‐effect sensitivity analysis)" data-id="CD014821-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 4: Flare‐ups/relapse (dichotomous; adults;  fixed‐effect sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 5: Flare‐ups (continuous; adults)" data-id="CD014821-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 5: Flare‐ups (continuous; adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 6: Flare‐ups/relapse (dichotomous; children)" data-id="CD014821-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 6: Flare‐ups/relapse (dichotomous; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 7: Quality of life (adults)" data-id="CD014821-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 7: Quality of life (adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 8: Quality of life (adults; fixed‐effect  sensitivity analysis)" data-id="CD014821-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 8: Quality of life (adults; fixed‐effect  sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 9: Medication adherence (continuous; adults)" data-id="CD014821-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 9: Medication adherence (continuous; adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 10: Medication adherence (continuous; children)" data-id="CD014821-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 10: Medication adherence (continuous; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Web‐based disease monitoring versus usual care, Outcome 11: Medication adherence (dichotomous; adults)" data-id="CD014821-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Web‐based disease monitoring versus usual care, Outcome 11: Medication adherence (dichotomous; adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 1: Flare‐ups/relapse (dichotomous; adults)" data-id="CD014821-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 1: Flare‐ups/relapse (dichotomous; adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 2: Flare‐ups/relapse (dichotomous; children)" data-id="CD014821-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 2: Flare‐ups/relapse (dichotomous; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 3: Quality of life (children)" data-id="CD014821-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 3: Quality of life (children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 4: Number of episodes accessing healthcare (one or more hospital admissions; children)" data-id="CD014821-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 4: Number of episodes accessing healthcare (one or more hospital admissions; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 5: Medication adherence (adults)" data-id="CD014821-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 5: Medication adherence (adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 6: Participant engagement (adults)" data-id="CD014821-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 6: Participant engagement (adults) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 7: Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children)" data-id="CD014821-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 7: Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 8: Rate of attendance/engagement with the intervention (missed consultations; children)" data-id="CD014821-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 8: Rate of attendance/engagement with the intervention (missed consultations; children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014821-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/urn:x-wiley:14651858:media:CD014821:CD014821-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 9: Rate of attendance of interactions with health professionals (children)" data-id="CD014821-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_t/tCD014821-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Telephone‐based disease monitoring versus face‐to‐face monitoring, Outcome 9: Rate of attendance of interactions with health professionals (children) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/media/CDSR/CD014821/image_n/nCD014821-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014821-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Web‐based disease monitoring compared to usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease <br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring <br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 higher<br/>(0.11 lower to 0.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 participants<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equivalent to a mean 36‐point reduction on the CDAI and a mean 1.7‐point reduction on the SCCAI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 6–12 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.09</b><br/>(0.93 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>868 participants<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000<br/>(375 to 512) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse (continuous; adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of flare‐ups was 0.19 (SD 0.42)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 more flare‐ups (0.06 fewer to 0.06 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>909 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; children)</b> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b><br/>(0.65 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>—</i> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>337 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/>(219 to 509) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.08 higher<br/>(0.04 lower to 0.20 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>—</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1099 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equivalent to a mean 22‐point increase on the IBDQ scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>IBDQ</b> : Inflammatory Bowel Disease Questionnaire; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SCCAI:</b> Simple Clinical Colitis Activity Index; <b>SMD:</b> standardised mean difference; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for risk of bias related to blinding.<br/><sup>b</sup> Downgraded once for risk of bias related to blinding, selective reporting, and other sources.<br/><sup>c</sup> Downgraded once for risk of bias related to blinding and imbalance in the numbers of participants reaching end of study, and once for imprecision due to low participant numbers.<br/><sup>d</sup> Downgraded once for risk of bias related to blinding and attrition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Web‐based disease monitoring compared to usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014821-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Web‐based disease monitoring compared to sham monitoring</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to sham monitoring</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring <br/><b>Comparison:</b> sham monitoring </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham monitoring</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 6 months–2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no changes in QoL. Another study reached no conclusion.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447 participants</p> <p>(2 studies)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for serious risk of bias concerns (all domains) and twice for very serious imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Web‐based disease monitoring compared to sham monitoring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014821-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Web‐based disease monitoring compared to self‐screening</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Web‐based disease monitoring compared to self‐screening</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> web‐based disease monitoring<br/><b>Comparison:</b> self‐screening </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with self‐screening</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no differences in disease activity.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported no differences in relapses.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported greater improvement in QoL in the control group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to serious risk of bias concerns (randomisation, blinding, and selective reporting), and twice for very serious imprecision (very low participant and event numbers). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Web‐based disease monitoring compared to self‐screening</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014821-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Telephone‐based disease monitoring compared to face‐to‐face monitoring</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Telephone‐based disease monitoring compared to face‐to‐face monitoring </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease <br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> telephone‐based disease monitoring <br/><b>Comparison:</b> face‐to‐face monitoring </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with face‐to‐face monitoring</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with telephone‐based disease monitoring</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity (adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study, whilst reporting no data on this outcome, mentioned there was no significant change. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b><br/>(0.47 to 2.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/>(134 to 586) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Flare‐ups/relapse (dichotomous; children)</b> </p> <p>Follow‐up: 6 months</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.24</b><br/>(0.03 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/>(3 to 195) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (adults)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study, whilst reporting no data on QoL, mentioned there was no significant change. Another study reported median QoL scores, which were not very different between groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 participants</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (children)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean of 106 points (SD 15.5) on the IMPACT QoL (35 lowest to 175 highest)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7 points higher<br/>(0.29 lower to 14.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once for serious risk of bias concerns related to blinding and selective reporting, and twice for very serious imprecision due to very low participant numbers and events.<br/><sup>b</sup> Downgraded one for serious risk of bias concerns related to blinding, and twice for very serious imprecision due to very low participant numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Telephone‐based disease monitoring compared to face‐to‐face monitoring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014821-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Cognitive behavioural therapy manual and telephone support compared to usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cognitive behavioural therapy manual and telephone support compared to usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> hospitals and tertiary centres, and remotely<br/><b>Intervention:</b> CBT manual and telephone support<br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT manual and telephone support</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Flare‐ups/relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.<br/><b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Cognitive behavioural therapy manual and telephone support compared to usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014821-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial registration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease type<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease state (relapse/remission)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Numbers randomised </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concurrent therapies<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ethnicity<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Socio‐economic status<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Conflicts of interest</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Funding</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02319798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 36; CG: 35 </p> <p>UC/IC:<br/>IG: 8; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 44<br/>CG: 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The authors report grants from Research for Patient Benefit Programme, UK National Institute for Health Research, during the conduct of the study" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The project was funded by Research for Patient Benefit Programme, UK National Institute for Health Research (grant number PB‐PG‐0408‐16218)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02492555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 13 (26%); CG: 10 (19.2%) </p> <p>UC:<br/>IG: 35 (70%); CG: 39 (75%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission or mild‐moderate disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 50<br/>CG: 52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None:<br/>IG: 9 (18.0%); CG: 10 (19.2%) </p> <p>5‐ASA:<br/>IG: 27 (54.0%); CG: 24 (46.2%) </p> <p>Corticosteroids:<br/>IG: 4 (8.0%); CG: 4 (7.7%) </p> <p>Immunomodulators:<br/>IG: 3 (6.0%); CG: 9 (17.3%) </p> <p>Biological therapy:<br/>IG: 7 (14.0%); CG: 5 (9.6%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of education after high school:</p> <p>Short:<br/>IG: 2; CG: 4<br/>Medium:<br/>IG: 40; CG: 31<br/>Higher/academic:<br/>IG: 6; CG: 13 </p> <p>Occupation:<br/>Yes:<br/>IG: 38; CG: 42<br/>No:<br/>IG: 12; CG: 10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ankersen DV has received grants from Ferring Pharmaceuticals, Crohn Colitis patient society Denmark, North Zealand University Hospital and nonfinancial support from Calpro AS; Weimers P has received grants from Ferring lægemidler and Tillotts Pharma AG as well as nonfinancial support from Janssen‐ Cilag A/S, Calpro AS, and Vifor Pharma Nordiska AB; Marker D has received non‐financial support from Calpro AS and Pharmacosmos; Bennedsen M has received other financial support from AbbVie, Tillotts, Takeda, MSD and Pfizer; Saboori S has received non‐financial support from Janssen‐Cilag and Salofalk; Paridaens K is an employee of Ferring Pharmaceuticals; Burisch J has received grants from AbbVie, Takeda, Tillotts Pharma and personal fees from AbbVie, Janssen‐Cilag, Celgene, Samsung Bioepis, MSD, Pfizer and Takeda; Munkholm P has none to declare." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Calpro AS; CrohnColitis patient society Denmark; and North Zealand UniversityHospital and FerringPharmaceuticals." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02322307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 162<br/>CG: 158 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>82.2%<br/>Black: 5.3%<br/>Hispanic: 9.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>College education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The study is supported by the Crohn's &amp; Colitis Foundation of America (grant #253624) and the National Institutes of Health (5K23 DK97451‐02)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01860651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 8; CG 13 </p> <p>UC:<br/>IG: 19; CG: 13<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD (remission):<br/>IG: 2; CG: 5 </p> <p>CD (mild):<br/>IG: 5; CG: 6 </p> <p>CD (moderate):<br/>IG: 0; CG: 2 </p> <p>CD (severe):<br/>IG: 1; CG: 0 </p> <p>UC (remission):</p> <p>IG: 14; CG: 9</p> <p>UC (mild):<br/>IG: 5; CG: 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 27<br/>CG: 26 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethnicity is reported in the trial registration, but not in the paper.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"European Crohn’s and Colitis Organization, Queen Louise’s Hospital Foundation, TrygFoundation, CALPRO A/S, Tillotts Pharma, Capital Region Denmark, Alice and Frimodts Foundation, Ulcerative colitis and Crohn’s Danish Patient Society, and Merck Sharp and Dome." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG+CG: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00620126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed: remission and active disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 25<br/>CG: 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids:<br/>Total: 5; IG: 3; CG: 2 </p> <p>Immune suppressants:<br/>Total: 20; IG: 14; CG: 6 </p> <p>Infliximab:<br/>Total: 14; IG: 7; CG: 7<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>Total: 31; IG: 16; CG: 15 </p> <p>Other:<br/>Total: 16; IG: 9; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease knowledge:<br/>Limited:<br/>Total: 7; IG: 4; CG: 3<br/>Good:<br/>Total: 30; IG: 15; CG: 15<br/>Excellent:<br/>Total: 10; IG: 4; CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Broad Medical Research Program (BRMP‐0190), University of Maryland General Clinical Research Center Grant (M01 RR 16500), General Clinical Research Centers Program, National Center for Research Resources (NCRR), NIH, and the Baltimore Education and Research Foundation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01692743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>IG1: 79; IG2: 78; CG: 79 </p> <p>UC/IC:<br/>IG1: 36; IG2: 38; CG: 38 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed, remission (148) and active disease (200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: 115<br/>IG2: 116<br/>CG: 117 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminosalicylates:<br/>Total: 108; IG1: 29; IG2: 39; CG: 40 </p> <p>Corticosteroids:<br/>Total: 64; IG1: 17; IG2: 27; CG: 20 </p> <p>Mercaptopurine/azathioprine:<br/>Total: 111; IG1: 33; IG2: 42; CG: 36 </p> <p>Anti‐TNF:<br/>Total: 206; IG1: 66; IG2: 68; CG: 72<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>Total: 319; IG1: 108; IG2: 111; CG: 100 </p> <p>African American:<br/>Total: 24; IG1: 5; IG2: 5; CG: 14 </p> <p>Asian: <br/>Total: 1; IG1: 1; IG2: 0; CG: 0 </p> <p>Other:<br/>Total: 3; IG1: 1; IG2: 0; CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insurance status:<br/>None:<br/>Total: 14; IG1: 0; IG2: 1; CG: 13<br/>Medical assistance:<br/>Total: 6; IG1: 1; IG2: 2; CG: 3<br/>Medicare:<br/>Total: 15; IG1: 6; IG2: 1; CG: 8<br/>Commercial:<br/>Total: 198; IG1: 67; IG2: 70; CG: 61<br/>Other:<br/>Total: 64; IG1: 24; IG2: 27; CG: 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Agency for Healthcare Research and Quality (1R01HS018975‐01A1) and the University of Maryland general clinical research centers program." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02173002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> <p>Remission:<br/>IG: 394; CG: 380 </p> <p>Active:<br/>IG: 71; CG: 64 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 465<br/>CG: 444 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No medication/mesalazine:<br/>IG: 147; CG: 173 </p> <p>Immunosuppresants:<br/>IG: 131; CG: 122 </p> <p>Biologics:<br/>IG: 166; CG: 170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education:<br/>University:<br/>IG: 54; CG: 49<br/>Higher vocational education:<br/>IG: 103; CG: 98<br/>Intermediate vocational education:<br/>IG: 160; CG: 157<br/>Secondary edication:<br/>IG: 56; CG: 55<br/>Primary education:<br/>IG: 6; CG: 8<br/>Missing data:<br/>IG: 86; CG: 77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"MJdJ reports non‐financial support from Merck Sharpe &amp; Dohme, outside the submitted work. AEvdM‐dJ reports grants and non‐financial<br/>support from Takeda, personal fees from AbbVie, and non‐financial support from Tramedico, all outside the submitted work. AAvB reports<br/>personal fees from AbbVie, MSD, Ferring, Tramedico, Takeda, Pfizer, and Janssen, all outside the submitted work. GD reports speaker’s fees from Shire, AbbVie, and Takeda, and a grant for investigator‐initiated<br/>research from Takeda, all outside the submitted work. AAM reports grants from Grünenthal, Zon MW GGG (government), Will Pharma, BioActor, Pentax Europe, Falk Pharma, and Almiral Pharma, all outside the submitted work. AB received research grants to her department from<br/>AbbVie, Amgen, and Merck, and advisory board honoraria from Janssen and Sandoz, all unrelated to the current work. MJP reports personal fees from AbbVie, Ferring, Janssen, and Takeda, and grants from Falk, all outside the submitted work. All other authors declare no competing<br/>interests." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Academic incentive fund of the Maastricht University Medical Centre (31962340B)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02943538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD: IG1: 13/21; IG2: 13/21; CG: 14/21</p> <p>UC:<br/>IG1: 8/21; IG2: 8/21; CG: 7/21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission and active</p> <p>Remission:<br/>CD:<br/>IG1: 6; IG2: 9; CG: 10<br/>UC: IG1: 2; IG2: 1; CG: 2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: 21<br/>IG2: 21<br/>CG: 21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunomodulators:<br/>IG1: 10; IG2: 9; CG: 10 </p> <p>Biologics:<br/>IG1: 4; IG2: 4; CG: 4 </p> <p>Combination therapy:<br/>IG1: 5; IG2: 6; CG: 6 </p> <p>Corticosteroids:<br/>IG1: 2; IG2: 2; CG: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education:<br/>Primary education: 9/30; secondary education: 21/30; university: 29/30 </p> <p>Work Productivity and Activity Impairment:<br/>Not working:<br/>IG1: 7/21; IG2: 5/21; CG: 8/21 </p> <p>Percentage of work hours missed:<br/>IG1: median 40% (IQR 15%–62.5%); IG2: median 32.5% (IQR 7.5%–57.5%); CG: median 27.5% (IQR 0%–52%) </p> <p>Work impairment score: IG1: median 7 (IQR 3–10); IG2: median 10 (IQR: 2.25–10); CG: median 7 (IQR 2.75–10) </p> <p>Social impairment score: IG1: median 3.5 (IQR 2–7); IG2: median 6 (IQR 2.75–8); CG: median 3.5 (IQR 1–5.75) </p> <p>Satisfaction score: CG: median 49.5 (IQR 42.5–53.75); IG1: median 53 (IQR 50–59); IG2: median 52 (IQR 47.5–55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"DD is the general manager of Connected Health Services."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Grants from the Instituto de Salud Carlos III‐Fondo de Investigaciones Sanitarias (FIS PI12/00277) and cofunded by FEDER (Fondo Europeo de Desarrollo Regional)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild/moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 117<br/>CG: 116 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA systemic:<br/>Asacol: <br/>IG: 78; CG: 68<br/>Pentasa:<br/>IG: 8; CG: 7<br/>Dipentum:<br/>IG: 2; CG: 4<br/>Premid:<br/>IG: 2; CG: 2<br/>Salazopyrin:<br/>IG: 3; CG: 6<br/>Mezavant:<br/>IG: 0; CG: 0<br/>None:<br/>IG: 12; CG: 19 </p> <p>Suppositories:<br/>Asacol:<br/>IG: 3; CG: 2<br/>Pentasa:<br/>IG: 12; CG: 9<br/>Mesasal:<br/>IG: 3; CG: 1<br/>Prednisolon:<br/>IG: 1; CG: 0<br/>None:<br/>IG: 88; CG: 94 </p> <p>Enema /Foam:<br/>Asacol:<br/>IG: 4; CG: 4<br/>Pentasa:<br/>IG: 7; CG: 6<br/>Colifoam:<br/>IG: 4; CG: 4<br/>Pred‐clysma:<br/>IG: 0; CG: 0<br/>None:<br/>IG: 90; CG: 92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marital status:<br/>Married:<br/>IG: 69/105: CG: 82/106<br/>Single:<br/>IG: 36/105; CG: 24/106 </p> <p>Education:<br/>Academic:<br/>IG: 33/105; CG: 29/106 in CG<br/>Other education:<br/>IG: 55/105; CG: 64/106<br/>During education:<br/>IG: 16/105; CG: 5/106<br/>No education:<br/>IG: 1/105; CG: 8/106 </p> <p>Occupation:<br/>Paid:<br/>IG: 82/105; CG: 86/106<br/>Unpaid:<br/>IG: 1/105; CG: 4/106<br/>Support:<br/>IG: 15/105; CG: 6/106<br/>Pensioner:<br/>IG: 7/105; CG: 10/106 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PM is member of the advisory boards in Ferring, Tillots, MSD and Swedish Orphan. ME is member of the advisory board in Swedish Orphan. HS is member of the advisory board in Swedish Orphan. CO’M is on the International Advisory Board of Abbott, MSD, and Shire Pharmaceutical Company. He has unrestricted educational grants from Abbott and MSD" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Colitis Crohn Patient Organisation, Moran’s Foundation, Vibeke Binder &amp; Povl Riis’ Foundation, Bayer Health Care Funding, Augustinus Foundation, Munkholms Foundation, Tillotts Funding, Scientific Council at Herlev Hospital, Prof. Fagerhol Research Foundation, Aase &amp; Einar Danielsen Foundation, Ole Trock‐Jansen &amp; Hustrus Foundation, and European Crohn Colitis Organisation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NTR3759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 39; CG: 42<br/>UC:<br/>IG: 45; CG: 44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 84<br/>CG: 86 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunomodulators:<br/>IG: 69; CG: 65 </p> <p>Aminosalicylates:<br/>IG: 57; CG: 52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emotional quotient:<br/>Low (≤ 89):<br/>IG: 5; CG: 5<br/>Average (90–109):<br/>IG: 37; CG: 30<br/>High (≥ 110):<br/>IG: 46; CG: 51<br/>Missing:<br/>IG: 21; CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PFvR, AH and AMK received funding for joint research projects from BÜHLMANN Laboratories and CisBio Bioassays. All other authors had no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 2 years, and no other relationships or activities that could appear to have influenced the submitted work." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This work was supported by ZonMw Health Care Efficiency Research [grant number 837001001], Innovation Fund Dutch Insurance Companies [grant number B12‐204–2509], and NutsOhra Fund [grant number 1301‐002]. RKW is supported by the Netherlands Organization for Scientific Research [NWO] [grant number 016.136.308]. Reagents for the Quantum Blue® calprotectin point‐of‐care tests were an unrestricted donation by Bühlmann Laboratories AG. An unrestricted start‐up grant for the development of the web‐based programme IBD‐live was awarded by Ferring Pharmaceuticals BV." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02707068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 32<br/>CG: 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 21<br/>CG: 18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lialda:<br/>IG: 7; CG: 11 </p> <p>Apriso:<br/>IG: 1; CG: 0 </p> <p>Balsalazide:<br/>IG: 5; CG: 4 </p> <p>Sulfasalazine:<br/>IG: 1; CG: 0 </p> <p>Asacol/delzicol:<br/>IG: 0; CG: 2 </p> <p>Asacol HD:<br/>IG: 7; CG: 1 </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Employment:<br/>Student:<br/>IG: 3; CG: 5<br/>Part‐time:<br/>IG: 1; CG: 1;<br/>Full‐time:<br/>IG: 16; CG: 11<br/>Unemployed:<br/>IG: 1; CG: 1 </p> <p>Education:<br/>High school:<br/>IG: 4; CG: 0<br/>College:<br/>IG: 3; CG: 5<br/>Bachelors and above:<br/>IG: 14; CG: 13 </p> <p>Marital status:<br/>Single:<br/>IG: 9; CG: 7<br/>Significant other/married:<br/>IG: 10; CG: 11<br/>Divorced/widowed:<br/>IG: 2; CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Freddy Caldera has received research support from Takeda Pharmaceuticals and Sanofi. He has been a consultant for Takeda and Celgene. All remaining authors report no proprietary interest in the products named in this article." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This study was supported by research support from Takeda Pharmaceuticals."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>IG: 44/94; CG: 19/37 </p> <p>UC: <br/>IG: 46/94; CG: 18/37 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 94<br/>CG: 37 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids:<br/>IG: 6; CG: 3 </p> <p>Azathioprine/6 ‐ mercaptopurine:<br/>IG: 30; CG: 17 </p> <p>Methotrexate:<br/>IG: 0; CG: 1 </p> <p>Mesalazine:<br/>IG: 49; CG: 20 </p> <p>Antibiotics:<br/>IG: 0; CG: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marital status:<br/>Single:<br/>IG: 29; CG: 14<br/>Married/partner:<br/>IG: 55; CG: 20<br/>Divorced/separated: IG: 6; CG: 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACTRN12615000342516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 37; CG: 36 </p> <p>UC:<br/>IG: 13; CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 53<br/>CG: 54 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA:<br/>IG: 20; CG: 20 </p> <p>Biologics:<br/>IG: 15; CG: 18 </p> <p>Thiopurine/methotrexate:<br/>IG: 37; CG: 27 </p> <p>None:<br/>IG: 2; CG: 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This work was supported by the Healthcare Otago Charitable Trust (no grant number) and The New Zealand Society of Gastroenterology Janssen Research Fellowship (no grant number) in 2015 and the gut health network, a research theme located at the Department of Medicine, University of Otago." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT03241992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed IBD</p> <p>CD:<br/>IG: 36; CG: 36 </p> <p>UC:<br/>IG: 28; CG: 27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 64<br/>CG: 63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mesalamine:<br/>IG:19; CG: 18 </p> <p>Immunomodulators:<br/>IG: 17; CG: 25 </p> <p>Biologics:<br/>IG 39; CG 40 </p> <p>Steroids:<br/>IG: 6; CG: 9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White:<br/>IG: 48; CG: 49 </p> <p>Black:<br/>IG: 8; CG: 7 </p> <p>Other:<br/>IG: 6; CG: 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"None"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This project was funded by a generous gift from Aimee &amp; Kleanthis Dendrinos and Robin &amp; Andrew Davis." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 133<br/>CG: 69 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐operative CD</p> <p>Relapse:<br/>IG: 33; CG: 39 </p> <p>Remission:<br/>IG: 87; CG: 80 </p> <p>CG: Relapse 39, Remission 80.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 120<br/>CG: 119 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The project was funded by Nursing Project of Military Medical Science and Technology Youth Cultivation Plan, No. 19QNP077." </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup> Numbers refer to number of participants unless otherwise specified. </p> <p>5‐ASA: 5‐aminosalicylic acid; CD: Crohn's disease; CG: control group; IBD: inflammatory bowel disease; IC: indeterminate colitis IG: intervention group; IQR: interquartile range; n: number of participants; NR: not reported; UC: ulcerative colitis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014821-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intervention details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of telehealth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control intervention description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of control intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention length</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Is the education part of a package of measures (e.g. diagnostic tools, etc.)?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measurement points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up measurement points</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"A call from the gastroenterology doctor at the time of their appointment. The consulting doctor contacted the patient and parents via a telephone number (home or mobile) that the parents and patient had previously supplied as the number they would like to be contacted on." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone consultations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Routine appointments in hospital as usual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 12, 18, 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"If patients experienced a recurrence of disease visualized on constant care web application (web‐app), they were instructed to contact the electronic care (eCare) personnel by phone or via the patient's personal web‐wall, for an early consultation to assess the need of individualized treatment adjustment or diagnostic investigation. Daily web ward rounds were performed by the eCare nurses in close collaboration with a medical doctor." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phone application disease monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients allocated to the CG were instructed in how to screen themselves every 3 months.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐screening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"HealthPROMISE app: Patients track their Quality Of Life and symptoms every 2 weeks, providers can use the visual data to provide better care." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phone application disease monitoring<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient education application, no further details provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient education application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 495, day 575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Electronic traffic light system, which guides the scheduling of infliximab treatment at intervals of 4 to 12 weeks. The traffic light system is based on patient‐registered symptom scores and measures of fecal calprotectin (FC), combined into a total inflammation burden score (TIBS). The repeatedly measured TIBS form a curve on a traffic light graph system consisting of the colors green, yellow, and red. Depending on the color, patients are advised regarding the timing of their next IFX treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based disease monitoring<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital's IBD care guidelines (national pediatric IBD standard<br/>care in Denmark), with outpatient visits every 3rd month, including <br/>blood samples and FC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone follow‐up visits by an IBD nurse practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone follow‐ups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic follow‐up visit by an IBD nurse practitioner</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mobile phone for participants and a decision support server and website for staff and providers. The web system send texts to participants grading their IBD symptoms and collected data from each testing session. Educational tips were also sent via text. The provider could individualise alerts and action plans for each participant. If pre‐determined criteria were met the nurse reviewed and if necessary management changes were made. Medication changes were also updated and communicated to the patient." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Comprehensive assessment, a guideline‐concordant therapy plan, scheduled and as‐needed clinic visits, scheduled and as‐needed telephone calls, administration of educational fact sheets about disease‐specific topics. Administration of educational materials was not standardised and was at the discretion of the provider."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific education provided by C&amp;C Foundation of America<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months, 12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mobile phone for participants and website for providers. The web system sends texts to participants to grade their IBD symptoms. The website provides an interface for staff and providers for participants profiles and collected data from each testing session. The provider can individualize alerts and action plans for each participant. If pre‐determined criteria were met after testing, simultaneous action plans and email alerts were sent to the participant and nurse respectively. The nurse reviewed the information and if necessary consulted the provider for management changes. Medication changes were updated in the participant profile and communicated to the participant." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The standard of care for participants in this study is modeled after the standard of care at all three study sites. Comprehensive assessment, a guideline concordant therapy plan scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease‐specific topics when appropriate."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Educational curriculum: education tips either twice weekly (IG1) or every week (IG2). Educational materials for CG administration was not standardized and was at the discretion of the treating provider."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"MyIBDcoach is a secured webpage with an HTML application for tablet or smartphone. The system includes monthly monitoring modules, as well as intensified monitoring modules, outpatient visit modules, e‐learning modules, a personal care plan, and an administrator page used by the health‐care provider. When parameters recorded by the monitoring modules exceeded predefined thresholds, the safety and continuity of care were ensured by the creation of alerts (red flags) on the administrator page of each local hospital. If an alert was received, a health‐care provider on the local team contacted the patient for further assessment within two working days. Visits to the outpatient clinic were based on the nature and severity of the clinical complaints. At any time, patients were able to communicate easily with their health‐care provider by sending a message to the health‐care providers’ administration office." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based care management portal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in the standard care group continued their routine follow‐up visits following the local protocol, with an opportunity to schedule an extra visit if symptoms relapsed."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: "Follow‐up and monitoring were performed telematically using the integrated platform for management of chronically ill patients (NOMHADCHRONIC app). Patients connected to the platform via the Internet using a computer or an app on a mobile phone or tablet had to self‐complete questionnaires. In addition, they received advice, reminders, educational material about their disease, and information on prevention. This information was received by the case managers and filtered using an intelligent prioritization system with generation of alerts and push notifications according to an integrated intervention protocol" </p> <p>IG2: "The G_NT patients were asked about their health through telephone calls by the nursing staff in the IBD Unit. Authors performed telephone assessment periodically by using structured interviews to evaluate health status, and clinical activity was self‐recorded at home. The interventions depended on the results of the interview and changes in the medication or follow‐up schedule established by nurses with the support of medical staff, according to the alerts and action plans designed in the intervention protocol. Furthermore, they provided these patients with all educational elements made available to the other 2 groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG1: remote web‐based monitoring</p> <p>IG2: nurse‐assisted telephone care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The CG patients received the normal care provided in the IBD Unit (Outpatient Clinic) for patients with moderately to highly complex IBD, based on national and European clinical guidelines. Treatment was adjusted according to the evolution of disease activity and medication adherence, which was measured using specific indexes and biological markers used to report the study outcomes during office visits or telephone calls. </p> <p>This care was complemented by ad hoc hospital care in case of flareups or if the patient’s health deteriorated for any reason. Ad hoc intensive care was maintained until the patient’s condition stabilized, at which point he or she returned to follow‐up based on standard care in the Unit." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 and 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients received a remote education session on IBD and training on the web‐based programme on how to recognise relapses and start treatment guided by the programme. </p> <p>In case of relapse, patients were requested to log on daily and complete the disease activity score (SCCAI) until they entered the green zone. Patients should then log on once a week for a total of 4 weeks after the initiation of relapse. Once remission was achieved patients had to use the program once a month until the next relapse occurred." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education and self‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in the control group continued the conventional treatment and follow‐up in the IBD out‐patient clinic." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web platform, education from staff members</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Participants received automated email alerts to fill in a symptom score and to send in a stool sample. The results of both the symptom score and the calprotectin stool test were uploaded on the IBD‐live website and cumulated in a colour‐coded disease flare risk stratification that was visible to the individual participant and the local IBD team. This resulted in an individual prediction for flare with associated treatment advice and test interval." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Automated email alerts, and web‐based telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular checks in the consultation room as before the trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Quality Of LIfe Tool for IBD (QOLITI). The cognitive‐behavioural therapy (CBT)‐inspired manual contains several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which is completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. 3 x 30 minutes of telephone support by a trained healthcare professional along with the manual were included. Telephone calls occurred at two, four and six weeks post‐randomisation." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT self‐complete manual and telephone consultations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (waitlist)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, educational manual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence iPhone application that included medication reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based phone application for medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham application installed that included educational materials and the capability of recording medication intake, without medication reminders </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients were telemonitored and connected with their doctors and IBD nurses through an IBD Assistant application. They received email reminders at regular intervals to fill in standard electronic assessments. In case of deterioration, they had an emergency questionnaire that advised on contacting a doctor. All communication with the doctor was made primarily through the IBD Assistant web application, personal visits were carried out only after a previous recommendation via the IBD Assistant application. FC was measured at least 4 times/12months with at home CalpoSmart system." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based application telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were usual check‐ups every 3 months in outpatient clinics with their gastroenterologists, during which the patients were examined clinically and laboratory. In case of any difficulties, patients had an unscheduled acute consultation, or were visited by a doctor on the basis of unfavorable examination results." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None after end of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"IBDsmart is an app that allows inflammatory bowel disease (IBD) patients to regularly fill in symptom scores and get them sent to their doctor. It is used by the patients by logging in and filling out a questionnaire. When they fill out the questionnaire, a score is produced which indicates the severity of the disease. This way long term trends of symptom scores are kept on the smartphone and the healthcare team can be contacted immediately via the app in cases where disease severity is high. IBDoc is an app that allows IBD patients to measure their faecal calprotectin levels and get their results sent to their doctor. The way the app works is the participant provides a stool sample which is analysed using a medical device which produces an output that can be read via the camera by an app. The calprotectin app communicates with the IBD app which produces a faecal calprotectin score which is high, medium, or low; the level indicates how much physical disease activity is occurring in the patient. These results can also be sent to the healthcare professional team." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based telemonitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Usual outpatient treatment. The usual treatment group will not have access to the smartphone apps. Usual outpatient treatment, for the purposes of this study, entails the patient seeing their treating gastroenterologist as they usually would." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, FC samples – diagnostic measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, 9, 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients received information via an application about IBD every 2 weeks along with reminders to take their medications. They also received a reminder about getting vaccinated for influenza and pneumococcal pneumonia at 2 weeks, and 3 months after enrollment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based IBD‐specific information and electronic reminders for medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were sent generic messages unrelated to IBD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham web‐based information unrelated to IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, educational information about IBD sent via messages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"A decision aid including an online program reviewing benefits and risks of treatment options combined with a personalised risk prediction tool for Crohn’s disease." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decision‐aid online programme for choice of combination therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard of care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, benefits and risks of treatment review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Subjects downloaded and used an application daily to record symptoms, track pain, stress levels, frequency and quality of bowel movements." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based application disease monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The control group was educated about websites providing information on IBD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of intervention (varied 8–38 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 104 days<br/>CG: 87 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Nurse‐led web‐based follow‐up program for disease monitoring, patient medication reminders, medication education and nurse‐caregiver‐patient communication" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based disease monitoring and medication adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The patients in the control group received regular health education and guidance on drugs by designated nurses during their in‐patient stay. They were handed a brochure with drug guidance upon discharge. The content of the brochure included basic knowledge of drugs, drug usage and effects, how to deal with common problems, and how to attend follow‐ups in outpatient clinic. Every two months, doctors followed‐up guidance by telephone." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Disease monitoring, patient reminders, patient education, nursing‐patient group chat for questions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of months 1, 2, 4, 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CG: control group; FC: faecal calprotectin; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intervention details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014821-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Telehealth details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Staff and programmes delivering the intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Resources required for the intervention and who provided them</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access issues as reported in studies (e.g. disabilities, financial issues)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Data security</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: gastroenterologist</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenterologist provided by the hospital; telephone access</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None apart from lack of access to a telephone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: eCare Nurse</p> <p>CG: eCare Nurse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone (participants' own); eCare nurses + doctors for the web rounds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone, access to the Internet (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: programme</p> <p>CG: hospital staff <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphone, access to internet (participants' own). Training by principal investigator<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD nurse practitioner<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Home telemanagement/ standard care staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] for participants without an active telephone line, a cell phone is provided to transmit self‐testing results over a secure wireless network." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data transmitted from the participant's home were deidentified and encrypted.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: "Results are available immediately after self‐test completion. Clinical care issues that require immediate attention are directed to the provider's office or on call service at each site. Providers are available to study nurse coordinators daily to provide guidance for management changes. </p> <p>CG: face‐to‐face appointments"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web portal, nursing staff, doctors</p> <p>CG: doctors, nursing staff<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: mobile phone (participants' own), electronic weight scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: "If an alert was received, a health‐care provider on the local team contacted the patient for further assessment within two working days." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: website</p> <p>CG: standard hospital care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: computer/tablet/smartphone and internet access (participants' own), administration office<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: the platform, specialised medical staff and nurses</p> <p>Telephone IG: nursing staff</p> <p>CG: hospital staff<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone, mobile phone, internet access (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"TECCU Web platform protects the confidentiality of health data. The access to patient station and to work station requires a personal password only known by the patient and healthcare providers, respectively. Moreover, healthcare providers register patients in the platform with a generic name and a code only identifiable by investigators. Finally, to avoid data correlation by a nonauthorized person, data included in the Web platform are not connected to other hospital information systems. Thus, only case managers and health professionals can see all the clinical history separately."<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: web platform, education from staff members</p> <p>CG: staff members (regular care)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer (participants' own)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: programme</p> <p>CG: specialists not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to telephone, internet, and email (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants required to have access to telephone, internet, and email, and good knowledge of Dutch </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: telephone calls + self‐management</p> <p>CG: self‐management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Manuals, task books, telephones and personnel, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Suicidal patients will be directly referred to liaison psychiatry or their GP and will not be able to access the study as the intensity of the manual intervention is within the low‐moderate range." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG/CG: iPhone app</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPhone, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: Web IBD Assistant App</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PC, tablet, or smartphone, and working email address (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: no smartphone/PC, language barrier, no email, no wifi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone app + gastroenterologist</p> <p>CG: gastroenterologist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone (can be borrowed). 17/50 participants used a borrowed smartphone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: people unable to provide written consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG/CG: Electronic Health Record (EHR) patient portal (EPIC's Mychart)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer with internet (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: non‐English speaking, cognitive impairment that would impair participation, no computer with internet. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: online programme</p> <p>CG: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: smartphone app</p> <p>CG: self‐education using websites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Smartphones (participants' own)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients with Blackberry® smart phones were excluded as the app was not fully optimized for this device." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: mobile app</p> <p>CG: nurses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mobile phones, provider not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People "not able to use the app" were excluded from the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CG: control group; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Telehealth details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014821-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Primary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1a. Disease activity at study end</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1b. Flare‐ups/relapses measured clinically/endoscopically/histologically (n, unless otherwise specified)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1c. Quality of life</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease relapses over 24 months<br/>IG: 1/44<br/>CG: 4/42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median IMPACT QoL at 12 months:<br/>IG (n = 36): median 113 points (IQR 105–125); calculated SD 14.8<br/>CG (n = 31): median 106 points (IQR 95–116); calculated SD 15.5 </p> <p>Mean IMPACT QoL:<br/>IG: mean 108.2 points (95% CI 101.6–114.7)<br/>CG: mean 102.5 points (95% CI 96.5–108.4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Two assessors classified disease activity as (1) Chronic continuous course, red throughout 1 year; (2) Chronic continuous course, yellow throughout 1 year; (3) Chronic continuous course, red and yellow throughout1 year; (4) Continuous remission course, green throughout 1 year; (5) Intermittent course; green, yellow and red throughout 1 year; and (6) Intermittent course; green with a single relapse (yellow or red) throughout 1 year." </p> <p>Mean % over 1 year:</p> <p>SCCAI scores:<br/>IG (n = 37) green/yellow/red: 82%/15%/3%<br/>CG (n = 35) green/yellow/red: 87%/10%/3% </p> <p>HBI scores:<br/>IG (n = 6) green/yellow/red: 72%/28%/0%<br/>CG (n = 9) green/yellow/red: 66%/34%/0% </p> <p>TIBS scores:<br/>IG (n = 43) green/yellow/red: 60%/26%/14%<br/>CG (n = 39)<br/>green/yellow/red: 61%/22%/16% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors stated they "analysed the number of relapses (FC and SCCAI) in each intervention group based on 83 (99%) and 70 (97%) patients respectively"; however, the numbers randomised were 50 and 52. </p> <p>"Moderate" and "Severe" relapses combined:<br/>IG (FC): 22<br/>CG (FC): 17<br/>IG (SCCAI): 14<br/>CG (SCCAI): 9 </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short IBDQ change in QoL:<br/>IG: mean 0.56 points (SD 6.78)<br/>CG: mean 4.04 points (SD 9.24) </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: SIBDQ QoL at 575 days mean 25.2 points (SD 11.3)<br/>CG: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated as an outcome but no data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated as an outcome but no data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not provide data, but commented there was no significant change.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not provide data, but commented there was no significant change.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seo index scores:<br/>IG: mean 122 points (SD 39.3)<br/>CG: mean 113.6 points (SD 28) </p> <p>Remission rates at 12 months: <br/>IG: n = 19/25 (77%)<br/>CG: n = 16/22 (76%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapses at 12 months:<br/>IG: 6 <br/>CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ:<br/>IG: mean 178.1 points (unspecified variance measure 32.1)<br/>CG: mean 187.3 points (unspecified variance measure 32.2) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI:<br/>CG: mean 3.7 points (SD 3.6)<br/>IG1: mean 4.2 points (SD 3.9)<br/>IG2: mean 3.2 points (SD 3.4) </p> <p>SCCAI:<br/>CG: mean 1.4 points (SD 1.4)<br/>IG1: mean 1.7 points (SD 1.9)<br/>IG2: mean 2.0 points (SD 1.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD:<br/>CG: 29/79 (36.5%) <br/>IG1: 31/79 (39.1%) <br/>IG2: 23/78 (29.6%) </p> <p>UC/IC:<br/>CG: 7/36 (18.5%) <br/>IG1: 8/36 (21.7%) <br/>IG2: 13/38 (33.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ at study end:<br/>CG: mean 179.3 points (unspecified variance measure 28.2)<br/>IG1: mean 181.5 points (unspecified variance measure 28.2)<br/>IG2: mean 179.2 points (unspecified variance measure 32.8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of flares during the 12 months of follow‐up:<br/>"Flares were defined as clinical symptoms indicative of disease activity with, as a rule, concomitant calprotectin of more than 250 μg/g in the stool or active disease determined by endoscopy, MRI, or CT. In daily practice, in case of clinically severe symptoms suggestive for disease activity, the treating physician occasionally judged these symptoms to be evident enough to adjust therapy. Therefore, to capture all clinical flares, clinical episodes were defined as flares if symptoms suggestive of disease activity resulted in a dose escalation or initiation of a new drug to induce remission." </p> <p>IG: mean 0.19 events (unspecified variance measure 0.42)<br/>CG: mean 0.19 events (unspecified variance measure 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIBDQ at study end:<br/>IG mean 54.44 points (unspecified variance measure 9.05)<br/>CG: mean 53.71 points (unspecified variance measure 9.87) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured only by proxy (FC levels) and no variance given:</p> <p>"At 24 weeks, the median FC level for clinical activity improved progressively from a baseline value of 490 μg/g to 137 μg/g in IG2(teccu) and from 526 μg/g to 115.5 μg/g in IG1(tele); however, this reduction was smaller in CG, from 330 μg/g to 230 μg/g." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive disease after 24 weeks<br/>IG1: 14/21 (66.7%) → 7 relapses<br/>IG2: 17/21 (81%) → 4 relapses<br/>CG: 15/21 (71.4%) → 6 relapses </p> <p>"Remission was evaluated using the modified HBI for patients with CD. For patients with UC, we used the SCCAI (also known as the Walmsley index) for remote checkups together with the partial Mayo score for face‐to‐face visits. For remote checkups in patients with UC, clinical remission was defined as a Walmsley score ≤ 2,whereas mild‐to‐moderate and severe activities were defined as scores of 3‐5 and &gt;5, respectively. Patients with CD and an HBI &lt; 5 were considered to be in clinical remission, whereas patients with scores of 5‐7, 8‐16, or &gt;16 were considered to have mild, moderate, or severe activity, respectively. In the face‐to‐face visits, clinical remission was defined as a partial Mayo score ≤2 and no individual Mayo sub‐score &gt; 1; scores of 2‐5, 6‐8, and were defined as mild, moderate, and severe disease activity, respectively" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured with the IBDQ‐9 and the EQ‐5D. VAS were also used.</p> <p>Median IBDQ‐9 at end:<br/>IG1: 53 points <br/>IG2: 52.5 points <br/>CG: 53 points  </p> <p>Median EQ‐5D at end:<br/>IG1: 1 point<br/>IG2: 1 point<br/>CG: 1 point </p> <p>Median VAS values at study end:<br/>NR </p> <p>Figure 6 possibly presents variance but unclear if SDs or something else.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI score &gt; 5 used to define a relapse.</p> <p>Total relapses:<br/>IG: 93/169<br/>CG: 87/164 </p> <p>Denmark:<br/>IG: 60/105 (51%) + 12 (randomised but did not participate) = 72/117<br/>CG: 60/106 (52%) + 10 (randomised but did not participate) = 70/116<br/>Mean relapses:<br/>IG: mean 1.1 events (range 0–6)<br/>CG: mean 0.8 events (range 0–4) </p> <p>Ireland:<br/>IG: 20/51 (39%) + 1 (randomised but did not participate) = 21/52<br/>CG: 10/41 (24%) + 7 (randomised but did not participate) = 17/48<br/>Mean relapses:<br/>IG: mean 0.6 events (range 0–4)<br/>CG: 0.2 events (range 0–1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Disease specific QoL was improved in the web‐group, as well as general health, vitality, role emotional, and social functioning, compared to control group"<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Disease flares – disease activity requiring therapy intensification (steroid therapy, exclusive enteral nutrition, aminosalicylate dose escalation, or introduction of anti‐TNF antibodies)" </p> <p>Flare‐ups during 52 weeks:<br/>IG: 28/84<br/>CG: 29/86 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐specific IMPACT‐III scores</p> <p>Mean change in QoL:<br/>IG: 1.32 points<br/>CG: −0.32 points<br/>No variance provided. </p> <p>IG: 54% reported a positive change.</p> <p>CG: 44% reported a positive change.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI mean score at end of study (no variance provided):<br/>IG: 3.48 points<br/>CG: 2.71 points </p> <p>Partial Mayo mean scores at end of study (no variance provided):<br/>IG: 2.71 points<br/>CG: 2.57 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR, study only reported the relapses that required hospitalisation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI:<br/>3 months<br/>IG: mean 1.6 points (SD 1.7)<br/>CG: mean 0.5 points (SD 0.7)<br/>6 months<br/>IG: mean 2.5 points (SD 2.2)<br/>CG: mean 1.9 points (SD 2.0)<br/>9 months<br/>IG: mean 3.4 points (SD 2.7)<br/>CG: mean 2.6 points (SD 4.8) <br/>12 months<br/>IG: mean 1.5 points (SD 1.1)<br/>CG: mean 1.7 points (SD 1.9) </p> <p>HBI:<br/>3 months<br/>IG: mean 4.3 points (SD 3.5)<br/>CG: mean 3.6 points (SD 2.3)<br/>6 months: <br/>IG: mean 4.2 points (SD 3.8)<br/>CG: mean 2.5 points (SD 3.1)<br/>9 months: <br/>IG: mean 3.9 points (SD 4.0)<br/>CG: mean 1.8 points (SD 1.9)<br/>12 months: <br/>IG: mean 2.4 points (SD 3.4)<br/>CG: mean 2.0 points (SD 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC flare‐ups (months 3–12)<br/>IG: 9/13 (70%)<br/>CG: 6.14 (42.7%) </p> <p>CD flare‐ups (months 3–12)<br/>IG: 17/37 (47.2%)<br/>CG: 9/36 (25.7%) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ (CD)<br/>3 months<br/>IG: mean 173.9 points (SD 30.0)<br/>CG: mean 160.1 points (SD 35.1)<br/>6 months<br/>IG: mean 177.5 points (SD 27.9)<br/>CG: mean 163.1 points (SD 36.7)<br/>9 months<br/>IG: mean 178.9 points (SD 27.8)<br/>CG: mean 159.0 points (SD 31.4)<br/>12 months<br/>IG: mean 178.0 points (SD 20.6)<br/>CG: mean 167.3 points (SD 32.6) </p> <p>IBDQ (UC)<br/>3 months<br/>IG: mean 184.6 points (SD 21.7)<br/>CG: mean 186.6 points (SD 21.0)<br/>6 months<br/>IG: mean 188.0 points (SD 28.6)<br/>CG: mean 175.5 points (SD 31.8)<br/>9 months<br/>IG: mean 181.6 points (SD 30.4)<br/>CG: mean 181.9 points (SD 27.7)<br/>12 months<br/>IG: mean 189.5 points (SD 24.5)<br/>CG: mean 179.6 points (SD 24.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median SIBDQ at 6 months (no variance provided):<br/>IG: 58 points<br/>CG: 57.5 points </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ at study end:<br/>IG: mean 172.9 points (unspecified variance measure 26.8)<br/>CG: mean 169.3 points (unspecified variance measure 29.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CD: Crohn's disease; CG: control group; CT: computerised tomography; EQ‐5D: EuroQol five‐dimension questionnaire; FC: faecal calprotectin; HBI: Harvey‐Bradshaw Index; IBD: inflammatory bowel disease; IBDQ: Inflammatory Bowel Disease Questionnaire; IG: intervention group; IQR: interquartile range; MRI: magnetic resonance imaging; n: number of participants; NR: not reported; QoL: quality of life; SCCAI: Simple Colitis Clinical Activity Index; SD: standard deviation; SIBDQ: Short Inflammatory Bowel Disease Questionnaire TIBS: total inflammation burden scoring; TNF: tumour necrosis factor; UC: ulcerative colitis; VAS: visual analogue scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Primary outcome data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014821-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Secondary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2a. Number of episodes of accessing healthcare (outpatient/remote/inpatient)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2b. Medication adherence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2c. Participant engagement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2d. Rate of attendance/engagement (number of planned appointments/interactions attended)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2e. Rate of attendance of interactions with professionals</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2f. Costs or cost/time‐effectiveness (as judged by study authors)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Akobeng 2015</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with ≥ 1 hospital admissions due to IBD:<br/>IG: 1/44<br/>CG: 1/42 </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of consultations scheduled by the hospital for each participant that were not then cancelled by the hospital:<br/>IG: median 4.5 (IQR 3–5.3); imputed SD 1.7<br/>CG: median 5 (IQR 3–6); imputed SD 2.2 </p> <p>Number of consultations attended per participant:<br/>IG: median 4 (IQR 3–4); imputed SD 0.74<br/>CG: median 3 (IQR 2–4); imputed SD 1.48 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with ≥ 1 consultation, as allocated before the 12‐ month follow‐up:<br/>IG: 36 (82%)<br/>CG: 40 (95%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs to the NHS:</p> <p>"Estimates of NHS costs for the intervention (including staff costs and telephone costs) showed that telephone consultation had a mean cost of UK £35.41 per patient consultation compared with £51.12 for face–face consultation, difference £15.71" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ankersen 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication was measured by a self‐assessment questionnaire (MARS)</p> <p>MARS score:<br/>IG: median 23.57 points (IQR 21.50–24.25); calculated SD 2.03<br/>CG: median 24.17 points (IQR 23.50–24.80); calculated SD 0.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The 88 patients that completed the study were asked seven questions at follow‐up. There was no statistical difference between the two intervention groups on any of the seven yes/no questions assessing patient satisfaction." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atreja 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carlsen 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits:<br/>IG: total 85; median 2 (IQR 2–3) </p> <p>CG: total 185; median 8 (IQR 4‐9)</p> <p>On‐demand outpatient visits:<br/>IG: total 47; median (IQR 0–3); </p> <p>CG: total 39; median 1 (IQR 0–2)</p> <p>Acute/hospitalisations:<br/>IG: total 3; median 0 (IQR 0–0); </p> <p>CG: total 10; median 0 (IQR 0–1)</p> <p>Planned outpatient visits:<br/>IG: total 38; median 2 (IQR 1–2); </p> <p>CG: total 146; median 7 (IQR 3–7)</p> <p>Contacts in total:<br/>IG: total 88; median 2 (IQR 2–4); </p> <p>CG: total 195; median 8.5 (IQR 4–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean MARS scores (from trial registration):<br/>IG: mean 23.3 points (95% CI 22.9–23.6); calculated SD 0.88<br/>CG: mean 23.3 points (95% CI 22.9–23.7); calculated SD 0.97<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The adherence to the web program was 81% (384/475 expected entries)."<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Planned outpatient visits:<br/>IG: total 38; median 2 (IQR 1–2) <br/>CG: total 146; median 7 (IQR 3–7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"From a socioeconomic perspective, the reduced school absence and fewer outpatient visits in the web group represent an economic gain, as parents do not require leave from work, and it saves the time and expense of travel to/from our hospital." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chauhan 2016</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The average parking and travel costs for patients randomised to intervention were CAN $25.83, and their average loss of income was CAN $17.00. The median duration of healthcare contact was longer in the intervention group (52 minutes [IQR 38–81] vs 17 minutes [IQR 15.0–21.2]), with wait time was longer in intervention (median 31.6 minutes [IQR 8–56] vs 0 minutes" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on the MMAS.</p> <p>For the purpose of evaluating percent of participants adherent to therapy, the variable was dichotomised to "adherent" or "non‐adherent." Any response of yes to one of the 4 items was scored as "non‐adherent." </p> <p>IG: 14/25 (57%)<br/>CG: 14/22 (67%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extracted from the electronic medical records during 1 year before and after randomization. Post‐randomisation numbers reported as rates adjusted for 100 participants per year (hospitalisations, surgery, emergency department and office visits, procedures, intravenous therapeutics, and telephone and electronic encounters). Unclear if these are only for the randomised participants. </p> <p>CG: 2099<br/>IG1: 2235<br/>IG2: 1935 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Adherence was defined as the completion of 80% (278/348) or more of the weekly or every other week self‐assessments." </p> <p>No data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Jong 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of hospital admissions, unique participants:<br/>IG: 16<br/>CG: 29  </p> <p>Mean outpatient visits:<br/>IG: gastroenterologist: mean 1.26 (SD 1.18); nurse: mean 0.29 (0.68); total: mean 1.55 (SD 1.50)<br/>CG: gastroenterologist: mean 1.98 (SD 1.19); nurse: mean 0.36 (0.84); total: mean 2.34 (SD 1.64) </p> <p>Mean telephone consultations:<br/>IG: gastroenterologist: mean 0.58 (SD 0.98); nurse: mean 0.7 (SD 1.59); total: mean 1.28 (SD 2.06)<br/>CG: gastroenterologist: mean 0.84 (SD 1.11): nurse: mean 0.74 (SD 1.9); total: mean 1.57 (SD 2.44) </p> <p>The number of outpatient visits and telephone consultations with gastroenterologists and nurses during the 12‐month period were retrieved from participants’ electronic medical records. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean MMAS score: <br/>IG: mean 7.01 points (SD 1.40)<br/>CG: mean 6.77 points (SD 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calculated mean annual direct costs, per participant:<br/>IG: EUR 7048<br/>CG EUR 7423 </p> <p>Calculated mean indirect costs, per participant:<br/>IG: EUR 1886<br/>CG: EUR 2058 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Del Hoyo 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits:<br/>IG1 85 (29.5%)<br/>IG2 72 (25%)<br/>CG 131 (45.5%) </p> <p>Telephone calls:<br/>IG1 118 (66.7%)<br/>IG2 12 (6.8%)<br/>CG 47 (26.5%) </p> <p>Study authors recorded the number of outpatient visits and telephone consultations for all 3 groups during the study. As these numbers were per participant, we could not use them for meta‐analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medication adherence according to Morisky‐Green index:<br/>IG1 33.3% (7/21)<br/>IG2 57.1% (12/21) <br/>CG 66.7% (14/21) CG </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants who adhered to &gt; 80% of checkups (considered compliant):<br/>IG1 20 (95.2%)<br/>IG2 18 (85.7%)<br/>CG 19 (90.5%)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There is a high probability that the use of the TECCU Web‐platform produces a greater improvement in disease activity at a lower societal cost." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elkjaer 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute visits:<br/>IG: 21<br/>CG: 107 </p> <p>Routine visits:<br/>IG: 35<br/>CG: 92 </p> <p>Emails/phone calls:<br/>IG: 86/21<br/>CG 7/17  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance:<br/>IG: 73%<br/>CG: 42%<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study authors converted the numbers of medications and professional visits into financial savings for department and found it cost‐effective.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heida 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean face‐to‐face encounters with health providers:<br/>IG: 3.6<br/>CG: 4.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance with study protocol (&gt; 80% response to alerts):<br/>IG: 48<br/>CG: 72 </p> <p>Did not respond to any emails:<br/>IG: 10<br/>CG: NR </p> <p>Insufficient compliance (&lt; 80% response to alerts):<br/>IG: 26<br/>CG: 14 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Home tele‐monitoring led to a mean annual cost‐saving of €89 per participant in the intention‐to‐treat analysis. The intervention was most cost‐saving in participants who were compliant (mean annual saving 360 euros)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hughes 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed at least 1 telephone session:<br/>IG: 80%<br/>CG: NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ley 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean adherence at study end (measured by MPR):<br/>IG: 0.539<br/>CG: 0.462 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malickova 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median number of visits to doctor per participant<br/>IG: 0<br/>CG: 4 </p> <p>Median number of visits to IBD nurse per participant<br/>IG: 0.3<br/>CG: 0.9 </p> <p>Median number of hospitalisations<br/>IG: 1<br/>CG: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IG: 4 non‐compliant<br/>CG: NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Annual average costs remotely / tele‐medically monitored patient (CZK 2,060 / patient / year) were 25% lower than the cost of the same standardly outpatient patient (CZK 2,580 / patient / year)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>McCombie 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenterologist appointments:<br/>IG: mean 0.6 (SD 0.9)<br/>CG: mean 1.7 (SD 0.8) </p> <p>Surgical appointments:<br/>IG: mean 0.1: (SD 0.4)<br/>CG: mean 0.1: (SD 0.4) </p> <p>IBD hospitalisations:<br/>IG: mean 0.1 (SD 0.3)<br/>CG: mean 0.1 (SD 0.4) </p> <p>Nights in hospital:<br/>IG: mean 0.1 (SD 0.4)<br/>CG: mean 0.8 (SD 3.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"At the end of 12 months, patients in the smartphone app group completed 2 system usability scales. The questionnaires asked about the instructions provided for the apps, what issues with the apps they experienced during the study, and whether they would keep using the apps in the future and recommend them to other people with IBD." </p> <p>No data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For IBDoc,<br/>15 (30%) completed all readings.<br/>14 (28%) completed 4.<br/>6 (12%) completed 3.<br/>2 (4%) completed 2.<br/>6 (12%) completed 1.<br/>7 (14%) completed 0. </p> <p>For IBDsmart,<br/>25 (50%) completed all readings.<br/>9 (18%) completed 4.<br/>7 (14%) completed 3.<br/>1 (2%) completed 2.<br/>7 (14%) completed 1.<br/>1 (2%) completed 0. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reich 2019</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33% reported logging onto MyChart monthly, whereas 32% logged on weekly, and 13% logged on every other week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Siegel 2018</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stunkel 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The experimental group did feel that the mobile app was easy to use and subjectively improved their ability to track and correlate symptoms" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wang 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Month 1<br/>MMAS &lt; 6:<br/>IG: 27<br/>CG: 34<br/>MMAS ≥ 6:<br/>IG: 93<br/>CG: 85 </p> <p>Month 2<br/>MMAS &lt; 6:<br/>IG: 30<br/>CG: 35<br/>MMAS ≥ 6:<br/>IG: 90<br/>CG: 84 </p> <p>Month 4<br/>MMAS &lt; 6:<br/>IG: 23<br/>CG: 37<br/>MMAS ≥ 6:<br/>IG: 97<br/>CG: 82 </p> <p>Month 6<br/>MMAS &lt; 6:<br/>IG: 22<br/>CG: 42<br/>MMAS ≥ 6:<br/>IG: 98<br/>CG: 77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>IBD: inflammatory bowel disease; IQR: interquartile range; MARS: Medication Adherence Rating Scale; MMAS: Morisky Medication Adherence Scale; MPR: Medication Possession Ratio; NHS: UK National Health Service; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Secondary outcome data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/full#CD014821-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014821-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Web‐based disease monitoring versus usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Disease activity (adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.11, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.21, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.13, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Disease activity (adults; fixed‐effect sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.11, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.21, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.13, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Flare‐ups/relapse (dichotomous; adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.93, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Mixed inflammatory bowel disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.47, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Flare‐ups/relapse (dichotomous; adults;  fixed‐effect sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.94, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Mixed inflammatory bowel disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.47, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.91, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Flare‐ups (continuous; adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.06, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Flare‐ups/relapse (dichotomous; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.65, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Mixed inflammatory bowel disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.65, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Quality of life (adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.04, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Mixed inflammatory bowel disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.06, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.09, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.62, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Quality of life (adults; fixed‐effect  sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.04, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Mixed inflammatory bowel disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.06, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.09, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.50, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Medication adherence (continuous; adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Medication adherence (continuous; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.63, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Medication adherence (dichotomous; adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.62, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Mixed inflammatory bowel syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.53, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Ulcerative colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Web‐based disease monitoring versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014821-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Telephone‐based disease monitoring versus face‐to‐face monitoring</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Flare‐ups/relapse (dichotomous; adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.47, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Flare‐ups/relapse (dichotomous; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Quality of life (children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [‐0.29, 14.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Number of episodes accessing healthcare (one or more hospital admissions; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.06, 14.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Medication adherence (adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Participant engagement (adults) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.38, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Rate of attendance/engagement with the intervention (missed consultations; children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.48, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Rate of attendance of interactions with health professionals (children) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.74, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Telephone‐based disease monitoring versus face‐to‐face monitoring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014821.pub2/references#CD014821-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014821.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014821-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014821-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014821-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014821-note-0019">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD014821-note-0020">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD014821-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014821-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD014821-note-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014821-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014821-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014821\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014821\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014821\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014821\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014821\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014821.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014821.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014821.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014821.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014821.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724585408"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014821.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724585412"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014821.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e66664a20f44a',t:'MTc0MDcyNDU4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 